Nutzendossier für Sotorasib (LUMYKRAS®)

Zusätzliche Analysen zum ersten Datenschnitt vom 01.09.2020 sowie Analysen zum Datenschnitt 01.12.2020 für den Anhang 4-G

AMGEN GmbH

Inhaltsverzeichnis

1 Datenschnitt vom 01.09.2020

1.1 ANCOVA-Kurven – PRO (Metrische Endpunkte)

1.1.1 EORTC QLQ-C30



Abbildung 1: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Globaler Gesundheitsstatus" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 2: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Fatigue" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 3: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Übelkeit und Erbrechen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 4: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Schmerz" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 5: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Atemnot" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 6: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Insomnie" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 7: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Appetitverlust" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 8: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Obstipation" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 9: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Diarrhoe" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 10: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Physisches Funktionsniveau" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 11: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Rollen-Funktionsniveau" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 12: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Emotionales Funktionsniveau" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 13: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Kognitives Funktionsniveau" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 14: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-C30 Soziales Funktionsniveau" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

1.1.2 EORTC QLQ-LC13



Abbildung 15: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Dysphagie" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 16: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Dyspnoe" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 17: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Haarausfall" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 18: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Husten" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 19: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Periphere Neuropathie" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 20: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Schmerzen (Arm/Schulter)" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 21: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Schmerzen (andere)" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 22: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Schmerzen (Thorax)" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 23: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Wirksamkeit der Schmerzmedikation" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 24: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Wunder Mund" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 25: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "QLQ-LC13 Bluthusten" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

1.1.3 EQ5D-VAS



Abbildung 26: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "EQ-5D VAS" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

1.1.4 PG-IC



Abbildung 27: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PG-IC Husten" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 28: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PG-IC Brustschmerz" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 29: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PG-IC Kurzatmigkeit" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

1.1.5 PRO-CTCAE



Abbildung 31: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von Wunden oder offenen Stellen in Mund oder Hals" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 32: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von rissigen Mundwinkeln" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 33: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von Taubheitsgefühl in Händen oder Füßen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 34: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von juckender Haut" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 35: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von Schmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 36: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von Muskelschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 37: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schweregrad von Gelenkschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

Zeitverlauf nicht darstellbar wegen Konvergenzproblemen im MMRM
Abbildung 38: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Beeinträchtigung durch Wunden oder offene Stellen in Mund oder Hals" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 39: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Beeinträchtigung durch Taubheitsgefühl in Händen oder Füßen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 40: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Beeinträchtigung durch Schmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 41: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Beeinträchtigung durch Muskelschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 42: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Beeinträchtigung durch Gelenkschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 43: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Schmerzfrequenz" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 44: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Frequenz von Muskelschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.



Abbildung 45: Verlaufskurve der Veränderung zu Baseline aus ANCOVA-Modellen "PRO-CTCAE, Frequenz von Gelenkschmerzen" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

1.2 Subgruppenanalysen – Gesamtüberleben

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	26/67	10.4 (8.0, NE)	75.6 (63.3, 84.3)	47.9 (26.8, 66.3)
≥ 65 years	22/59	12.0 (9.5, 12.0)	75.4 (62.1, 84.7)	56.6 (39.0, 70.8)
Prior lines of anti-cancer therapy				
1	23/54	10.4 (7.9, NE)	75.0 (60.9, 84.7)	45.2 (22.0, 65.9)
2	16/44	NE (8.6, NE)	74.1 (58.1, 84.7)	NE (NE, NE)
> 2	9/28	NE (7.5, NE)	78.6 (58.4, 89.8)	NE (NE, NE)
Prior anti PD-1 or anti PD-L1				
Yes	44/115	12.0 (9.5, NE)	74.8 (65.7, 81.9)	56.1 (44.6, 66.1)
No	4/11	10.4 (4.8, NE)	81.8 (44.7, 95.1)	NE (NE, NE)
Prior platinum-base chemotherapy				
Yes	47/113	10.4 (8.6, NE)	72.8 (63.4, 80.1)	47.3 (32.1, 61.0)
No	1/13	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 03OCT20:18:19:50) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	43/102	12.0 (8.3, NE)	71.8 (61.8, 79.6)	51.4 (39.1, 62.4)
No	5/24	NE (10.4, NE)	91.3 (69.5, 97.8)	NE (NE, NE)
PD-L1 protein expression				
< 1%	14/33	10.4 (8.3, 12.0)	78.3 (59.8, 89.0)	46.7 (21.0, 69.0)
≥ 1% and < 50%	7/24	NE (7.5, NE)	78.8 (56.2, 90.6)	68.3 (44.3, 83.6)
≥ 50%	18/35	9.5 (5.7, NE)	63.8 (45.1, 77.5)	NE (NE, NE)
ECOG status at baseline				
0	6/38	NE (NE, NE)	86.3 (70.2, 94.1)	77.7 (51.5, 90.8)
1	42/88	9.5 (7.5, 12.0)	70.8 (59.9, 79.2)	42.1 (26.9, 56.6)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 03OCT20:18:19:50) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	39/103	12.0 (9.5, NE)	75.2 (65.6, 82.5)	52.4 (36.7, 65.9)
Black	2/2	4.7 (1.8, 7.6)	50.0 (0.6, 91.0)	0.0 (NE, NE)
Asian	7/19	NE (6.3, NE)	77.3 (50.1, 90.8)	NE (NE, NE)
Other	0/2	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Sex				
Male	20/63	12.0 (9.5, NE)	83.1 (70.9, 90.5)	62.5 (45.6, 75.5)
Female	28/63	10.4 (7.5, NE)	68.2 (55.2, 78.2)	NE (NE, NE)
Histopathology type				
Squamous	0/1	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Non-squamous	48/125	12.0 (9.5, NE)	75.3 (66.6, 82.0)	51.4 (36.6, 64.4)
Metastatic				
Yes	47/122	12.0 (9.5, NE)	75.5 (66.7, 82.3)	50.2 (34.6, 63.9)
No	1/4	NE (3.2, NE)	75.0 (12.8, 96.1)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 03OCT20:18:19:50) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Liver metastasis				
Yes	14/26	8.8 (4.0, NE)	60.0 (38.4, 76.1)	NE (NE, NE)
No	34/100	12.0 (10.4, NE)	79.4 (69.9, 86.2)	57.1 (39.5, 71.3)
Brain metastasis				
Yes	12/26	10.4 (4.1, 10.4)	71.8 (49.7, 85.4)	0.0 (NE, NE)
No	36/100	12.0 (9.5, NE)	76.5 (66.8, 83.7)	59.4 (47.1, 69.7)
Bone metastasis				
Yes	33/61	8.6 (5.7, 12.0)	63.7 (49.9, 74.7)	35.9 (21.0, 51.1)
No	15/65	NE (10.4, NE)	86.0 (74.8, 92.5)	67.5 (43.4, 83.1)
Smoking history				
Never	2/6	NE (4.0, NE)	60.0 (12.6, 88.2)	NE (NE, NE)
Current	5/15	NE (5.7, NE)	78.6 (47.2, 92.5)	NE (NE, NE)
Former	41/102	10.4 (9.5, NE)	74.9 (65.2, 82.3)	49.3 (32.5, 64.1)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 03OCT20:18:19:50) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Region				
North America	30/79	12.0 (9.5, NE)	75.2 (63.9, 83.4)	55.0 (38.3, 68.8)
Europe	12/30	9.5 (7.9, NE)	76.5 (57.0, 88.1)	NE (NE, NE)
Asia	5/12	NE (1.7, NE)	73.3 (37.9, 90.6)	NE (NE, NE)
Rest of the world	1/5	NE (5.6, NE)	80.0 (20.4, 96.9)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 03OCT20:18:19:50) Source: adam.adsl, adam.adtte

1.3 Subgruppenanalysen – Progressionsfreies Überleben

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	39/65	5.5 (2.9, 8.1)	47.5 (34.4, 59.5)	0.0 (NE, NE)
≥ 65 years	31/58	7.0 (4.9, 11.5)	56.0 (41.5, 68.3)	0.0 (NE, NE)
Prior lines of anti-cancer therapy				
1	29/53	7.8 (5.4, 11.5)	56.2 (40.8, 69.0)	0.0 (NE, NE)
2	27/43	4.1 (2.7, 8.3)	41.5 (26.3, 56.0)	NE (NE, NE)
> 2	14/27	7.0 (4.1, NE)	59.3 (37.3, 75.8)	NE (NE, NE)
Prior anti PD-1 or anti PD-L1				
Yes	63/112	6.8 (4.9, 8.2)	53.5 (43.3, 62.6)	0.0 (NE, NE)
No	7/11	5.4 (1.3, NE)	32.7 (8.3, 60.6)	NE (NE, NE)
Prior platinum-base chemotherapy				
Yes	66/110	5.5 (4.1, 7.0)	46.1 (36.1, 55.6)	0.0 (NE, NE)
No	4/13	9.6 (8.0, 9.6)	100.0 (NE, NE)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:19:13) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	59/99	5.5 (4.1, 7.3)	47.7 (37.0, 57.6)	0.0 (NE, NE)
No	11/24	9.6 (5.4, 9.6)	67.9 (44.1, 83.3)	0.0 (NE, NE)
PD-L1 protein expression				
< 1%	14/33	11.5 (5.5, 11.5)	69.5 (49.2, 83.0)	0.0 (NE, NE)
≥ 1% and < 50%	14/22	5.3 (1.4, NE)	43.3 (22.0, 63.0)	NE (NE, NE)
≥ 50%	21/34	5.5 (2.8, 8.3)	47.3 (28.9, 63.6)	0.0 (NE, NE)
ECOG status at baseline				
0	14/37	NE (5.4, NE)	59.8 (40.8, 74.5)	NE (NE, NE)
1	56/86	5.5 (2.9, 7.3)	48.0 (36.7, 58.5)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:19:13) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	57/101	7.0 (5.3, 8.3)	53.1 (42.4, 62.7)	0.0 (NE, NE)
Black	2/2	2.6 (1.3, 3.9)	0.0 (NE, NE)	0.0 (NE, NE)
Asian	10/18	2.9 (1.4, NE)	48.8 (22.9, 70.5)	NE (NE, NE)
Other	1/2	NE (2.8, NE)	50.0 (0.6, 91.0)	NE (NE, NE)
Sex				
Male	33/61	6.8 (4.1, 11.5)	52.4 (38.2, 64.8)	0.0 (NE, NE)
Female	37/62	6.7 (2.9, 8.1)	50.6 (37.2, 62.6)	NE (NE, NE)
Histopathology type				
Squamous	1/1	1.4 (NE, NE)	0.0 (NE, NE)	0.0 (NE, NE)
Non-squamous	69/122	6.7 (5.1, 8.2)	52.0 (42.3, 60.8)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:19:13) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Metastatic				
Yes	69/119	6.7 (4.1, 8.1)	51.1 (41.4, 60.1)	0.0 (NE, NE)
No	1/4	NE (5.5, NE)	66.7 (5.4, 94.5)	NE (NE, NE)
Liver metastasis				
Yes	20/26	2.9 (1.6, 6.8)	31.7 (14.8, 50.0)	NE (NE, NE)
No	50/97	7.3 (5.4, 11.5)	57.1 (46.0, 66.7)	0.0 (NE, NE)
Brain metastasis				
Yes	16/26	4.9 (2.5, 8.3)	48.8 (27.5, 67.0)	NE (NE, NE)
No	54/97	6.7 (5.3, 8.3)	52.3 (41.4, 62.1)	0.0 (NE, NE)
Bone metastasis				
Yes	37/58	4.1 (2.8, 7.8)	38.3 (25.0, 51.5)	0.0 (NE, NE)
No	33/65	7.3 (5.5, NE)	62.5 (49.1, 73.4)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:19:13) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Smoking history				
Never	5/5	2.8 (1.2, 5.5)	0.0 (NE, NE)	0.0 (NE, NE)
Current	8/15	6.3 (1.4, NE)	56.0 (26.6, 77.6)	NE (NE, NE)
Former	56/100	7.0 (5.1, 8.3)	53.1 (42.3, 62.8)	0.0 (NE, NE)
Region				
North America	43/79	7.3 (5.4, 8.3)	55.5 (43.1, 66.2)	0.0 (NE, NE)
Europe	18/28	4.1 (2.8, NE)	40.9 (22.5, 58.5)	NE (NE, NE)
Asia	7/11	2.8 (0.9, NE)	40.0 (12.3, 67.0)	NE (NE, NE)
Rest of the world	2/5	NE (4.1, NE)	80.0 (20.4, 96.9)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:19:13) Source: adam.adsl, adam.adtte

1.4 Subgruppenanalysen – Ansprechen

Table 14n-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	NSCLC (N = 123) Events[a]/Subjects (%) (95% CI)
Age at baseline	
< 65 years	21/65 (32.3) (21.2, 45.1)
≥ 65 years	25/58 (43.1) (30.2, 56.8)
Prior lines of anti-cancer therapy	
1	22/53 (41.5) (28.1, 55.9)
2	14/43 (32.6) (19.1, 48.5)
> 2	10/27 (37.0) (19.4, 57.6)
Prior anti PD-1 or anti PD-L1	
Yes	41/112 (36.6) (27.7, 46.2)
No	5/11 (45.5) (16.7, 76.6)
Prior platinum-base chemotherapy	
Yes	37/110 (33.6) (24.9, 43.3)
No	9/13 (69.2) (38.6, 90.9)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1	
Yes	32/99 (32.3) (23.3, 42.5)
No	14/24 (58.3) (36.6, 77.9)
PD-L1 protein expression	
< 1%	16/33 (48.5) (30.8, 66.5)
≥ 1% and < 50%	9/22 (40.9) (20.7, 63.6)
≥ 50%	9/34 (26.5) (12.9, 44.4)
ECOG status at baseline	
0	16/37 (43.2) (27.1, 60.5)
1	30/86 (34.9) (24.9, 45.9)
Race	
White	42/101 (41.6) (31.9, 51.8)
Black	0/2 (0.0) (0.0, 84.2)
Asian	3/18 (16.7) (3.6, 41.4)
Other	1/2 (50.0) (1.3, 98.7)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-sub-orr-nsclc-p2.sas
Output: t14n-04-001-002-eff-orr-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:22:14) Source: adam.adsl, adam.adrs

Table 14n-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	NSCLC (N = 123) Events[a]/Subjects (%) (95% CI)
Sex	
Male	26/61 (42.6) (30.0, 55.9)
Female	20/62 (32.3) (20.9, 45.3)
Histopathology type	
Squamous	0/1 (0.0) (0.0, 97.5)
Non-squamous	46/122 (37.7) (29.1, 46.9)
Metastatic	
Yes	44/119 (37.0) (28.3, 46.3)
No	2/4 (50.0) (6.8, 93.2)
Liver metastasis	
Yes	9/26 (34.6) (17.2, 55.7)
No	37/97 (38.1) (28.5, 48.6)
Brain metastasis	
Yes	4/26 (15.4) (4.4, 34.9)
No	42/97 (43.3) (33.3, 53.7)
Bone metastasis	
Yes	19/58 (32.8) (21.0, 46.3)
No	27/65 (41.5) (29.4, 54.4)
Smoking history	
Never	1/5 (20.0) (0.5, 71.6)
Current	4/15 (26.7) (7.8, 55.1)
Former	41/100 (41.0) (31.3, 51.3)
Region	
North America	35/79 (44.3) (33.1, 55.9)
Europe	8/28 (28.6) (13.2, 48.7)
Asia	1/11 (9.1) (0.2, 41.3)
Rest of the world	2/5 (40.0) (5.3, 85.3)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-sub-orr-nsclc-p2.sas
Output: t14n-04-001-002-eff-orr-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:22:14) Source: adam.adsl, adam.adrs

Table 14o-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 Other Tumors in ORR Analysis Set)

	Other Tumor Types (N = 33) Events[a]/Subjects (%) (95% CI)
Type of cancer	
Appendiceal	0/2 (0.0) (0.0, 84.2)
Carcinoma of unknown primary	0/4 (0.0) (0.0, 60.2)
Cervical	1/2 (50.0) (1.3, 98.7)
Cholangiocarcinoma	1/3 (33.3) (0.8, 90.6)
Colon	0/1 (0.0) (0.0, 97.5)
Endocrine tumor	0/1 (0.0) (0.0, 97.5)
Liver	0/1 (0.0) (0.0, 97.5)
Pancreatic	1/16 (6.3) (0.2, 30.2)
Small bowel	0/1 (0.0) (0.0, 97.5)
Small cell lung carcinoma	1/1 (100.0) (2.5, 100.0)
Thyroid	0/1 (0.0) (0.0, 97.5)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-sub-orr-p2.sas
Output: t14o-04-001-002-eff-orr-sub-oth-p2orr.rtf (Date Generated: 03OCT20:18:21:28) Source: adam.adsl, adam.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Overall	99/123 (80.5) (72.4, 87.1)
Age at baseline	
< 65 years	49/65 (75.4) (63.1, 85.2)
≥ 65 years	50/58 (86.2) (74.6, 93.9)
Prior lines of anti-cancer therapy	
1	41/53 (77.4) (63.8, 87.7)
2	32/43 (74.4) (58.8, 86.5)
> 2	26/27 (96.3) (81.0, 99.9)
Prior anti PD-1 or anti PD-L1	
Yes	90/112 (80.4) (71.8, 87.3)
No	9/11 (81.8) (48.2, 97.7)
Prior platinum-base chemotherapy	
Yes	87/110 (79.1) (70.3, 86.3)
No	12/13 (92.3) (64.0, 99.8)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1	
Yes	78/99 (78.8) (69.4, 86.4)
No	21/24 (87.5) (67.6, 97.3)
PD-L1 protein expression	
< 1%	29/33 (87.9) (71.8, 96.6)
≥ 1% and < 50%	15/22 (68.2) (45.1, 86.1)
≥ 50%	27/34 (79.4) (62.1, 91.3)
ECOG status at baseline	
0	34/37 (91.9) (78.1, 98.3)
1	65/86 (75.6) (65.1, 84.2)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:34:53) Source: adam.adsl, a0543pa.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Race	
White	84/101 (83.2) (74.4, 89.9)
Black	1/2 (50.0) (1.3, 98.7)
Asian	12/18 (66.7) (41.0, 86.7)
Other	2/2 (100.0) (15.8, 100.0)
Sex	
Male	49/61 (80.3) (68.2, 89.4)
Female	50/62 (80.6) (68.6, 89.6)
Histopathology type	
Squamous	0/1 (0.0) (0.0, 97.5)
Non-squamous	99/122 (81.1) (73.1, 87.7)
Metastatic	
Yes	95/119 (79.8) (71.5, 86.6)
No	4/4 (100.0) (39.8, 100.0)
Liver metastasis	
Yes	17/26 (65.4) (44.3, 82.8)
No	82/97 (84.5) (75.8, 91.1)
Brain metastasis	
Yes	19/26 (73.1) (52.2, 88.4)
No	80/97 (82.5) (73.4, 89.4)
Bone metastasis	
Yes	43/58 (74.1) (61.0, 84.7)
No	56/65 (86.2) (75.3, 93.5)
Smoking history	
Never	3/5 (60.0) (14.7, 94.7)
Current	12/15 (80.0) (51.9, 95.7)
Former	81/100 (81.0) (71.9, 88.2)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:34:53) Source: adam.adsl, a0543pa.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Region	
North America	65/79 (82.3) (72.1, 90.0)
Europe	22/28 (78.6) (59.0, 91.7)
Asia	7/11 (63.6) (30.8, 89.1)
Rest of the world	5/5 (100.0) (47.8, 100.0)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:34:53) Source: adam.adsl, a0543pa.adrs

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	7/21	8.4 (6.8, 8.4)	78.9 (53.2, 91.5)	0.0 (NE, NE)
≥ 65 years	7/25	7.1 (5.8, NE)	73.1 (45.9, 88.1)	NE (NE, NE)
Prior lines of anti-cancer therapy				
1	7/22	8.4 (6.8, 8.4)	84.2 (58.7, 94.6)	0.0 (NE, NE)
2	3/14	NE (3.5, NE)	76.0 (42.2, 91.6)	NE (NE, NE)
> 2	4/10	6.9 (2.8, NE)	62.5 (22.9, 86.1)	NE (NE, NE)
Prior anti PD-1 or anti PD-L1				
Yes	11/41	8.4 (6.9, 8.4)	82.2 (64.4, 91.6)	0.0 (NE, NE)
No	3/5	3.4 (2.8, NE)	NE (NE, NE)	NE (NE, NE)
Prior platinum-base chemotherapy				
Yes	11/37	NE (5.8, NE)	69.2 (48.9, 82.8)	NE (NE, NE)
No	3/9	8.4 (6.8, 8.4)	100.0 (NE, NE)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:20:24) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	8/32	NE (6.9, NE)	76.2 (54.3, 88.6)	NE (NE, NE)
No	6/14	7.1 (4.0, 8.4)	76.9 (44.2, 91.9)	0.0 (NE, NE)
PD-L1 protein expression				
< 1%	4/16	NE (6.9, NE)	84.6 (51.2, 95.9)	NE (NE, NE)
≥ 1% and < 50%	4/9	5.8 (3.5, NE)	46.9 (12.0, 76.3)	NE (NE, NE)
≥ 50%	4/9	8.4 (2.5, 8.4)	88.9 (43.3, 98.4)	0.0 (NE, NE)
ECOG status at baseline				
0	2/16	NE (NE, NE)	84.6 (51.2, 95.9)	NE (NE, NE)
1	12/30	7.1 (5.8, 8.4)	71.8 (49.4, 85.6)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:20:24) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	14/42	8.4 (6.9, 8.4)	75.0 (57.3, 86.2)	0.0 (NE, NE)
Asian	0/3	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Other	0/1	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Sex				
Male	7/26	8.4 (6.9, 8.4)	80.0 (55.1, 92.0)	0.0 (NE, NE)
Female	7/20	NE (5.8, NE)	70.9 (42.6, 87.1)	NE (NE, NE)
Histopathology type				
Non-squamous	14/46	8.4 (6.9, 8.4)	76.2 (59.1, 86.9)	0.0 (NE, NE)
Metastatic				
Yes	13/44	8.4 (6.9, 8.4)	77.6 (60.0, 88.2)	0.0 (NE, NE)
No	1/2	NE (2.8, NE)	50.0 (0.6, 91.0)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:20:24) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Liver metastasis				
Yes	4/9	7.1 (3.5, NE)	77.8 (36.5, 93.9)	NE (NE, NE)
No	10/37	8.4 (6.9, 8.4)	76.0 (55.9, 87.9)	0.0 (NE, NE)
Brain metastasis				
Yes	1/4	NE (3.5, NE)	75.0 (12.8, 96.1)	NE (NE, NE)
No	13/42	8.4 (6.9, 8.4)	76.4 (58.1, 87.5)	0.0 (NE, NE)
Bone metastasis				
Yes	6/19	7.1 (6.8, NE)	81.9 (53.8, 93.8)	NE (NE, NE)
No	8/27	8.4 (5.8, 8.4)	72.9 (49.1, 86.8)	0.0 (NE, NE)
Smoking history				
Never	1/1	2.8 (NE, NE)	0.0 (NE, NE)	0.0 (NE, NE)
Current	0/4	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Former	13/41	8.4 (6.9, 8.4)	76.6 (58.4, 87.6)	0.0 (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:20:24) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Region				
North America	12/35	8.4 (6.8, 8.4)	71.9 (51.3, 84.9)	0.0 (NE, NE)
Europe	2/8	6.9 (3.5, NE)	85.7 (33.4, 97.9)	NE (NE, NE)
Asia	0/1	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Rest of the world	0/2	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)

Phase 1 data cut-off date 06JUL2020. Phase 2 data cut-off date 01SEP2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/primary/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 03OCT20:18:20:24) Source: adam.adsl, adam.adtte

1.5 Subgruppenanalysen – PRO (Metrische Endpunkte)

1.5.1 EORTC QLQ-C30

Tabelle 1-1: Ergebnisse der MMRM-Subgruppenanalysen für den Endpunkt "QLQ-C30, Veränderung zu Baseline" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
QLQ-C30 Globaler Gesundheitsstatus				
Alter[1]	< 65 Jahre	49	59,7 (23,3)	-2,76 [-7,92; 2,40]
	≥ 65 Jahre	43	69,0 (19,1)	-2,83 [-8,07; 2,41]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	73,3 (28,5)	0,14 [-81350,00; 81350,00]
	2	15	55,0 (22,2)	-1,96 [-81352,00; 81348,00]
	>2	72	65,3 (21,1)	-3,20 [-81353,00; 81347,00]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	63,8 (22,1)	-2,49 [-6,74; 1,75]
	Nein	7	66,7 (20,4)	-6,03 [-16,98; 4,93]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	63,6 (21,7)	-3,18 [n.b.; n.b.]
	Nein	7	69,0 (24,9)	1,33 [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	63,4 (21,9)	-2,88 [-7,26; 1,50]
	Nein	14	67,9 (21,9)	-2,37 [-10,40; 5,65]
ECOG bei Baseline[1]	0	27	71,0 (21,5)	-0,25 [-6,53; 6,04]
	1	65	61,2 (21,5)	-3,91 [-8,55; 0,72]
Geschlecht	Weiblich	41	62,8 (23,2)	-2,84 [-8,21; 2,54]
	Männlich	51	65,0 (20,9)	-2,76 [-7,74; 2,22]
Lebermetastasen[1]	Ja	15	61,7 (22,2)	-7,05 [n.b.; n.b.]
	Nein	77	64,5 (21,9)	-2,10 [n.b.; n.b.]
Hirnmetastasen[1]	Ja	13	58,3 (21,5)	1,19 [n.b.; n.b.]
	Nein	79	65,0 (21,9)	-3,40 [n.b.; n.b.]
Knochenmetastasen	Ja	42	60,7 (20,1)	-3,74 [-9,13; 1,65]
	Nein	50	66,8 (23,1)	-2,04 [-7,00; 2,92]
QLQ-C30 Fatigue				
Alter[1]	< 65 Jahre	49	41,3 (23,2)	-2,37 [-39,34; 34,61]
	≥ 65 Jahre	43	33,6 (20,9)	-5,37 [-43,51; 32,76]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	35,6 (26,5)	-10,19 [-25,63; 5,26]
	2	15	40,7 (29,6)	0,09 [-9,21; 9,40]
	>2	72	37,2 (20,7)	-4,17 [-9,11; 0,77]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	38,4 (22,8)	-4,31 [n.b.; n.b.]
	Nein	7	28,6 (15,5)	1,65 [-74,07; 77,38]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	37,8 (22,6)	-3,55 [-8,38; 1,28]
	Nein	7	36,5 (22,0)	-6,73 [-19,87; 6,40]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	38,6 (23,0)	-4,06 [-35,17; 27,05]
	Nein	14	32,5 (18,7)	-2,55 [-63,05; 57,95]
ECOG bei Baseline[1]	0	27	27,2 (18,8)	-6,59 [-15,62; 2,44]
	1	65	42,1 (22,4)	-2,61 [-9,98; 4,77]
Geschlecht	Weiblich	41	38,5 (20,5)	0,03 [-5,95; 6,01]
	Männlich	51	37,0 (24,0)	-6,92 [-12,43; -1,42]
Lebermetastasen[1]	Ja	15	40,0 (17,2)	-4,75 [-19,05; 9,55]
	Nein	77	37,2 (23,3)	-3,65 [-15,18; 7,88]
Hirnmetastasen[1]	Ja	13	40,2 (20,6)	-3,74 [-94,65; 87,16]
	Nein	79	37,3 (22,8)	-3,82 [-74,48; 66,84]
Knochenmetastasen[1]	Ja	42	39,7 (20,6)	-1,62 [-7,67; 4,43]
	Nein	50	36,0 (23,9)	-5,59 [-11,16; -0,01]
QLQ-C30 Übelkeit und Erbrechen				

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Alter	< 65 Jahre	49	8,8 (14,9)	3,18 [-0,35; 6,71]
	≥ 65 Jahre	43	4,3 (9,7)	-0,17 [-3,74; 3,40]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	0,0 (0,0)	-1,04 [-155,54; 153,46]
	2	15	8,9 (17,7)	1,59 [-146,36; 149,53]
	>2	72	6,7 (12,1)	1,74 [-143,42; 146,89]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	7,1 (13,2)	1,70 [-1,28; 4,68]
	Nein	7	2,4 (6,3)	-0,18 [-7,58; 7,23]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	7,1 (13,2)	1,71 [-1,28; 4,69]
	Nein	7	2,4 (6,3)	-0,21 [-7,65; 7,23]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	7,5 (13,6)	1,91 [-1,16; 4,97]
	Nein	14	2,4 (6,1)	-0,21 [-5,65; 5,23]
ECOG bei Baseline[1]	0	27	4,3 (9,9)	0,92 [n.b.; n.b.]
	1	65	7,7 (13,8)	1,81 [n.b.; n.b.]
Geschlecht	Weiblich	41	7,7 (11,8)	2,33 [-1,39; 6,04]
	Männlich	51	5,9 (13,7)	0,91 [-2,54; 4,35]
Lebermetastasen	Ja	15	7,8 (10,7)	3,41 [-2,43; 9,26]
	Nein	77	6,5 (13,3)	1,24 [-1,78; 4,26]
Hirnmetastasen[1]	Ja	13	6,4 (14,5)	4,64 [n.b.; n.b.]
	Nein	79	6,8 (12,7)	1,06 [n.b.; n.b.]
Knochenmetastasen[1]	Ja	42	7,1 (13,8)	2,95 [-0,75; 6,65]
	Nein	50	6,3 (12,1)	0,41 [-3,01; 3,84]
QLQ-C30 Schmerz				
Alter[1]	< 65 Jahre	49	34,7 (28,8)	9,20 [0,82; 17,57]
	≥ 65 Jahre	43	22,1 (25,1)	0,87 [-7,61; 9,36]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	36,7 (44,7)	-7,76 [n.b.; n.b.]
	2	15	30,0 (31,0)	2,78 [n.b.; n.b.]
	>2	72	28,0 (26,1)	6,62 [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	30,2 (28,1)	5,27 [-0,27; 10,80]
	Nein	7	11,9 (15,9)	4,12 [-11,10; 19,33]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	28,2 (26,6)	5,81 [0,31; 11,31]
	Nein	7	35,7 (41,3)	-2,10 [-17,20; 13,00]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	29,7 (26,9)	5,99 [n.b.; n.b.]
	Nein	14	23,8 (32,5)	1,06 [n.b.; n.b.]
ECOG bei Baseline[1]	0	27	24,7 (29,4)	1,15 [-7,81; 10,11]
	1	65	30,5 (27,1)	6,90 [0,06; 13,74]
Geschlecht[1]	Weiblich	41	31,7 (30,2)	7,28 [n.b.; n.b.]
	Männlich	51	26,5 (25,6)	3,47 [n.b.; n.b.]
Lebermetastasen	Ja	15	28,9 (26,3)	10,53 [-0,81; 21,88]
	Nein	77	28,8 (28,2)	4,25 [-1,37; 9,87]
Hirnmetastasen	Ja	13	24,4 (26,0)	13,61 [2,01; 25,21]
	Nein	79	29,5 (28,1)	3,80 [-1,78; 9,37]
Knochenmetastasen	Ja	42	33,3 (27,1)	8,24 [1,14; 15,33]
	Nein	50	25,0 (28,0)	2,70 [-3,82; 9,22]
QLQ-C30 Atemnot				
Alter	< 65 Jahre	49	40,8 (26,6)	-2,54 [-9,15; 4,08]
	≥ 65 Jahre	43	38,0 (30,5)	-7,28 [-14,11; -0,45]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	33,3 (0,0)	-8,37 [-26,28; 9,53]
	2	15	31,1 (34,4)	-2,19 [-13,06; 8,69]
	>2	72	41,7 (27,8)	-5,11 [-10,90; 0,68]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	39,2 (27,3)	-5,72 [-11,13; -0,32]
	Nein	7	42,9 (41,8)	5,26 [-9,60; 20,13]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	39,6 (28,4)	-4,37 [-9,81; 1,07]
	Nein	7	38,1 (30,0)	-9,66 [-24,70; 5,38]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	39,3 (27,3)	-5,33 [-10,95; 0,28]
	Nein	14	40,5 (35,0)	-2,17 [-13,03; 8,70]
ECOG bei Baseline[1]	0	27	29,6 (26,7)	-9,68 [-64,47; 45,12]
	1	65	43,6 (28,2)	-2,71 [-42,47; 37,05]
Geschlecht	Weiblich	41	41,5 (22,1)	-2,78 [-9,82; 4,27]
	Männlich	51	37,9 (32,7)	-6,45 [-12,93; 0,03]
Lebermetastasen	Ja	15	40,0 (25,8)	-5,25 [-16,57; 6,06]
	Nein	77	39,4 (29,0)	-4,73 [-10,30; 0,83]
Hirnmetastasen[1]	Ja	13	38,5 (26,7)	-2,30 [n.b.; n.b.]
	Nein	79	39,7 (28,8)	-5,21 [n.b.; n.b.]
Knochenmetastasen	Ja	42	39,7 (25,8)	-2,95 [-9,99; 4,08]
	Nein	50	39,3 (30,6)	-6,32 [-12,81; 0,18]
QLQ-C30 Insomnie				
Alter[1]	< 65 Jahre	49	34,7 (32,6)	-3,08 [-9,72; 3,55]
	≥ 65 Jahre	43	31,0 (27,6)	-4,87 [-11,64; 1,90]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	40,0 (36,5)	-14,26 [n.b.; n.b.]
	2	15	37,8 (30,5)	-2,83 [n.b.; n.b.]
	>2	72	31,5 (30,1)	-3,41 [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	32,9 (30,6)	-4,05 [-9,60; 1,51]
	Nein	7	33,3 (27,2)	-2,94 [-16,99; 11,11]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	31,8 (29,5)	-2,84 [-12,89; 7,20]
	Nein	7	47,6 (37,8)	-16,13 [-32,41; 0,16]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	31,6 (29,9)	-2,84 [-8,54; 2,85]
	Nein	14	40,5 (32,5)	-9,41 [-19,70; 0,87]
ECOG bei Baseline[1]	0	27	27,2 (29,3)	-5,11 [-14,24; 4,02]
	1	65	35,4 (30,5)	-3,45 [-10,79; 3,89]
Geschlecht	Weiblich	41	27,6 (28,8)	-0,68 [-7,58; 6,22]
	Männlich	51	37,3 (31,0)	-6,67 [-13,10; -0,24]
Lebermetastasen[1]	Ja	15	28,9 (30,5)	-2,59 [-13,61; 8,42]
	Nein	77	33,8 (30,3)	-4,18 [-9,82; 1,47]
Hirnmetastasen[1]	Ja	13	38,5 (30,0)	0,07 [-149,46; 149,60]
	Nein	79	32,1 (30,4)	-4,58 [-140,67; 131,51]
Knochenmetastasen[1]	Ja	42	36,5 (31,1)	-2,08 [-9,06; 4,89]
	Nein	50	30,0 (29,5)	-5,44 [-11,89; 1,00]
QLQ-C30 Appetitverlust				
Alter[1]	< 65 Jahre	49	26,5 (31,9)	-1,24 [-7,95; 5,47]
	≥ 65 Jahre	43	17,1 (26,6)	-3,55 [-10,38; 3,28]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	20,0 (29,8)	-6,20 [-23,54; 11,15]
	2	15	33,3 (39,8)	-2,68 [-13,37; 8,02]
	>2	72	19,9 (27,2)	-2,01 [-7,83; 3,81]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	23,5 (30,4)	-2,39 [-7,93; 3,16]
	Nein	7	4,8 (12,6)	-2,16 [-16,84; 12,52]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	22,4 (30,2)	-2,07 [-7,60; 3,45]
	Nein	7	19,0 (26,2)	-5,56 [-20,15; 9,03]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	23,9 (30,8)	-2,05 [-12,52; 8,41]
	Nein	14	11,9 (21,1)	-3,87 [-17,60; 9,85]
ECOG bei Baseline[1]	0	27	11,1 (18,5)	-5,54 [n.b.; n.b.]
	1	65	26,7 (32,4)	-0,95 [n.b.; n.b.]
Geschlecht[1]	Weiblich	41	23,6 (31,8)	-3,14 [-10,19; 3,90]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
	Männlich	51	20,9 (28,3)	-1,75 [-8,25; 4,75]
Lebermetastasen[1]	Ja	15	31,1 (26,6)	2,61 [-8,61; 13,84]
	Nein	77	20,3 (30,2)	-3,17 [-8,78; 2,43]
Hirnmetastasen[1]	Ja	13	25,6 (36,4)	1,96 [-11,44; 15,35]
	Nein	79	21,5 (28,8)	-3,04 [-12,02; 5,94]
Knochenmetastasen[1]	Ja	42	27,0 (31,4)	1,52 [-5,85; 8,88]
	Nein	50	18,0 (27,9)	-5,44 [-12,26; 1,38]
QLQ-C30 Obstipation				
Alter	< 65 Jahre	49	21,8 (26,8)	-9,57 [-15,09; -4,05]
	≥ 65 Jahre	43	20,9 (25,2)	-8,59 [-14,21; -2,97]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	6,7 (14,9)	-15,19 [-29,01; -1,38]
	2	15	28,9 (27,8)	-9,24 [-17,77; -0,71]
	>2	72	20,8 (25,9)	-8,59 [-13,45; -3,72]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	21,6 (26,1)	-8,84 [-13,98; -3,70]
	Nein	7	19,0 (26,2)	-11,76 [-23,50; -0,03]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	22,4 (26,4)	-8,98 [-13,64; -4,33]
	Nein	7	9,5 (16,3)	-10,25 [-21,93; 1,43]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	22,6 (26,6)	-8,69 [-13,46; -3,91]
	Nein	14	14,3 (21,5)	-11,03 [-19,53; -2,52]
ECOG bei Baseline	0	27	13,6 (16,7)	-11,38 [-18,12; -4,64]
	1	65	24,6 (28,4)	-8,07 [-13,10; -3,05]
Geschlecht[1]	Weiblich	41	23,6 (27,1)	-8,55 [-66,24; 49,14]
	Männlich	51	19,6 (25,1)	-9,53 [-65,62; 46,56]
Lebermetastasen[1]	Ja	15	31,1 (23,5)	-11,88 [n.b.; n.b.]
	Nein	77	19,5 (26,1)	-8,64 [n.b.; n.b.]
Hirnmetastasen	Ja	13	23,1 (28,5)	-9,51 [-18,76; -0,26]
	Nein	79	21,1 (25,7)	-9,03 [-13,74; -4,32]
Knochenmetastasen[1]	Ja	42	27,0 (29,7)	-9,78 [-15,61; -3,95]
	Nein	50	16,7 (21,6)	-8,54 [-13,93; -3,16]
QLQ-C30 Diarrhoe				
Alter[1]	< 65 Jahre	49	5,4 (14,2)	10,80 [4,95; 16,65]
	≥ 65 Jahre	43	8,5 (14,7)	11,47 [5,59; 17,35]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	6,7 (14,9)	19,80 [5,12; 34,49]
	2	15	11,1 (20,6)	11,05 [0,48; 21,62]
	>2	72	6,0 (12,9)	10,45 [2,24; 18,65]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	6,7 (14,4)	10,90 [5,87; 15,92]
	Nein	7	9,5 (16,3)	13,59 [2,28; 24,90]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	7,1 (14,6)	10,84 [5,81; 15,87]
	Nein	7	4,8 (12,6)	14,10 [2,75; 25,44]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	6,8 (14,6)	10,54 [n.b.; n.b.]
	Nein	14	7,1 (14,2)	13,84 [n.b.; n.b.]
ECOG bei Baseline[1]	0	27	7,4 (14,1)	10,94 [2,13; 19,75]
	1	65	6,7 (14,7)	11,22 [3,50; 18,94]
Geschlecht	Weiblich	41	6,5 (13,4)	11,38 [5,34; 17,43]
	Männlich	51	7,2 (15,4)	10,93 [5,24; 16,62]
Lebermetastasen[1]	Ja	15	6,7 (13,8)	13,76 [4,43; 23,09]
	Nein	77	6,9 (14,6)	10,74 [5,67; 15,81]
Hirnmetastasen[1]	Ja	13	2,6 (9,2)	11,63 [-82,32; 105,58]
	Nein	79	7,6 (15,0)	11,06 [-68,17; 90,29]
Knochenmetastasen[1]	Ja	42	7,1 (15,7)	12,69 [6,61; 18,77]
	Nein	50	6,7 (13,5)	9,93 [4,28; 15,58]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
QLQ-C30 Physisches Funktionsniveau				
Alter	< 65 Jahre	49	71,2 (22,8)	-1,68 [-6,51; 3,15]
	≥ 65 Jahre	43	73,0 (21,1)	2,73 [-2,29; 7,75]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	78,7 (27,2)	2,32 [-11,57; 16,21]
	2	15	61,8 (27,2)	2,02 [-6,72; 10,76]
	>2	72	73,7 (20,0)	-0,05 [-5,16; 5,05]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	72,2 (21,9)	0,56 [-25,32; 26,43]
	Nein	7	70,5 (24,3)	-1,10 [-74,15; 71,95]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	72,2 (21,6)	0,04 [-179,08; 179,15]
	Nein	7	70,5 (28,0)	4,82 [-186,89; 196,54]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	78	72,3 (21,5)	0,15 [-7,81; 8,10]
	Nein	14	70,5 (25,2)	1,85 [-8,79; 12,49]
ECOG bei Baseline[1]	0	27	84,2 (18,5)	3,35 [-5,53; 12,23]
	1	65	67,0 (21,4)	-0,86 [-8,47; 6,76]
Geschlecht[1]	Weiblich	41	70,1 (22,2)	-2,35 [-7,50; 2,80]
	Männlich	51	73,6 (21,8)	2,65 [-2,05; 7,36]
Lebermetastasen[1]	Ja	15	71,6 (17,7)	0,17 [-51,57; 51,91]
	Nein	77	72,1 (22,8)	0,47 [-20,85; 21,79]
Hirnmetastasen[1]	Ja	13	65,6 (18,0)	2,91 [-5,87; 11,70]
	Nein	79	73,1 (22,4)	0,03 [-3,97; 4,03]
Knochenmetastasen	Ja	42	70,8 (21,5)	-1,93 [-7,32; 3,45]
	Nein	50	73,1 (22,4)	2,35 [-2,65; 7,35]
QLQ-C30 Rollen-Funktionsniveau				
Alter[1]	< 65 Jahre	49	68,0 (30,0)	-6,87 [-16,67; 2,92]
	≥ 65 Jahre	43	76,4 (24,5)	-1,77 [-11,69; 8,15]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	73,3 (30,3)	2,15 [-15,55; 19,85]
	2	15	71,1 (35,3)	-5,62 [-16,32; 5,09]
	>2	72	72,0 (26,2)	-4,68 [-10,45; 1,09]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	85	70,8 (28,0)	-4,56 [-10,03; 0,90]
	Nein	7	85,7 (20,2)	-3,01 [-18,01; 11,98]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	71,8 (27,8)	-4,59 [n.b.; n.b.]
	Nein	7	73,8 (28,6)	-2,78 [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	70,5 (28,2)	-4,74 [-10,38; 0,89]
	Nein	14	79,8 (24,6)	-2,89 [-13,72; 7,93]
ECOG bei Baseline[1]	0	27	85,8 (21,5)	-0,30 [-8,89; 8,30]
	1	65	66,2 (28,1)	-6,22 [-12,39; -0,05]
Geschlecht[1]	Weiblich	41	69,5 (29,1)	-5,72 [-450,87; 439,43]
	Männlich	51	73,9 (26,7)	-3,39 [-448,19; 441,41]
Lebermetastasen	Ja	15	74,4 (24,3)	-10,54 [-21,76; 0,69]
	Nein	77	71,4 (28,5)	-3,39 [-8,94; 2,17]
Hirnmetastasen[1]	Ja	13	64,1 (27,1)	-4,99 [-16,68; 6,69]
	Nein	79	73,2 (27,8)	-4,35 [-9,90; 1,21]
Knochenmetastasen	Ja	42	71,0 (25,8)	-8,24 [-15,20; -1,28]
	Nein	50	72,7 (29,5)	-1,31 [-7,74; 5,11]
QLQ-C30 Emotionales Funktionsniveau				
Alter[1]	< 65 Jahre	49	69,7 (23,4)	1,87 [-2,79; 6,53]
	≥ 65 Jahre	43	82,4 (20,8)	2,86 [-1,87; 7,60]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	71,7 (26,1)	-0,30 [n.b.; n.b.]
	2	15	75,6 (24,1)	2,59 [n.b.; n.b.]
	>2	72	75,9 (22,9)	2,50 [n.b.; n.b.]
	Ja	85	75,5 (22,7)	2,36 [-37,79; 42,52]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Nein	7	77,4 (28,8)	2,27 [-68,31; 72,86]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	76,4 (21,9)	2,56 [-1,26; 6,38]
	Nein	7	66,7 (35,0)	0,08 [-9,90; 10,05]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	76,3 (21,4)	2,59 [-1,34; 6,52]
	Nein	14	72,0 (31,3)	1,19 [-6,03; 8,41]
ECOG bei Baseline	0	27	77,8 (22,4)	3,78 [-1,85; 9,40]
	1	65	74,7 (23,4)	1,74 [-2,41; 5,89]
Geschlecht[1]	Weiblich	41	70,1 (22,1)	1,90 [-53,73; 57,54]
	Männlich	51	80,1 (23,0)	2,72 [-51,55; 56,99]
Lebermetastasen	Ja	15	78,3 (14,7)	2,24 [-5,41; 9,89]
	Nein	77	75,1 (24,4)	2,37 [-1,51; 6,26]
Hirnmetastasen[1]	Ja	13	75,6 (17,8)	4,70 [-3,10; 12,50]
	Nein	79	75,6 (23,9)	1,99 [-1,89; 5,86]
Knochenmetastasen	Ja	42	76,6 (22,0)	1,54 [-3,28; 6,37]
	Nein	50	74,8 (24,1)	3,01 [-1,46; 7,48]
QLQ-C30 Kognitives Funktionsniveau				
Alter[1]	< 65 Jahre	49	83,0 (20,0)	-2,21 [-6,81; 2,38]
	≥ 65 Jahre	43	81,8 (21,1)	0,91 [-3,84; 5,65]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	80,0 (27,4)	7,38 [-4,68; 19,45]
	2	15	75,6 (25,1)	3,97 [-3,38; 11,33]
	>2	72	84,0 (18,9)	-2,31 [-6,27; 1,65]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	82,0 (20,6)	-1,18 [-122719,00; 122716,00]
	Nein	7	88,1 (18,5)	4,28 [-122713,00; 122722,00]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	85	82,2 (20,2)	-0,92 [n.b.; n.b.]
	Nein	7	85,7 (24,4)	1,43 [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	81,6 (20,4)	-1,44 [-5,35; 2,47]
	Nein	14	86,9 (20,9)	2,87 [-4,61; 10,34]
ECOG bei Baseline[1]	0	27	88,3 (17,8)	0,07 [-5,77; 5,91]
	1	65	80,0 (21,1)	-1,06 [-5,26; 3,14]
Geschlecht[1]	Weiblich	41	81,7 (19,3)	-3,03 [-11,99; 5,94]
	Männlich	51	83,0 (21,5)	1,14 [-7,63; 9,91]
Lebermetastasen	Ja	15	80,0 (18,0)	-3,52 [-11,36; 4,31]
	Nein	77	82,9 (20,9)	-0,25 [-4,12; 3,62]
Hirnmetastasen[1]	Ja	13	71,8 (25,8)	0,47 [-7,82; 8,75]
	Nein	79	84,2 (19,0)	-0,90 [-4,92; 3,11]
Knochenmetastasen	Ja	42	79,4 (21,7)	-0,85 [-5,77; 4,07]
	Nein	50	85,0 (19,1)	-0,61 [-5,13; 3,91]
QLQ-C30 Soziales Funktionsniveau				
Alter	< 65 Jahre	49	65,6 (29,7)	2,56 [-3,67; 8,79]
	≥ 65 Jahre	43	77,1 (24,4)	6,43 [0,05; 12,81]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	66,7 (35,4)	10,64 [-5,36; 26,64]
	2	15	68,9 (32,0)	0,66 [-9,10; 10,41]
	>2	72	71,8 (26,8)	4,77 [-0,63; 10,18]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	85	70,2 (28,3)	4,61 [-219029,00; 219038,00]
	Nein	7	81,0 (20,2)	2,54 [-219031,00; 219036,00]
Vorangegangene Platinum-basierte Chemotherapie	Ja	85	72,0 (26,8)	3,80 [-1,32; 8,93]
	Nein	7	59,5 (39,5)	11,33 [-2,24; 24,90]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	78	71,2 (27,2)	3,94 [-1,35; 9,23]
	Nein	14	70,2 (32,1)	6,86 [-2,95; 16,66]
ECOG bei Baseline[1]	0	27	82,7 (27,1)	7,57 [-100,53; 115,67]
	1	65	66,2 (26,8)	3,07 [-99,50; 105,65]
Geschlecht[1]	Weiblich	41	67,9 (27,7)	2,68 [-38,38; 43,74]
	Männlich	51	73,5 (27,9)	5,86 [-32,03; 43,74]
Lebermetastasen[1]	Ja	15	75,6 (17,7)	-0,23 [-27886,00; 27885,00]
	Nein	77	70,1 (29,4)	5,21 [-27880,00; 27891,00]
Hirnmetastasen	Ja	13	51,3 (20,9)	9,96 [-0,97; 20,88]
	Nein	79	74,3 (27,6)	3,58 [-1,63; 8,80]
Knochenmetastasen	Ja	42	73,8 (26,3)	-0,95 [-7,35; 5,46]
	Nein	50	68,7 (29,1)	8,80 [2,88; 14,72]
1) Konvergenzkriterien erfüllt aber finale Hessematrix ist nicht positiv definit.				
KI = Konfidenzintervall; LS-Mean = Kleinste Quadrate Mittelwert (least squares mean); QLQ-C30 = Quality of Life Questionnaire Core 30; n.b. = nicht berechenbar; Stdabw. = Standardabweichung				

1.5.2 EORTC QLQ-LC13

Tabelle 1-2: Ergebnisse der MMRM-Subgruppenanalysen für den Endpunkt "QLQ-LC13, Veränderung zu Baseline" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
QLQ-LC13 Dysphagie				
Alter[1]	< 65 Jahre	43	7,8 (16,0)	-3,71 [-32013,00; 32006,00]
	≥ 65 Jahre	42	6,3 (16,8)	0,89 [-32008,00; 32010,00]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	6,7 (14,9)	-1,05 [-70,47; 68,36]
	2	14	4,8 (12,1)	-3,67 [-54,25; 46,91]
	>2	66	7,6 (17,3)	-0,85 [-39,61; 37,90]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	7,6 (16,8)	-1,23 [-20,79; 18,33]
	Nein	6	0,0 (0,0)	-2,57 [-58,22; 53,07]
Vorangegangene Platinum-basierte Chemotherapie	Ja	80	7,1 (16,5)	-1,35 [-4,47; 1,76]
	Nein	5	6,7 (14,9)	-1,05 [-10,64; 8,54]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	74	7,7 (17,0)	-1,24 [-4,45; 1,96]
	Nein	11	3,0 (10,1)	-1,88 [-8,49; 4,72]
ECOG bei Baseline[1]	0	24	5,6 (12,7)	-3,97 [-11,62; 3,69]
	1	61	7,7 (17,6)	-0,23 [-7,17; 6,72]
Geschlecht[1]	Weiblich	38	6,1 (13,1)	-2,29 [-24,17; 19,60]
	Männlich	47	7,8 (18,7)	-0,56 [-20,25; 19,14]
Lebermetastasen[1]	Ja	15	8,9 (19,8)	2,47 [-39,07; 44,02]
	Nein	70	6,7 (15,6)	-2,03 [-26,01; 21,96]
Hirnmetastasen[1]	Ja	11	12,1 (27,0)	-4,26 [-11,26; 2,74]
	Nein	74	6,3 (14,3)	-0,93 [-4,30; 2,44]
Knochenmetastasen[1]	Ja	41	8,1 (19,4)	0,39 [-5,88; 6,66]
	Nein	44	6,1 (13,0)	-2,85 [-9,01; 3,31]
QLQ-LC13 Dyspnoe				
Alter[1]	< 65 Jahre	43	31,0 (21,4)	0,36 [-5,32; 6,04]
	≥ 65 Jahre	42	32,3 (23,3)	-2,68 [-8,30; 2,94]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	22,2 (11,1)	-0,25 [-15,30; 14,79]
	2	14	34,9 (28,2)	-4,48 [-13,75; 4,79]
	>2	66	31,6 (21,5)	-0,53 [-5,32; 4,25]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	79	30,9 (22,1)	-1,22 [-5,68; 3,25]
	Nein	6	40,7 (24,0)	-0,65 [-14,31; 13,00]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	32,2 (22,6)	-1,23 [-5,76; 3,29]
	Nein	5	22,2 (11,1)	-0,27 [-15,28; 14,74]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	31,5 (22,5)	-1,28 [-5,86; 3,30]
	Nein	11	32,3 (20,8)	-0,49 [-10,66; 9,68]
ECOG bei Baseline[1]	0	24	22,2 (20,7)	-7,27 [-14,44; -0,10]
	1	61	35,3 (21,8)	1,33 [-3,56; 6,23]
Geschlecht[1]	Weiblich	38	33,6 (17,2)	1,07 [-185550,00; 185552,00]
	Männlich	47	30,0 (25,6)	-3,00 [-185554,00; 185548,00]
Lebermetastasen[1]	Ja	15	29,6 (23,6)	3,78 [-47,60; 55,15]
	Nein	70	32,1 (22,0)	-2,14 [-3,90; -0,37]
Hirnmetastasen[1]	Ja	11	30,3 (21,7)	-2,56 [-181984,00; 181979,00]
	Nein	74	31,8 (22,4)	-0,98 [-181983,00; 181981,00]
Knochenmetastasen	Ja	41	31,7 (23,0)	0,33 [-5,45; 6,10]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
	Nein	44	31,6 (21,7)	-2,53 [-8,07; 3,00]
QLQ-LC13 Haarausfall				
Alter[1]	< 65 Jahre	43	12,4 (27,2)	0,73 [-3,98; 5,44]
	≥ 65 Jahre	42	3,2 (9,9)	-0,72 [-5,30; 3,87]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	0,0 (0,0)	0,77 [-9,92; 11,45]
	2	14	11,9 (28,1)	3,43 [-3,29; 10,15]
	>2	66	7,6 (20,1)	-0,83 [-4,48; 2,82]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	8,0 (21,5)	-0,13 [-8,10; 7,83]
	Nein	6	5,6 (13,6)	1,27 [-10,74; 13,28]
Vorangegangene Platinum-basierte Chemotherapie	Ja	80	8,3 (21,5)	-0,08 [-3,52; 3,37]
	Nein	5	0,0 (0,0)	0,78 [-9,94; 11,49]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	8,6 (22,1)	-0,20 [-3,74; 3,34]
	Nein	11	3,0 (10,1)	1,05 [-6,28; 8,39]
ECOG bei Baseline	0	24	0,0 (0,0)	-4,42 [-9,66; 0,81]
	1	61	10,9 (24,1)	1,87 [-1,87; 5,62]
Geschlecht	Weiblich	38	11,4 (23,6)	2,60 [-1,81; 7,01]
	Männlich	47	5,0 (18,4)	-2,12 [-6,18; 1,93]
Lebermetastasen[1]	Ja	15	6,7 (13,8)	0,99 [-6,17; 8,16]
	Nein	70	8,1 (22,3)	-0,21 [-4,27; 3,85]
Hirnmetastasen	Ja	11	12,1 (30,8)	-0,79 [-8,53; 6,94]
	Nein	74	7,2 (19,3)	0,08 [-3,42; 3,58]
Knochenmetastasen[1]	Ja	41	8,9 (22,4)	0,59 [n.b.; n.b.]
	Nein	44	6,8 (19,8)	-0,57 [n.b.; n.b.]
QLQ-LC13 Husten				
Alter	< 65 Jahre	43	41,1 (31,6)	-9,80 [-16,61; -3,00]
	≥ 65 Jahre	42	30,2 (20,6)	-8,79 [-15,44; -2,15]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	33,3 (23,6)	-15,04 [n.b.; n.b.]
	2	14	23,8 (30,5)	-10,85 [n.b.; n.b.]
	>2	66	38,4 (26,3)	-8,46 [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	79	37,1 (27,2)	-9,34 [-14,82; -3,85]
	Nein	6	16,7 (18,3)	-8,64 [-23,77; 6,50]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	35,8 (27,4)	-8,89 [n.b.; n.b.]
	Nein	5	33,3 (23,6)	-15,02 [-101,87; 71,83]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	37,4 (27,6)	-8,90 [-14,50; -3,30]
	Nein	11	24,2 (21,6)	-11,59 [-22,98; -0,20]
ECOG bei Baseline	0	24	38,9 (21,2)	-11,50 [-19,70; -3,30]
	1	61	34,4 (29,2)	-8,34 [-14,29; -2,39]
Geschlecht[1]	Weiblich	38	42,1 (27,6)	-6,85 [n.b.; n.b.]
	Männlich	47	30,5 (25,8)	-11,28 [n.b.; n.b.]
Lebermetastasen	Ja	15	24,4 (23,5)	-6,94 [-17,78; 3,89]
	Nein	70	38,1 (27,4)	-9,70 [-15,30; -4,09]
Hirnmetastasen	Ja	11	24,2 (15,6)	-6,99 [-18,99; 5,02]
	Nein	74	37,4 (28,1)	-9,60 [-15,14; -4,05]
Knochenmetastasen	Ja	41	26,8 (27,1)	-5,50 [-12,39; 1,39]
	Nein	44	43,9 (24,7)	-12,60 [-19,16; -6,05]
QLQ-LC13 Periphere Neuropathie				
Alter[1]	< 65 Jahre	43	14,7 (23,3)	2,19 [-29,47; 33,86]
	≥ 65 Jahre	42	20,6 (26,5)	0,73 [-29,91; 31,38]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	13,3 (18,3)	-0,12 [-15,17; 14,92]
	2	14	11,9 (16,6)	-1,64 [-11,11; 7,83]
	>2	66	19,2 (26,8)	2,23 [-2,84; 7,30]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	17,3 (25,0)	1,84 [-310,73; 314,41]
	Nein	6	22,2 (27,2)	-3,26 [-326,17; 319,65]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	17,9 (25,4)	1,54 [n.b.; n.b.]
	Nein	5	13,3 (18,3)	-0,08 [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	17,6 (25,4)	1,98 [-2,89; 6,84]
	Nein	11	18,2 (22,9)	-1,82 [-12,05; 8,40]
ECOG bei Baseline[1]	0	24	12,5 (19,2)	-2,86 [n.b.; n.b.]
	1	61	19,7 (26,8)	3,22 [n.b.; n.b.]
Geschlecht	Weiblich	38	16,7 (25,4)	4,99 [-1,08; 11,07]
	Männlich	47	18,4 (24,9)	-1,45 [-7,07; 4,17]
Lebermetastasen[1]	Ja	15	17,8 (30,5)	-0,46 [-11,94; 11,01]
	Nein	70	17,6 (23,9)	1,79 [-6,21; 9,80]
Hirnmetastasen	Ja	11	21,2 (34,2)	-2,28 [-12,97; 8,41]
	Nein	74	17,1 (23,6)	1,96 [-2,86; 6,79]
Knochenmetastasen	Ja	41	16,3 (24,9)	1,14 [-4,93; 7,21]
	Nein	44	18,9 (25,3)	1,71 [-4,08; 7,50]
QLQ-LC13 Schmerzen (Arm/Schulter)				
Alter	< 65 Jahre	43	23,3 (33,0)	2,79 [-3,44; 9,01]
	≥ 65 Jahre	42	12,7 (19,4)	-6,73 [-12,81; -0,66]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	33,3 (40,8)	-8,26 [-23,60; 7,08]
	2	14	21,4 (28,1)	-5,15 [-14,82; 4,52]
	>2	66	16,2 (26,3)	-0,93 [-6,37; 4,51]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	19,0 (28,1)	-1,71 [-10,28; 6,85]
	Nein	6	5,6 (13,6)	-6,90 [-22,32; 8,53]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	17,1 (26,5)	-1,69 [-255,54; 252,16]
	Nein	5	33,3 (40,8)	-8,21 [-278,12; 261,69]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	74	18,0 (27,1)	-1,24 [-196,37; 193,88]
	Nein	11	18,2 (31,1)	-7,37 [-210,69; 195,95]
ECOG bei Baseline[1]	0	24	18,1 (26,0)	-3,78 [n.b.; n.b.]
	1	61	18,0 (28,3)	-1,41 [n.b.; n.b.]
Geschlecht[1]	Weiblich	38	15,8 (25,4)	1,77 [-110,72; 114,27]
	Männlich	47	19,9 (29,2)	-5,32 [-116,83; 106,18]
Lebermetastasen[1]	Ja	15	15,6 (27,8)	-3,19 [-13,25; 6,87]
	Nein	70	18,6 (27,6)	-1,92 [-7,20; 3,35]
Hirnmetastasen[1]	Ja	11	21,2 (40,2)	-2,77 [-13,87; 8,33]
	Nein	74	17,6 (25,4)	-2,02 [-7,25; 3,20]
Knochenmetastasen[1]	Ja	41	17,9 (29,9)	-1,20 [n.b.; n.b.]
	Nein	44	18,2 (25,4)	-2,91 [n.b.; n.b.]
QLQ-LC13 Schmerzen (andere)				
Alter[1]	< 65 Jahre	43	31,8 (30,8)	9,09 [-25,84; 44,02]
	≥ 65 Jahre	42	27,8 (31,2)	3,51 [-29,53; 36,55]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	33,3 (33,3)	2,21 [-16,45; 20,86]
	2	14	26,2 (26,7)	6,63 [-5,13; 18,39]
	>2	66	30,3 (31,9)	6,48 [-0,00; 12,96]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	30,8 (31,5)	6,42 [0,31; 12,54]
	Nein	6	16,7 (18,3)	3,90 [-12,94; 20,73]
Vorangegangene Platinum-basierte Chemotherapie	Ja	80	29,6 (30,9)	6,49 [0,42; 12,56]
	Nein	5	33,3 (33,3)	2,21 [-16,30; 20,73]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	30,6 (31,6)	6,73 [0,49; 12,98]
	Nein	11	24,2 (26,2)	3,15 [-9,55; 15,86]
ECOG bei Baseline	0	24	22,2 (25,4)	3,70 [-5,54; 12,94]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
	1	61	32,8 (32,5)	7,30 [0,62; 13,99]
Geschlecht[1]	Weiblich	38	32,5 (31,5)	11,33 [1,86; 20,80]
	Männlich	47	27,7 (30,5)	1,99 [-7,01; 11,00]
Lebermetastasen[1]	Ja	15	35,6 (34,4)	12,29 [-251,20; 275,78]
	Nein	70	28,6 (30,2)	5,12 [-250,02; 260,27]
Hirnmetastasen	Ja	11	42,4 (39,7)	-4,53 [-17,83; 8,77]
	Nein	74	27,9 (29,2)	7,59 [1,50; 13,69]
Knochenmetastasen[1]	Ja	41	35,0 (34,1)	7,64 [-0,07; 15,35]
	Nein	44	25,0 (27,0)	4,99 [-2,31; 12,28]
QLQ-LC13 Schmerzen (Thorax)				
Alter	< 65 Jahre	43	17,1 (25,6)	2,17 [-2,95; 7,29]
	≥ 65 Jahre	42	13,5 (20,9)	-4,60 [-9,58; 0,37]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	13,3 (18,3)	-7,14 [-182727,00; 182713,00]
	2	14	14,3 (25,2)	0,24 [-182720,00; 182720,00]
	>2	66	15,7 (23,5)	-1,15 [-182721,00; 182719,00]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	16,5 (23,8)	-0,94 [-43560,00; 43559,00]
	Nein	6	0,0 (0,0)	-5,53 [-43565,00; 43554,00]
Vorangegangene Platinum-basierte Chemotherapie	Ja	80	15,4 (23,7)	-0,92 [-5,11; 3,28]
	Nein	5	13,3 (18,3)	-7,14 [-19,56; 5,27]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	74	16,7 (24,2)	-0,49 [-5,83; 4,86]
	Nein	11	6,1 (13,5)	-6,29 [-15,43; 2,86]
ECOG bei Baseline	0	24	11,1 (18,8)	-2,42 [-8,72; 3,88]
	1	61	16,9 (24,8)	-0,83 [-5,43; 3,76]
Geschlecht[1]	Weiblich	38	12,3 (23,8)	-1,09 [-57746,00; 57744,00]
	Männlich	47	17,7 (22,9)	-1,48 [-57747,00; 57744,00]
Lebermetastasen[1]	Ja	15	17,8 (21,3)	3,45 [-4,70; 11,61]
	Nein	70	14,8 (23,8)	-2,18 [-6,46; 2,10]
Hirnmetastasen	Ja	11	18,2 (22,9)	-2,49 [-11,57; 6,59]
	Nein	74	14,9 (23,5)	-1,15 [-5,42; 3,12]
Knochenmetastasen[1]	Ja	41	19,5 (25,8)	-2,40 [-7,67; 2,88]
	Nein	44	11,4 (20,3)	-0,39 [-5,40; 4,62]
QLQ-LC13 Wirksamkeit der Schmerzmedikation				
Alter	< 65 Jahre	25	2,7 (0,6)	-0,02 [-0,26; 0,21]
	≥ 65 Jahre	20	2,7 (0,6)	0,25 [0,01; 0,49]
Vorangegangene Linien von Anti-Krebs Therapien	1	3	3,0 (1,0)	0,47 [-0,10; 1,05]
	2	7	2,9 (0,7)	0,15 [-0,25; 0,55]
	>2	35	2,6 (0,6)	0,06 [-0,15; 0,27]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	43	2,7 (0,6)	0,12 [-0,12; 0,36]
	Nein	2	2,5 (0,7)	-0,01 [-0,73; 0,70]
Vorangegangene Platinum-basierte Chemotherapie	Ja	42	2,6 (0,6)	0,07 [-0,12; 0,27]
	Nein	3	3,0 (1,0)	0,47 [-0,10; 1,04]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	40	2,7 (0,6)	0,09 [-0,12; 0,29]
	Nein	5	2,8 (0,8)	0,27 [-0,18; 0,71]
ECOG bei Baseline[1]	0	10	2,6 (0,5)	-0,15 [-0,49; 0,19]
	1	35	2,7 (0,6)	0,18 [-0,02; 0,38]
Geschlecht	Weiblich	25	2,7 (0,7)	0,18 [-0,05; 0,42]
	Männlich	20	2,7 (0,5)	0,02 [-0,24; 0,28]
Lebermetastasen[1]	Ja	7	2,9 (0,4)	-0,20 [-0,62; 0,23]
	Nein	38	2,6 (0,6)	0,16 [-0,04; 0,35]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Hirnmetastasen	Ja	5	2,8 (0,8)	0,42 [-0,05; 0,89]
	Nein	40	2,7 (0,6)	0,07 [-0,13; 0,27]
Knochenmetastasen	Ja	26	2,7 (0,6)	0,20 [-0,04; 0,44]
	Nein	19	2,6 (0,6)	0,01 [-0,25; 0,26]
QLQ-LC13 Wunder Mund				
Alter[1]	< 65 Jahre	43	8,5 (20,7)	0,72 [-2,62; 4,06]
	≥ 65 Jahre	42	1,6 (7,2)	-0,59 [-3,78; 2,60]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	6,7 (14,9)	4,30 [-2,60; 11,21]
	2	14	9,5 (27,5)	-3,43 [-8,07; 1,22]
	>2	66	4,0 (12,4)	0,38 [-2,50; 3,26]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	5,5 (16,4)	0,30 [-2,49; 3,09]
	Nein	6	0,0 (0,0)	-3,22 [-9,56; 3,13]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	5,0 (16,0)	-0,30 [-3,08; 2,48]
	Nein	5	6,7 (14,9)	4,35 [-2,62; 11,33]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	74	5,4 (16,6)	-0,02 [-195,24; 195,20]
	Nein	11	3,0 (10,1)	0,17 [-196,77; 197,11]
ECOG bei Baseline[1]	0	24	1,4 (6,8)	-0,30 [-4,12; 3,51]
	1	61	6,6 (18,1)	0,15 [-2,85; 3,16]
Geschlecht[1]	Weiblich	38	7,9 (21,1)	1,88 [-1,43; 5,18]
	Männlich	47	2,8 (9,4)	-1,53 [-4,66; 1,61]
Lebermetastasen	Ja	15	4,4 (11,7)	0,57 [-4,46; 5,60]
	Nein	70	5,2 (16,7)	-0,08 [-2,91; 2,75]
Hirnmetastasen	Ja	11	9,1 (15,6)	0,18 [-5,23; 5,59]
	Nein	74	4,5 (15,9)	-0,01 [-2,83; 2,81]
Knochenmetastasen[1]	Ja	41	7,3 (20,4)	-0,22 [-3,56; 3,13]
	Nein	44	3,0 (9,7)	0,20 [-2,98; 3,37]
QLQ-LC13 Bluthusten				
Alter	< 65 Jahre	43	3,9 (13,0)	-0,81 [-3,74; 2,13]
	≥ 65 Jahre	42	2,4 (11,4)	-0,50 [-3,42; 2,42]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	6,7 (14,9)	-3,36 [-11,33; 4,61]
	2	14	4,8 (17,8)	-0,31 [-5,17; 4,56]
	>2	66	2,5 (10,6)	-0,51 [-2,95; 1,93]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	79	3,4 (12,6)	-0,56 [-2,82; 1,70]
	Nein	6	0,0 (0,0)	-1,80 [-9,02; 5,41]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	80	2,9 (12,1)	-0,48 [-3,65; 2,70]
	Nein	5	6,7 (14,9)	-3,37 [-11,58; 4,85]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	3,2 (12,5)	-0,36 [-2,68; 1,95]
	Nein	11	3,0 (10,1)	-2,50 [-7,85; 2,86]
ECOG bei Baseline	0	24	5,6 (16,1)	-2,72 [-6,45; 1,02]
	1	61	2,2 (10,3)	0,18 [-2,32; 2,67]
Geschlecht	Weiblich	38	3,5 (12,9)	1,36 [-1,65; 4,36]
	Männlich	47	2,8 (11,7)	-2,30 [-5,04; 0,45]
Lebermetastasen	Ja	15	4,4 (17,2)	0,83 [-4,05; 5,71]
	Nein	70	2,9 (11,0)	-0,95 [-3,40; 1,51]
Hirnmetastasen	Ja	11	9,1 (21,6)	1,30 [-4,26; 6,87]
	Nein	74	2,3 (10,1)	-0,93 [-3,24; 1,37]
Knochenmetastasen[1]	Ja	41	1,6 (10,4)	-0,89 [-3,88; 2,10]
	Nein	44	4,5 (13,6)	-0,43 [-3,31; 2,44]
1) Konvergenzkriterien erfüllt aber finale Hessematrix ist nicht positiv definit.				
KI = Konfidenzintervall; LS-Mean = Kleinste Quadrate Mittelwert (least squares mean); n.b. = nicht berechenbar; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer 13; Stdabw. = Standardabweichung				

1.5.3 EQ5D-VAS

Tabelle 1-3: Ergebnisse der MMRM-Subgruppenanalysen für den Endpunkt "EQ-5D VAS, Veränderung zu Baseline" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
EQ-5D VAS				
Alter[1]	< 65 Jahre	43	65,2 (19,5)	0,06 [-11,92; 12,05]
	≥ 65 Jahre	42	75,0 (13,9)	-2,01 [-13,93; 9,91]
Vorangegangene Linien von Anti-Krebs Therapien[2]	1	5	74,2 (23,0)	n.b.
	2	14	66,6 (23,0)	n.b.
	>2	66	70,5 (16,0)	n.b.
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	79	69,7 (17,9)	-0,46 [-105,38; 104,46]
	Nein	6	75,2 (13,0)	-7,54 [-129,23; 114,16]
Vorangegangene Platinum-basierte Chemotherapie	Ja	80	69,8 (17,3)	-1,28 [-5,02; 2,45]
	Nein	5	74,2 (23,0)	2,79 [-8,71; 14,30]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	74	69,4 (17,7)	-0,71 [-4,55; 3,13]
	Nein	11	74,7 (17,2)	-2,90 [-10,81; 5,02]
ECOG bei Baseline	0	24	73,6 (16,9)	1,68 [-4,02; 7,38]
	1	61	68,7 (17,8)	-2,17 [-6,25; 1,92]
Geschlecht[1]	Weiblich	38	70,6 (19,0)	-1,27 [-6,49; 3,95]
	Männlich	47	69,6 (16,6)	-0,82 [-5,72; 4,07]
Lebermetastasen[1]	Ja	15	68,7 (18,6)	-4,27 [-13,31; 4,78]
	Nein	70	70,4 (17,5)	-0,43 [-6,88; 6,02]
Hirnmetastasen	Ja	11	66,5 (24,2)	4,56 [-3,69; 12,80]
	Nein	74	70,6 (16,5)	-1,79 [-5,56; 1,99]
Knochenmetastasen[2]	Ja	41	68,0 (17,2)	n.b.
	Nein	44	72,0 (18,0)	n.b.

1) Konvergenzkriterien erfüllt aber finale Hessematrix ist nicht positiv definit.
2) Modellierung wegen unendlicher Likelihood angehalten.

KI = Konfidenzintervall; LS-Mean = Kleinste Quadrate Mittelwert (least squares mean); n.b. = nicht berechenbar; Stdabw. = Standardabweichung; VAS = Visuelle Analogskala

1.5.4 PG-IC

Tabelle 1-4: Ergebnisse der MMRM-Subgruppenanalysen für den Endpunkt "PG-IC, Veränderung zu Baseline" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib
Subgruppe	**Kategorie**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
PG-IC Husten		
Alter[1]	< 65 Jahre	1,61 [-1064,35; 1067,58]
	≥ 65 Jahre	1,54 [-1064,42; 1067,51]
Vorangegangene Linien von Anti-Krebs Therapien	1	1,56 [0,62; 2,50]
	2	1,45 [0,72; 2,17]
	>2	1,60 [1,22; 1,98]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	1,62 [1,26; 1,97]
	Nein	0,97 [-0,04; 1,99]
Vorangegangene Platinum-basierte Chemotherapie	Ja	1,55 [1,19; 1,92]
	Nein	1,71 [0,94; 2,48]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	1,60 [1,23; 1,98]
	Nein	1,45 [0,81; 2,09]
ECOG bei Baseline	0	1,47 [0,97; 1,97]
	1	1,63 [1,22; 2,04]
Geschlecht	Weiblich	1,49 [1,04; 1,94]
	Männlich	1,65 [1,21; 2,08]
Lebermetastasen	Ja	1,32 [0,51; 2,13]
	Nein	1,61 [1,24; 1,97]
Hirnmetastasen	Ja	1,83 [1,15; 2,52]
	Nein	1,52 [1,15; 1,89]
Knochenmetastasen	Ja	1,50 [1,04; 1,97]
	Nein	1,63 [1,20; 2,05]
PG-IC Brustschmerz		
Alter[1]	< 65 Jahre	2,25 [1,83; 2,67]
	≥ 65 Jahre	1,87 [1,49; 2,25]
Vorangegangene Linien von Anti-Krebs Therapien	1	2,23 [1,38; 3,08]
	2	2,02 [1,36; 2,67]
	>2	2,01 [1,65; 2,37]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	2,07 [1,74; 2,41]
	Nein	1,47 [0,55; 2,38]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	1,97 [1,63; 2,31]
	Nein	2,46 [1,77; 3,14]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	2,01 [1,66; 2,36]
	Nein	2,11 [1,53; 2,69]
ECOG bei Baseline	0	2,09 [1,63; 2,55]
	1	1,99 [1,61; 2,37]
Geschlecht	Weiblich	2,12 [1,71; 2,54]
	Männlich	1,95 [1,55; 2,35]
Lebermetastasen	Ja	1,97 [1,23; 2,71]
	Nein	2,04 [1,70; 2,38]
Hirnmetastasen	Ja	2,17 [1,54; 2,80]
	Nein	2,00 [1,66; 2,35]
Knochenmetastasen	Ja	1,67 [1,27; 2,08]
	Nein	2,31 [1,94; 2,68]
PG-IC Kurzatmigkeit		
Alter	< 65 Jahre	2,37 [1,91; 2,83]
	≥ 65 Jahre	1,89 [1,47; 2,30]

		Sotorasib
Subgruppe	**Kategorie**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Linien von Anti-Krebs Therapien	1	2,28 [1,37; 3,19]
	2	1,96 [1,25; 2,67]
	>2	2,09 [1,70; 2,49]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	2,14 [1,77; 2,50]
	Nein	1,51 [0,54; 2,48]
Vorangegangene Platinum-basierte Chemotherapie	Ja	2,06 [1,68; 2,43]
	Nein	2,32 [1,58; 3,07]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	2,10 [1,72; 2,49]
	Nein	2,04 [1,41; 2,66]
ECOG bei Baseline	0	2,06 [1,55; 2,56]
	1	2,11 [1,69; 2,53]
Geschlecht	Weiblich	2,28 [1,83; 2,73]
	Männlich	1,93 [1,50; 2,36]
Lebermetastasen	Ja	1,94 [1,14; 2,75]
	Nein	2,11 [1,73; 2,48]
Hirnmetastasen	Ja	2,20 [1,52; 2,88]
	Nein	2,07 [1,69; 2,45]
Knochenmetastasen	Ja	1,83 [1,37; 2,29]
	Nein	2,29 [1,87; 2,70]
1) Konvergenzkriterien erfüllt aber finale Hessematrix ist nicht positiv definit.		
KI = Konfidenzintervall; LS-Mean = Kleinste Quadrate Mittelwert (least squares mean); PG-IC = Patienten-Eindruck der Veränderung; Stdabw. = Standardabweichung		

1.5.5 PRO-CTCAE

Tabelle 1-6: Ergebnisse der MMRM-Subgruppenanalysen für den Endpunkt "PRO-CTCAE, Veränderung zu Baseline" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
PRO-CTCAE, Schweregrad von Wunden oder offenen Stellen in Mund oder Hals				
Alter	< 65 Jahre	44	1,2 (0,6)	0,04 [-0,07; 0,15]
	≥ 65 Jahre	43	1,0 (0,2)	0,10 [-0,01; 0,20]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	1,2 (0,4)	0,20 [-0,02; 0,41]
	2	14	1,3 (0,7)	-0,01 [-0,16; 0,13]
	>2	68	1,1 (0,4)	0,08 [-0,02; 0,17]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	80	1,2 (0,5)	0,08 [-0,01; 0,17]
	Nein	7	1,0 (0,0)	-0,01 [-0,19; 0,18]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	1,1 (0,4)	0,06 [-0,03; 0,16]
	Nein	5	1,2 (0,4)	0,20 [-0,02; 0,41]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	1,1 (0,5)	0,07 [n.b.; n.b.]
	Nein	12	1,1 (0,3)	0,08 [n.b.; n.b.]
ECOG bei Baseline[1]	0	25	1,1 (0,3)	0,04 [-0,12; 0,20]
	1	62	1,2 (0,5)	0,09 [-0,06; 0,23]
Geschlecht	Weiblich	39	1,2 (0,5)	0,08 [-0,03; 0,19]
	Männlich	48	1,1 (0,4)	0,07 [-0,04; 0,17]
Lebermetastasen[1]	Ja	15	1,0 (0,0)	0,04 [-0,12; 0,21]
	Nein	72	1,2 (0,5)	0,08 [-0,02; 0,17]
Hirnmetastasen[1]	Ja	11	1,1 (0,3)	0,03 [-0,14; 0,20]
	Nein	76	1,1 (0,5)	0,08 [-0,02; 0,17]
Knochenmetastasen	Ja	41	1,2 (0,6)	0,09 [-0,02; 0,20]
	Nein	46	1,1 (0,3)	0,06 [-0,04; 0,16]
PRO-CTCAE, Schweregrad von rissigen Mundwinkeln				
Alter	< 65 Jahre	44	1,2 (0,6)	-0,03 [-0,12; 0,06]
	≥ 65 Jahre	43	1,1 (0,3)	-0,02 [-0,11; 0,06]
Vorangegangene Linien von Anti-Krebs Therapien[2]	1	5	1,2 (0,4)	n.b.
	2	14	1,3 (0,6)	n.b.
	>2	68	1,1 (0,4)	n.b.
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	80	1,2 (0,5)	-0,02 [-0,10; 0,05]
	Nein	7	1,0 (0,0)	-0,06 [-0,23; 0,10]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	1,1 (0,4)	-0,03 [n.b.; n.b.]
	Nein	5	1,2 (0,4)	0,08 [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	1,2 (0,5)	-0,03 [-0,11; 0,04]
	Nein	12	1,1 (0,3)	-0,00 [-0,14; 0,13]
ECOG bei Baseline	0	25	1,1 (0,4)	-0,04 [-0,14; 0,06]
	1	62	1,2 (0,5)	-0,02 [-0,10; 0,06]
Geschlecht	Weiblich	39	1,3 (0,6)	-0,01 [-0,10; 0,08]
	Männlich	48	1,1 (0,2)	-0,04 [-0,12; 0,04]
Lebermetastasen	Ja	15	1,1 (0,3)	-0,04 [-0,17; 0,10]
	Nein	72	1,2 (0,5)	-0,02 [-0,10; 0,05]
Hirnmetastasen	Ja	11	1,1 (0,3)	-0,03 [-0,18; 0,11]
	Nein	76	1,2 (0,5)	-0,03 [-0,10; 0,05]
Knochenmetastasen[1]	Ja	41	1,2 (0,5)	-0,03 [-0,12; 0,05]
	Nein	46	1,1 (0,4)	-0,02 [-0,10; 0,06]
PRO-CTCAE, Schweregrad von Taubheitsgefühl in Händen oder Füßen				

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Alter	< 65 Jahre	44	1,7 (1,0)	-0,12 [-0,31; 0,07]
	≥ 65 Jahre	43	1,7 (0,9)	-0,02 [-0,20; 0,17]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	1,2 (0,4)	0,13 [-0,34; 0,60]
	2	14	1,6 (0,9)	-0,14 [-0,44; 0,15]
	>2	68	1,7 (1,0)	-0,07 [-0,23; 0,09]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	80	1,7 (1,0)	-0,07 [-0,23; 0,08]
	Nein	7	1,7 (0,8)	0,01 [-0,38; 0,40]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	1,7 (1,0)	-0,08 [-0,28; 0,12]
	Nein	5	1,2 (0,4)	0,13 [-0,35; 0,61]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	1,7 (1,0)	-0,09 [n.b.; n.b.]
	Nein	12	1,5 (0,7)	0,06 [n.b.; n.b.]
ECOG bei Baseline[1]	0	25	1,4 (0,7)	-0,15 [-0,42; 0,12]
	1	62	1,7 (1,0)	-0,03 [-0,25; 0,19]
Geschlecht[1]	Weiblich	39	1,5 (0,9)	0,06 [-0,13; 0,25]
	Männlich	48	1,8 (1,0)	-0,17 [-0,35; 0,00]
Lebermetastasen[1]	Ja	15	2,1 (1,5)	-0,40 [-0,74; -0,06]
	Nein	72	1,6 (0,8)	-0,01 [-0,23; 0,22]
Hirnmetastasen[1]	Ja	11	1,7 (1,4)	-0,18 [-0,52; 0,15]
	Nein	76	1,6 (0,9)	-0,05 [-0,20; 0,10]
Knochenmetastasen[1]	Ja	41	1,7 (1,1)	-0,03 [-0,23; 0,16]
	Nein	46	1,6 (0,9)	-0,09 [-0,28; 0,09]
PRO-CTCAE, Schweregrad von juckender Haut				
Alter[1]	< 65 Jahre	44	1,4 (0,7)	0,05 [n.b.; n.b.]
	≥ 65 Jahre	43	1,3 (0,6)	0,15 [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	1,4 (0,5)	0,18 [-0,34; 0,70]
	2	14	1,3 (0,5)	0,23 [-0,09; 0,56]
	>2	68	1,4 (0,7)	0,07 [-0,10; 0,24]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	80	1,4 (0,7)	0,12 [-0,05; 0,28]
	Nein	7	1,3 (0,5)	-0,05 [-0,49; 0,38]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	1,4 (0,7)	0,10 [-1,12; 1,32]
	Nein	5	1,4 (0,5)	0,18 [-3,17; 3,54]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	1,4 (0,7)	0,11 [-0,07; 0,29]
	Nein	12	1,3 (0,5)	0,04 [-0,30; 0,39]
ECOG bei Baseline	0	25	1,4 (0,8)	0,03 [-0,23; 0,28]
	1	62	1,3 (0,6)	0,14 [-0,04; 0,32]
Geschlecht	Weiblich	39	1,4 (0,6)	0,11 [-0,11; 0,32]
	Männlich	48	1,3 (0,7)	0,10 [-0,10; 0,30]
Lebermetastasen	Ja	15	1,2 (0,4)	-0,23 [-0,56; 0,09]
	Nein	72	1,4 (0,7)	0,16 [-0,00; 0,33]
Hirnmetastasen	Ja	11	1,4 (0,7)	-0,15 [-0,52; 0,21]
	Nein	76	1,4 (0,6)	0,14 [-0,03; 0,30]
Knochenmetastasen[1]	Ja	41	1,4 (0,7)	0,20 [-0,00; 0,41]
	Nein	46	1,3 (0,6)	0,02 [-0,18; 0,21]
PRO-CTCAE, Schweregrad von Schmerzen				
Alter[1]	< 65 Jahre	33	3,1 (0,9)	0,22 [-0,09; 0,53]
	≥ 65 Jahre	26	2,8 (0,7)	-0,11 [-0,44; 0,22]
Vorangegangene Linien von Anti-Krebs Therapien	1	3	3,7 (1,2)	-0,35 [-1,19; 0,49]
	2	9	3,0 (0,9)	-0,06 [-0,58; 0,45]
	>2	47	2,9 (0,8)	0,13 [-0,14; 0,40]
	Ja	55	3,0 (0,9)	0,11 [-0,19; 0,40]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Nein	4	2,8 (0,5)	-0,32 [-1,04; 0,40]
Vorangegangene Platinum-basierte Chemotherapie	Ja	56	2,9 (0,8)	0,10 [-0,16; 0,36]
	Nein	3	3,7 (1,2)	-0,35 [-1,19; 0,49]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	52	2,9 (0,8)	0,14 [-0,12; 0,40]
	Nein	7	3,1 (0,9)	-0,32 [-0,86; 0,21]
ECOG bei Baseline[1]	0	16	2,9 (1,0)	-0,13 [-0,55; 0,28]
	1	43	3,0 (0,8)	0,15 [-0,15; 0,44]
Geschlecht	Weiblich	26	3,0 (0,9)	0,27 [-0,05; 0,60]
	Männlich	33	3,0 (0,8)	-0,09 [-0,39; 0,21]
Lebermetastasen[1]	Ja	10	3,0 (0,9)	0,51 [-0,38; 1,40]
	Nein	49	3,0 (0,8)	0,01 [-0,74; 0,75]
Hirnmetastasen[1]	Ja	6	3,3 (1,2)	0,22 [-0,49; 0,92]
	Nein	53	2,9 (0,8)	0,06 [-0,27; 0,38]
Knochenmetastasen	Ja	30	3,2 (0,8)	0,14 [-0,19; 0,47]
	Nein	29	2,8 (0,9)	0,01 [-0,31; 0,33]
PRO-CTCAE, Schweregrad von Muskelschmerzen				
Alter[1]	< 65 Jahre	25	2,9 (0,8)	-0,02 [-0,34; 0,30]
	≥ 65 Jahre	23	2,4 (0,7)	-0,30 [-0,62; 0,01]
Vorangegangene Linien von Anti-Krebs Therapien	1	3	3,3 (0,6)	-0,18 [-0,92; 0,56]
	2	11	2,8 (0,9)	-0,21 [-0,63; 0,20]
	>2	34	2,6 (0,8)	-0,15 [-0,41; 0,11]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	43	2,7 (0,8)	-0,14 [-0,38; 0,10]
	Nein	5	2,4 (0,5)	-0,33 [-0,90; 0,23]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	45	2,6 (0,8)	-0,16 [-0,43; 0,11]
	Nein	3	3,3 (0,6)	-0,18 [-0,92; 0,56]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	40	2,7 (0,8)	-0,14 [-0,38; 0,11]
	Nein	8	2,8 (0,7)	-0,27 [-0,72; 0,18]
ECOG bei Baseline[1]	0	14	2,6 (0,7)	-0,19 [-0,61; 0,22]
	1	34	2,7 (0,8)	-0,15 [-0,47; 0,17]
Geschlecht	Weiblich	22	2,8 (1,0)	-0,09 [-0,39; 0,22]
	Männlich	26	2,5 (0,6)	-0,23 [-0,51; 0,05]
Lebermetastasen	Ja	8	2,9 (0,6)	0,01 [-0,48; 0,50]
	Nein	40	2,6 (0,8)	-0,19 [-0,43; 0,05]
Hirnmetastasen	Ja	7	2,7 (1,0)	-0,14 [-0,66; 0,39]
	Nein	41	2,7 (0,8)	-0,17 [-0,40; 0,07]
Knochenmetastasen	Ja	25	2,8 (0,7)	-0,15 [-0,45; 0,14]
	Nein	23	2,5 (0,9)	-0,17 [-0,47; 0,13]
PRO-CTCAE, Schweregrad von Gelenkschmerzen				
Alter	< 65 Jahre	24	2,7 (0,8)	0,05 [-0,28; 0,38]
	≥ 65 Jahre	16	2,6 (0,9)	-0,07 [-0,42; 0,28]
Vorangegangene Linien von Anti-Krebs Therapien	1	3	3,7 (1,2)	-0,20 [-1,03; 0,63]
	2	8	2,5 (0,5)	-0,15 [-0,65; 0,35]
	>2	29	2,6 (0,8)	0,06 [-0,24; 0,36]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	38	2,7 (0,8)	0,03 [-0,24; 0,29]
	Nein	2	2,0 (0,0)	-0,42 [-1,33; 0,49]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	37	2,6 (0,8)	0,01 [-0,62; 0,64]
	Nein	3	3,7 (1,2)	-0,21 [-1,20; 0,79]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	35	2,6 (0,8)	0,04 [-0,23; 0,32]
	Nein	5	3,0 (1,2)	-0,28 [-0,88; 0,31]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
ECOG bei Baseline	0	14	2,6 (1,0)	-0,13 [-0,54; 0,28]
	1	26	2,7 (0,7)	0,05 [-0,25; 0,35]
Geschlecht	Weiblich	16	2,8 (0,8)	0,12 [-0,25; 0,49]
	Männlich	24	2,5 (0,8)	-0,09 [-0,41; 0,23]
Lebermetastasen[1]	Ja	9	2,4 (0,9)	-0,09 [-0,65; 0,47]
	Nein	31	2,7 (0,8)	0,01 [-0,35; 0,38]
Hirnmetastasen	Ja	5	3,4 (0,5)	-0,01 [-0,70; 0,68]
	Nein	35	2,5 (0,8)	-0,01 [-0,28; 0,27]
Knochenmetastasen	Ja	23	2,7 (0,8)	-0,06 [-0,39; 0,28]
	Nein	17	2,6 (0,9)	0,05 [-0,30; 0,41]
PRO-CTCAE, Beeinträchtigung durch Wunden oder offene Stellen in Mund oder Hals				
Alter	< 65 Jahre	4	1,8 (1,0)	0,01 [-1,12; 1,13]
	≥ 65 Jahre	2	1,0 (0,0)	0,46 [-1,29; 2,21]
Vorangegangene Linien von Anti-Krebs Therapien	1	1	1,0 (n.b.)	0,24 [-3,40; 3,88]
	2	1	3,0 (n.b.)	-1,00 [-7,12; 5,12]
	>2	4	1,3 (0,5)	0,27 [-1,38; 1,92]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[2]	Ja	6	1,5 (0,8)	n.b.
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	5	1,6 (0,9)	0,25 [-0,76; 1,26]
	Nein	1	1,0 (n.b.)	0,14 [-1,98; 2,26]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	5	1,6 (0,9)	0,25 [-0,76; 1,26]
	Nein	1	1,0 (n.b.)	0,14 [-1,98; 2,26]
ECOG bei Baseline	0	2	1,0 (0,0)	0,54 [-0,98; 2,06]
	1	4	1,8 (1,0)	0,05 [-1,46; 1,57]
Geschlecht[1]	Weiblich	2	1,5 (0,7)	0,34 [-1,17; 1,85]
	Männlich	4	1,5 (1,0)	0,08 [-1,16; 1,33]
Lebermetastasen[2]	Nein	6	1,5 (0,8)	n.b.
Hirnmetastasen[1]	Ja	1	2,0 (n.b.)	0,76 [-0,99; 2,51]
	Nein	5	1,4 (0,9)	0,10 [-3,59; 3,78]
Knochenmetastasen	Ja	2	2,0 (1,4)	0,03 [-1,88; 1,94]
	Nein	4	1,3 (0,5)	0,29 [-0,80; 1,37]
PRO-CTCAE, Beeinträchtigung durch Taubheitsgefühl in Händen oder Füßen				
Alter[1]	< 65 Jahre	17	2,1 (1,3)	-0,04 [-0,53; 0,45]
	≥ 65 Jahre	17	1,5 (0,8)	0,06 [-0,41; 0,54]
Vorangegangene Linien von Anti-Krebs Therapien	1	1	1,0 (n.b.)	0,31 [-0,99; 1,60]
	2	6	1,7 (1,2)	-0,07 [-0,65; 0,51]
	>2	27	1,9 (1,1)	0,02 [-0,27; 0,30]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	30	1,8 (1,1)	0,02 [-0,26; 0,30]
	Nein	4	1,8 (1,0)	-0,02 [-0,66; 0,62]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	33	1,8 (1,1)	0,01 [-0,37; 0,38]
	Nein	1	1,0 (n.b.)	0,31 [-0,99; 1,61]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	29	1,9 (1,1)	0,01 [-0,37; 0,39]
	Nein	5	1,6 (0,9)	0,05 [-0,58; 0,68]
ECOG bei Baseline[1]	0	7	1,7 (0,8)	0,18 [-0,36; 0,72]
	1	27	1,9 (1,2)	-0,02 [-0,32; 0,27]
Geschlecht	Weiblich	12	1,8 (1,0)	0,21 [-0,17; 0,59]
	Männlich	22	1,8 (1,1)	-0,10 [-0,40; 0,21]
Lebermetastasen	Ja	5	3,0 (1,4)	-0,27 [-1,00; 0,46]
	Nein	29	1,6 (0,9)	0,05 [-0,22; 0,32]
Hirnmetastasen	Ja	3	2,7 (2,1)	-0,56 [-1,41; 0,29]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
	Nein	31	1,7 (1,0)	0,06 [-0,20; 0,32]
Knochenmetastasen	Ja	16	1,8 (1,2)	0,08 [-0,28; 0,45]
	Nein	18	1,8 (1,0)	-0,04 [-0,37; 0,29]
PRO-CTCAE, Beeinträchtigung durch Schmerzen				
Alter	< 65 Jahre	33	2,7 (1,2)	0,35 [-0,01; 0,72]
	≥ 65 Jahre	26	2,2 (0,9)	0,04 [-0,35; 0,44]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	3	3,3 (2,1)	-0,43 [-1,46; 0,59]
	2	9	2,6 (1,5)	0,01 [-0,62; 0,64]
	>2	47	2,4 (0,9)	0,31 [-0,03; 0,64]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	55	2,5 (1,1)	0,26 [-0,05; 0,56]
	Nein	4	2,0 (0,8)	-0,24 [-1,11; 0,64]
Vorangegangene Platinum-basierte Chemotherapie	Ja	56	2,4 (1,0)	0,26 [-0,04; 0,55]
	Nein	3	3,3 (2,1)	-0,43 [-1,45; 0,59]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	52	2,5 (1,1)	0,30 [-0,00; 0,61]
	Nein	7	2,6 (1,5)	-0,31 [-0,96; 0,35]
ECOG bei Baseline	0	16	2,3 (1,1)	-0,03 [-0,51; 0,46]
	1	43	2,6 (1,1)	0,30 [-0,02; 0,63]
Geschlecht	Weiblich	26	2,8 (1,3)	0,40 [0,00; 0,80]
	Männlich	33	2,2 (0,9)	0,06 [-0,30; 0,43]
Lebermetastasen	Ja	10	2,5 (1,0)	0,40 [-0,24; 1,05]
	Nein	49	2,5 (1,1)	0,18 [-0,12; 0,49]
Hirnmetastasen	Ja	6	3,2 (1,0)	0,21 [-0,60; 1,03]
	Nein	53	2,4 (1,1)	0,21 [-0,09; 0,52]
Knochenmetastasen	Ja	30	2,7 (1,1)	0,23 [-0,15; 0,62]
	Nein	29	2,3 (1,1)	0,20 [-0,18; 0,57]
PRO-CTCAE, Beeinträchtigung durch Muskelschmerzen				
Alter[1]	< 65 Jahre	25	2,3 (1,0)	0,23 [-2,11; 2,56]
	≥ 65 Jahre	22	2,0 (1,0)	-0,25 [-2,63; 2,13]
Vorangegangene Linien von Anti-Krebs Therapien	1	3	2,7 (1,5)	-0,10 [-1,09; 0,89]
	2	11	2,1 (1,0)	-0,06 [-0,60; 0,49]
	>2	33	2,2 (0,9)	0,02 [-0,31; 0,36]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	42	2,3 (0,9)	0,01 [-0,29; 0,31]
	Nein	5	1,4 (0,9)	-0,11 [-0,89; 0,68]
Vorangegangene Platinum-basierte Chemotherapie	Ja	44	2,1 (0,9)	0,00 [-0,29; 0,30]
	Nein	3	2,7 (1,5)	-0,10 [-1,07; 0,88]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	39	2,2 (0,9)	0,02 [-1,95; 1,99]
	Nein	8	1,9 (1,2)	-0,10 [-3,93; 3,73]
ECOG bei Baseline	0	14	1,8 (1,0)	-0,11 [-0,59; 0,38]
	1	33	2,3 (0,9)	0,04 [-0,29; 0,37]
Geschlecht[1]	Weiblich	21	2,4 (1,0)	0,05 [-0,38; 0,48]
	Männlich	26	2,0 (0,9)	-0,05 [-0,44; 0,35]
Lebermetastasen	Ja	8	2,4 (0,5)	0,21 [-0,42; 0,84]
	Nein	39	2,1 (1,0)	-0,04 [-0,35; 0,26]
Hirnmetastasen[1]	Ja	7	2,4 (1,0)	0,02 [-0,81; 0,85]
	Nein	40	2,1 (1,0)	-0,01 [-0,56; 0,55]
Knochenmetastasen[1]	Ja	25	2,2 (0,9)	0,04 [-2,37; 2,46]
	Nein	22	2,1 (1,1)	-0,05 [-2,56; 2,45]
PRO-CTCAE, Beeinträchtigung durch Gelenkschmerzen				
Alter[1]	< 65 Jahre	22	2,1 (1,0)	0,21 [-43917,00; 43918,00]
	≥ 65 Jahre	14	2,4 (1,0)	0,01 [-43918,00; 43918,00]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	3	3,0 (2,0)	-0,17 [-1,19; 0,84]
	2	8	1,8 (0,9)	0,14 [-0,53; 0,81]
	>2	25	2,3 (0,8)	0,15 [-0,29; 0,58]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	34	2,3 (1,0)	0,12 [-0,21; 0,46]
	Nein	2	1,5 (0,7)	0,08 [-1,07; 1,22]
Vorangegangene Platinum-basierte Chemotherapie	Ja	33	2,2 (0,9)	0,15 [-0,19; 0,48]
	Nein	3	3,0 (2,0)	-0,17 [-1,15; 0,81]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	31	2,2 (0,9)	0,15 [-0,19; 0,50]
	Nein	5	2,4 (1,7)	-0,06 [-0,79; 0,68]
ECOG bei Baseline[1]	0	13	1,8 (1,2)	-0,12 [-0,63; 0,39]
	1	23	2,4 (0,8)	0,24 [-0,13; 0,62]
Geschlecht[1]	Weiblich	16	2,5 (1,0)	0,30 [-0,15; 0,74]
	Männlich	20	2,0 (0,9)	-0,03 [-0,44; 0,38]
Lebermetastasen	Ja	7	2,0 (0,6)	0,08 [-0,58; 0,75]
	Nein	29	2,3 (1,1)	0,13 [-0,22; 0,48]
Hirnmetastasen	Ja	4	2,8 (1,0)	0,48 [-0,36; 1,32]
	Nein	32	2,2 (1,0)	0,08 [-0,26; 0,41]
Knochenmetastasen	Ja	20	2,1 (0,9)	0,12 [-0,30; 0,54]
	Nein	16	2,4 (1,1)	0,12 [-0,33; 0,56]
PRO-CTCAE, Schmerzfrequenz				
Alter[1]	< 65 Jahre	44	2,8 (1,3)	0,12 [-1,78; 2,02]
	≥ 65 Jahre	43	2,3 (1,3)	-0,10 [-1,96; 1,76]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	3,0 (2,0)	-0,30 [-33498,00; 33497,00]
	2	14	2,3 (1,3)	0,13 [-33497,00; 33498,00]
	>2	68	2,6 (1,3)	0,00 [-33498,00; 33498,00]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	80	2,6 (1,4)	0,01 [-0,23; 0,25]
	Nein	7	2,1 (1,1)	-0,02 [-0,64; 0,60]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	2,5 (1,3)	0,02 [-0,21; 0,26]
	Nein	5	3,0 (2,0)	-0,30 [-1,03; 0,44]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	2,6 (1,3)	0,03 [-0,23; 0,29]
	Nein	12	2,5 (1,5)	-0,13 [-0,63; 0,36]
ECOG bei Baseline[1]	0	25	2,4 (1,4)	-0,08 [-0,54; 0,38]
	1	62	2,6 (1,3)	0,04 [-0,35; 0,43]
Geschlecht	Weiblich	39	2,6 (1,4)	0,15 [-0,15; 0,44]
	Männlich	48	2,5 (1,3)	-0,11 [-0,39; 0,17]
Lebermetastasen	Ja	15	2,4 (1,2)	0,18 [-0,29; 0,66]
	Nein	72	2,6 (1,4)	-0,03 [-0,27; 0,22]
Hirnmetastasen	Ja	11	2,4 (1,4)	0,14 [-0,39; 0,66]
	Nein	76	2,6 (1,3)	-0,01 [-0,25; 0,23]
Knochenmetastasen[1]	Ja	41	2,8 (1,3)	0,16 [-7260,68; 7261,01]
	Nein	46	2,4 (1,3)	-0,13 [-7260,98; 7260,72]
PRO-CTCAE, Frequenz von Muskelschmerzen				
Alter[1]	< 65 Jahre	44	2,3 (1,3)	0,04 [-0,23; 0,31]
	≥ 65 Jahre	43	2,0 (1,0)	-0,12 [-0,38; 0,15]
Vorangegangene Linien von Anti-Krebs Therapien	1	5	2,6 (1,5)	-0,24 [-0,92; 0,45]
	2	14	2,4 (1,1)	0,07 [-0,36; 0,50]
	>2	68	2,1 (1,2)	-0,05 [-0,28; 0,18]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	80	2,1 (1,2)	-0,04 [-0,25; 0,18]
	Nein	7	2,4 (1,1)	-0,08 [-0,65; 0,50]
	Ja	82	2,1 (1,2)	-0,03 [-0,24; 0,19]

		Sotorasib		
Subgruppe	**Kategorie**	**Anzahl Patienten**	**Mittelwert (Stdabw.) bei Baseline**	**LS-Mean Veränderung im Vergleich zu Baseline [95%-KI]**
Vorangegangene Platinum-basierte Chemotherapie	Nein	5	2,6 (1,5)	-0,24 [-0,92; 0,44]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	75	2,1 (1,2)	-0,02 [-0,24; 0,20]
	Nein	12	2,5 (1,2)	-0,15 [-0,60; 0,30]
ECOG bei Baseline	0	25	2,3 (1,2)	-0,26 [-0,59; 0,07]
	1	62	2,1 (1,2)	0,05 [-0,18; 0,29]
Geschlecht	Weiblich	39	2,2 (1,2)	0,10 [-0,18; 0,37]
	Männlich	48	2,1 (1,2)	-0,15 [-0,41; 0,10]
Lebermetastasen[1]	Ja	15	1,9 (1,0)	0,16 [n.b.; n.b.]
	Nein	72	2,2 (1,2)	-0,08 [n.b.; n.b.]
Hirnmetastasen[1]	Ja	11	2,5 (1,4)	-0,06 [-0,55; 0,43]
	Nein	76	2,1 (1,2)	-0,04 [-0,26; 0,18]
Knochenmetastasen	Ja	41	2,2 (1,2)	-0,03 [-0,31; 0,24]
	Nein	46	2,1 (1,2)	-0,05 [-0,31; 0,21]
PRO-CTCAE, Frequenz von Gelenkschmerzen				
Alter[1]	< 65 Jahre	44	2,1 (1,2)	0,12 [-0,17; 0,40]
	≥ 65 Jahre	43	1,8 (1,1)	0,02 [-0,26; 0,30]
Vorangegangene Linien von Anti-Krebs Therapien[1]	1	5	2,6 (1,7)	-0,57 [n.b.; n.b.]
	2	14	2,1 (1,1)	-0,04 [n.b.; n.b.]
	>2	68	1,9 (1,1)	0,14 [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien[1]	Ja	80	2,0 (1,2)	0,07 [-0,25; 0,39]
	Nein	7	1,4 (0,8)	-0,01 [-0,64; 0,63]
Vorangegangene Platinum-basierte Chemotherapie[1]	Ja	82	1,9 (1,1)	0,11 [-0,12; 0,34]
	Nein	5	2,6 (1,7)	-0,56 [-1,25; 0,12]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie[1]	Ja	75	2,0 (1,1)	0,12 [-0,30; 0,53]
	Nein	12	1,9 (1,3)	-0,23 [-0,80; 0,34]
ECOG bei Baseline[1]	0	25	2,0 (1,1)	-0,05 [-0,46; 0,36]
	1	62	1,9 (1,2)	0,11 [-0,22; 0,45]
Geschlecht[1]	Weiblich	39	1,8 (1,2)	0,09 [-0,20; 0,39]
	Männlich	48	2,1 (1,1)	0,05 [-0,23; 0,32]
Lebermetastasen	Ja	15	2,0 (1,0)	0,15 [-0,31; 0,61]
	Nein	72	2,0 (1,2)	0,05 [-0,19; 0,29]
Hirnmetastasen[1]	Ja	11	2,2 (1,5)	0,09 [n.b.; n.b.]
	Nein	76	1,9 (1,1)	0,06 [n.b.; n.b.]
Knochenmetastasen	Ja	41	2,1 (1,1)	0,02 [-0,27; 0,32]
	Nein	46	1,8 (1,2)	0,10 [-0,17; 0,38]

1) Konvergenzkriterien erfüllt aber finale Hessematrix ist nicht positiv definit.
2) Modellierung wegen unendlicher Likelihood angehalten.

KI = Konfidenzintervall; LS-Mean = Kleinste Quadrate Mittelwert (least squares mean); n.b. = nicht berechenbar; PRO-CTCAE = Patient-Reported Outcome Version der Common Technology Criteria for Adverse Events; Stdabw. = Standardabweichung

1.6 Subgruppenanalysen – PRO (Ereigniszeit-Endpunkte)

1.6.1 EORTC QLQ-C30

1.6.1.1 Verschlechterung um ≥10 Punkte

Tabelle 1-7: Ergebnisse der Subgruppenanalysen für den Endpunkt "QLQ-C30, Zeit bis zur Verschlechterung um ≥10 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
QLQ-C30 Globaler Gesundheitsstatus			
Alter	< 65 Jahre	22/49 (44,90)	177 [85; n.b.]
	≥ 65 Jahre	26/45 (57,78)	66 [23; 210]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	5/16 (31,25)	n.b. [43; n.b.]
	>2	41/72 (56,94)	86 [55; 210]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	45/86 (52,33)	107 [64; 254]
	Nein	3/8 (37,50)	177 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	45/86 (52,33)	107 [65; 254]
	Nein	3/8 (37,50)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	42/78 (53,85)	106 [55; 254]
	Nein	6/16 (37,50)	n.b. [71; n.b.]
ECOG bei Baseline	0	14/27 (51,85)	107 [64; n.b.]
	1	34/67 (50,75)	129 [53; n.b.]
Geschlecht	Weiblich	21/42 (50,00)	107 [50; n.b.]
	Männlich	27/52 (51,92)	127 [64; n.b.]
Lebermetastasen	Ja	8/16 (50,00)	65 [22; n.b.]
	Nein	40/78 (51,28)	129 [71; 282]
Hirnmetastasen	Ja	4/15 (26,67)	254 [85; 254]
	Nein	44/79 (55,70)	106 [55; 210]
Knochenmetastasen	Ja	23/44 (52,27)	86 [53; n.b.]
	Nein	25/50 (50,00)	210 [71; n.b.]
QLQ-C30 Fatigue			
Alter	< 65 Jahre	26/49 (53,06)	106 [43; n.b.]
	≥ 65 Jahre	21/45 (46,67)	128 [43; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	7/16 (43,75)	n.b. [30; n.b.]
	>2	39/72 (54,17)	105 [45; 238]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	43/86 (50,00)	106 [45; n.b.]
	Nein	4/8 (50,00)	169 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	45/86 (52,33)	106 [45; 238]
	Nein	2/8 (25,00)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	41/78 (52,56)	105 [44; 238]
	Nein	6/16 (37,50)	n.b. [22; n.b.]
ECOG bei Baseline	0	13/27 (48,15)	107 [43; n.b.]
	1	34/67 (50,75)	105 [44; n.b.]
Geschlecht	Weiblich	20/42 (47,62)	107 [43; n.b.]
	Männlich	27/52 (51,92)	106 [44; n.b.]
Lebermetastasen	Ja	7/16 (43,75)	128 [23; n.b.]
	Nein	40/78 (51,28)	106 [45; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	105 [22; n.b.]
	Nein	40/79 (50,63)	107 [45; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Knochenmetastasen	Ja	24/44 (54,55)	85 [41; 128]
	Nein	23/50 (46,00)	169 [45; n.b.]
QLQ-C30 Übelkeit und Erbrechen			
Alter	< 65 Jahre	21/49 (42,86)	298 [85; 337]
	≥ 65 Jahre	15/45 (33,33)	n.b. [108; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [23; n.b.]
	2	8/16 (50,00)	148 [43; 298]
	>2	26/72 (36,11)	337 [120; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	34/86 (39,53)	298 [108; n.b.]
	Nein	2/8 (25,00)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	32/86 (37,21)	337 [120; n.b.]
	Nein	4/8 (50,00)	298 [23; 298]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	337 [108; n.b.]
	Nein	6/16 (37,50)	298 [64; 298]
ECOG bei Baseline	0	7/27 (25,93)	n.b. [106; n.b.]
	1	29/67 (43,28)	298 [108; 337]
Geschlecht	Weiblich	18/42 (42,86)	210 [108; n.b.]
	Männlich	18/52 (34,62)	298 [106; n.b.]
Lebermetastasen	Ja	6/16 (37,50)	120 [44; n.b.]
	Nein	30/78 (38,46)	298 [108; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	148 [22; n.b.]
	Nein	29/79 (36,71)	298 [120; n.b.]
Knochenmetastasen	Ja	17/44 (38,64)	n.b. [64; n.b.]
	Nein	19/50 (38,00)	298 [148; n.b.]
QLQ-C30 Schmerz			
Alter	< 65 Jahre	28/49 (57,14)	64 [43; 177]
	≥ 65 Jahre	24/45 (53,33)	125 [65; 170]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [64; n.b.]
	2	9/16 (56,25)	85 [43; n.b.]
	>2	41/72 (56,94)	107 [44; 169]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	47/86 (54,65)	85 [63; 127]
	Nein	5/8 (62,50)	170 [43; 177]
Vorangegangene Platinum-basierte Chemotherapie	Ja	49/86 (56,98)	85 [63; 127]
	Nein	3/8 (37,50)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	44/78 (56,41)	73 [44; 127]
	Nein	8/16 (50,00)	170 [64; n.b.]
ECOG bei Baseline	0	13/27 (48,15)	107 [43; n.b.]
	1	39/67 (58,21)	85 [45; 169]
Geschlecht	Weiblich	24/42 (57,14)	85 [63; 210]
	Männlich	28/52 (53,85)	125 [43; 177]
Lebermetastasen	Ja	10/16 (62,50)	63 [23; 107]
	Nein	42/78 (53,85)	125 [64; 177]
Hirnmetastasen	Ja	8/15 (53,33)	64 [22; n.b.]
	Nein	44/79 (55,70)	107 [64; 170]
Knochenmetastasen	Ja	27/44 (61,36)	65 [43; 125]
	Nein	25/50 (50,00)	169 [44; n.b.]
QLQ-C30 Atemnot			
Alter	< 65 Jahre	18/49 (36,73)	n.b. [86; n.b.]
	≥ 65 Jahre	10/45 (22,22)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	5/16 (31,25)	n.b. [23; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	>2	23/72 (31,94)	n.b. [199; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	26/86 (30,23)	n.b. [199; n.b.]
	Nein	2/8 (25,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/86 (31,40)	n.b. [199; n.b.]
	Nein	1/8 (12,50)	n.b. [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	25/78 (32,05)	n.b. [199; n.b.]
	Nein	3/16 (18,75)	n.b. [127; n.b.]
ECOG bei Baseline	0	7/27 (25,93)	n.b. [127; n.b.]
	1	21/67 (31,34)	n.b. [199; n.b.]
Geschlecht	Weiblich	11/42 (26,19)	n.b. [n.b.; n.b.]
	Männlich	17/52 (32,69)	n.b. [127; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	n.b. [43; n.b.]
	Nein	24/78 (30,77)	n.b. [199; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [29; n.b.]
	Nein	24/79 (30,38)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	16/44 (36,36)	n.b. [85; n.b.]
	Nein	12/50 (24,00)	n.b. [n.b.; n.b.]
QLQ-C30 Insomnie			
Alter	< 65 Jahre	17/49 (34,69)	n.b. [83; n.b.]
	≥ 65 Jahre	16/45 (35,56)	293 [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [10; n.b.]
	2	6/16 (37,50)	n.b. [30; n.b.]
	>2	26/72 (36,11)	293 [106; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	30/86 (34,88)	n.b. [293; n.b.]
	Nein	3/8 (37,50)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	32/86 (37,21)	293 [106; n.b.]
	Nein	1/8 (12,50)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	29/78 (37,18)	293 [106; n.b.]
	Nein	4/16 (25,00)	n.b. [43; n.b.]
ECOG bei Baseline	0	10/27 (37,04)	n.b. [43; n.b.]
	1	23/67 (34,33)	293 [293; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	n.b. [44; n.b.]
	Männlich	16/52 (30,77)	n.b. [293; n.b.]
Lebermetastasen	Ja	6/16 (37,50)	293 [23; 293]
	Nein	27/78 (34,62)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	6/15 (40,00)	n.b. [21; n.b.]
	Nein	27/79 (34,18)	n.b. [293; n.b.]
Knochenmetastasen	Ja	15/44 (34,09)	293 [83; n.b.]
	Nein	18/50 (36,00)	n.b. [73; n.b.]
QLQ-C30 Appetitverlust			
Alter	< 65 Jahre	21/49 (42,86)	199 [85; n.b.]
	≥ 65 Jahre	15/45 (33,33)	n.b. [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [169; n.b.]
	2	5/16 (31,25)	n.b. [44; n.b.]
	>2	30/72 (41,67)	246 [85; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	n.b. [106; n.b.]
	Nein	4/8 (50,00)	177 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	34/86 (39,53)	246 [87; n.b.]
	Nein	2/8 (25,00)	n.b. [71; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	246 [87; n.b.]
	Nein	6/16 (37,50)	n.b. [71; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
ECOG bei Baseline	0	9/27 (33,33)	n.b. [85; n.b.]
	1	27/67 (40,30)	199 [85; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	169 [85; n.b.]
	Männlich	19/52 (36,54)	n.b. [85; n.b.]
Lebermetastasen	Ja	7/16 (43,75)	87 [43; n.b.]
	Nein	29/78 (37,18)	n.b. [169; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	199 [22; n.b.]
	Nein	29/79 (36,71)	n.b. [107; n.b.]
Knochenmetastasen	Ja	19/44 (43,18)	177 [65; n.b.]
	Nein	17/50 (34,00)	n.b. [85; n.b.]
QLQ-C30 Obstipation			
Alter	< 65 Jahre	15/49 (30,61)	n.b. [148; n.b.]
	≥ 65 Jahre	11/45 (24,44)	n.b. [211; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [211; n.b.]
	2	4/16 (25,00)	n.b. [148; n.b.]
	>2	21/72 (29,17)	n.b. [203; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/86 (29,07)	n.b. [203; n.b.]
	Nein	1/8 (12,50)	n.b. [148; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/86 (27,91)	n.b. [203; n.b.]
	Nein	2/8 (25,00)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	23/78 (29,49)	n.b. [203; n.b.]
	Nein	3/16 (18,75)	n.b. [148; n.b.]
ECOG bei Baseline	0	6/27 (22,22)	n.b. [203; n.b.]
	1	20/67 (29,85)	n.b. [168; n.b.]
Geschlecht	Weiblich	14/42 (33,33)	211 [148; n.b.]
	Männlich	12/52 (23,08)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	203 [43; n.b.]
	Nein	22/78 (28,21)	n.b. [211; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	168 [148; n.b.]
	Nein	22/79 (27,85)	n.b. [211; n.b.]
Knochenmetastasen	Ja	13/44 (29,55)	n.b. [168; n.b.]
	Nein	13/50 (26,00)	n.b. [n.b.; n.b.]
QLQ-C30 Diarrhoe			
Alter	< 65 Jahre	25/49 (51,02)	106 [64; n.b.]
	≥ 65 Jahre	22/45 (48,89)	129 [64; 260]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	43 [23; n.b.]
	2	7/16 (43,75)	113 [44; n.b.]
	>2	37/72 (51,39)	129 [85; 217]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	43/86 (50,00)	127 [85; 209]
	Nein	4/8 (50,00)	113 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	43/86 (50,00)	113 [85; 209]
	Nein	4/8 (50,00)	169 [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	39/78 (50,00)	127 [85; 217]
	Nein	8/16 (50,00)	113 [43; n.b.]
ECOG bei Baseline	0	13/27 (48,15)	106 [64; n.b.]
	1	34/67 (50,75)	127 [85; 217]
Geschlecht	Weiblich	21/42 (50,00)	129 [64; 260]
	Männlich	26/52 (50,00)	106 [64; 170]
Lebermetastasen	Ja	6/16 (37,50)	170 [23; n.b.]
	Nein	41/78 (52,56)	113 [85; 217]
Hirnmetastasen	Ja	7/15 (46,67)	106 [22; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Nein	40/79 (50,63)	129 [64; 209]
Knochenmetastasen	Ja	21/44 (47,73)	85 [43; n.b.]
	Nein	26/50 (52,00)	129 [85; 217]
QLQ-C30 Physisches Funktionsniveau			
Alter	< 65 Jahre	22/49 (44,90)	238 [86; n.b.]
	≥ 65 Jahre	16/45 (35,56)	n.b. [85; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	5/16 (31,25)	n.b. [85; n.b.]
	>2	31/72 (43,06)	238 [85; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	35/86 (40,70)	238 [106; n.b.]
	Nein	3/8 (37,50)	n.b. [85; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	36/86 (41,86)	210 [106; n.b.]
	Nein	2/8 (25,00)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	33/78 (42,31)	210 [86; n.b.]
	Nein	5/16 (31,25)	n.b. [107; n.b.]
ECOG bei Baseline	0	10/27 (37,04)	246 [85; n.b.]
	1	28/67 (41,79)	210 [85; n.b.]
Geschlecht	Weiblich	16/42 (38,10)	210 [86; n.b.]
	Männlich	22/52 (42,31)	238 [85; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	n.b. [43; n.b.]
	Nein	34/78 (43,59)	238 [106; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	148 [21; n.b.]
	Nein	31/79 (39,24)	246 [107; n.b.]
Knochenmetastasen	Ja	21/44 (47,73)	107 [43; n.b.]
	Nein	17/50 (34,00)	246 [169; n.b.]
QLQ-C30 Rollen-Funktionsniveau			
Alter	< 65 Jahre	25/49 (51,02)	86 [43; n.b.]
	≥ 65 Jahre	24/45 (53,33)	160 [65; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	4/6 (66,67)	33 [10; n.b.]
	2	9/16 (56,25)	85 [22; n.b.]
	>2	36/72 (50,00)	160 [63; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	44/86 (51,16)	160 [43; 255]
	Nein	5/8 (62,50)	85 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	44/86 (51,16)	160 [63; 255]
	Nein	5/8 (62,50)	33 [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	39/78 (50,00)	171 [63; 255]
	Nein	10/16 (62,50)	64 [22; n.b.]
ECOG bei Baseline	0	14/27 (51,85)	211 [43; n.b.]
	1	35/67 (52,24)	114 [43; n.b.]
Geschlecht	Weiblich	19/42 (45,24)	171 [43; n.b.]
	Männlich	30/52 (57,69)	86 [43; 255]
Lebermetastasen	Ja	10/16 (62,50)	43 [22; n.b.]
	Nein	39/78 (50,00)	171 [63; n.b.]
Hirnmetastasen	Ja	8/15 (53,33)	63 [21; n.b.]
	Nein	41/79 (51,90)	160 [44; 255]
Knochenmetastasen	Ja	26/44 (59,09)	85 [41; 211]
	Nein	23/50 (46,00)	238 [44; n.b.]
QLQ-C30 Emotionales Funktionsniveau			
Alter	< 65 Jahre	13/49 (26,53)	n.b. [148; n.b.]
	≥ 65 Jahre	13/45 (28,89)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	2	4/16 (25,00)	n.b. [106; n.b.]
	>2	20/72 (27,78)	n.b. [211; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	24/86 (27,91)	n.b. [211; n.b.]
	Nein	2/8 (25,00)	n.b. [85; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/86 (27,91)	n.b. [211; n.b.]
	Nein	2/8 (25,00)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	22/78 (28,21)	n.b. [169; n.b.]
	Nein	4/16 (25,00)	n.b. [148; n.b.]
ECOG bei Baseline	0	6/27 (22,22)	n.b. [107; n.b.]
	1	20/67 (29,85)	n.b. [169; n.b.]
Geschlecht	Weiblich	13/42 (30,95)	n.b. [107; n.b.]
	Männlich	13/52 (25,00)	n.b. [211; n.b.]
Lebermetastasen	Ja	5/16 (31,25)	n.b. [44; n.b.]
	Nein	21/78 (26,92)	n.b. [211; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [29; n.b.]
	Nein	22/79 (27,85)	n.b. [211; n.b.]
Knochenmetastasen	Ja	13/44 (29,55)	n.b. [107; n.b.]
	Nein	13/50 (26,00)	n.b. [211; n.b.]
QLQ-C30 Kognitives Funktionsniveau			
Alter	< 65 Jahre	19/49 (38,78)	282 [64; n.b.]
	≥ 65 Jahre	16/45 (35,56)	254 [93; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [23; n.b.]
	2	5/16 (31,25)	n.b. [44; n.b.]
	>2	29/72 (40,28)	254 [93; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	282 [107; n.b.]
	Nein	3/8 (37,50)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	33/86 (38,37)	254 [107; n.b.]
	Nein	2/8 (25,00)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	254 [107; n.b.]
	Nein	5/16 (31,25)	n.b. [43; n.b.]
ECOG bei Baseline	0	9/27 (33,33)	282 [64; n.b.]
	1	26/67 (38,81)	254 [93; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	211 [53; n.b.]
	Männlich	18/52 (34,62)	282 [107; n.b.]
Lebermetastasen	Ja	8/16 (50,00)	53 [43; n.b.]
	Nein	27/78 (34,62)	282 [211; n.b.]
Hirnmetastasen	Ja	5/15 (33,33)	n.b. [40; n.b.]
	Nein	30/79 (37,97)	282 [107; n.b.]
Knochenmetastasen	Ja	17/44 (38,64)	211 [64; n.b.]
	Nein	18/50 (36,00)	282 [254; n.b.]
QLQ-C30 Soziales Funktionsniveau			
Alter	< 65 Jahre	20/49 (40,82)	254 [107; 298]
	≥ 65 Jahre	16/45 (35,56)	n.b. [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	6/16 (37,50)	298 [43; 298]
	>2	29/72 (40,28)	217 [106; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	254 [199; n.b.]
	Nein	4/8 (50,00)	113 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	34/86 (39,53)	254 [107; n.b.]
	Nein	2/8 (25,00)	298 [22; 298]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	254 [107; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Nein	6/16 (37,50)	298 [43; 298]
ECOG bei Baseline	0	8/27 (29,63)	n.b. [106; n.b.]
	1	28/67 (41,79)	217 [107; 298]
Geschlecht	Weiblich	17/42 (40,48)	217 [73; n.b.]
	Männlich	19/52 (36,54)	298 [107; 298]
Lebermetastasen	Ja	7/16 (43,75)	107 [43; n.b.]
	Nein	29/78 (37,18)	298 [199; n.b.]
Hirnmetastasen	Ja	6/15 (40,00)	199 [43; 254]
	Nein	30/79 (37,97)	298 [107; n.b.]
Knochenmetastasen	Ja	21/44 (47,73)	107 [43; n.b.]
	Nein	15/50 (30,00)	298 [217; n.b.]
KI = Konfidenzintervall; n.b. = nicht berechenbar; QLQ-C30 = Quality of Life Questionnaire Core 30			

1.6.1.2 Verschlechterung um ≥15 Punkte

Tabelle 1-8: Ergebnisse der Subgruppenanalysen für den Endpunkt "QLQ-C30, Zeit bis zur Verschlechterung um ≥15 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
QLQ-C30 Globaler Gesundheitsstatus			
Alter	< 65 Jahre	22/49 (44,90)	177 [85; n.b.]
	≥ 65 Jahre	26/45 (57,78)	66 [23; 210]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	5/16 (31,25)	n.b. [43; n.b.]
	>2	41/72 (56,94)	86 [55; 210]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	45/86 (52,33)	107 [64; 254]
	Nein	3/8 (37,50)	177 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	45/86 (52,33)	107 [65; 254]
	Nein	3/8 (37,50)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	42/78 (53,85)	106 [55; 254]
	Nein	6/16 (37,50)	n.b. [71; n.b.]
ECOG bei Baseline	0	14/27 (51,85)	107 [64; n.b.]
	1	34/67 (50,75)	129 [53; n.b.]
Geschlecht	Weiblich	21/42 (50,00)	107 [50; n.b.]
	Männlich	27/52 (51,92)	127 [64; n.b.]
Lebermetastasen	Ja	8/16 (50,00)	65 [22; n.b.]
	Nein	40/78 (51,28)	129 [71; 282]
Hirnmetastasen	Ja	4/15 (26,67)	254 [85; 254]
	Nein	44/79 (55,70)	106 [55; 210]
Knochenmetastasen	Ja	23/44 (52,27)	86 [53; n.b.]
	Nein	25/50 (50,00)	210 [71; n.b.]
QLQ-C30 Fatigue			
Alter	< 65 Jahre	17/49 (34,69)	238 [107; n.b.]
	≥ 65 Jahre	13/45 (28,89)	n.b. [211; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	5/16 (31,25)	n.b. [43; n.b.]
	>2	24/72 (33,33)	238 [127; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	28/86 (32,56)	n.b. [199; n.b.]
	Nein	2/8 (25,00)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	28/86 (32,56)	238 [199; n.b.]
	Nein	2/8 (25,00)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	26/78 (33,33)	238 [199; n.b.]
	Nein	4/16 (25,00)	n.b. [86; n.b.]
ECOG bei Baseline	0	10/27 (37,04)	238 [92; n.b.]
	1	20/67 (29,85)	n.b. [199; n.b.]
Geschlecht	Weiblich	15/42 (35,71)	n.b. [73; n.b.]
	Männlich	15/52 (28,85)	n.b. [199; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	n.b. [43; n.b.]
	Nein	26/78 (33,33)	n.b. [199; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [43; n.b.]
	Nein	26/79 (32,91)	n.b. [127; n.b.]
Knochenmetastasen	Ja	15/44 (34,09)	n.b. [86; n.b.]
	Nein	15/50 (30,00)	n.b. [211; n.b.]
QLQ-C30 Übelkeit und Erbrechen			
Alter	< 65 Jahre	21/49 (42,86)	298 [85; 337]
	≥ 65 Jahre	15/45 (33,33)	n.b. [108; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [23; n.b.]
	2	8/16 (50,00)	148 [43; 298]
	>2	26/72 (36,11)	337 [120; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	34/86 (39,53)	298 [108; n.b.]
	Nein	2/8 (25,00)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	32/86 (37,21)	337 [120; n.b.]
	Nein	4/8 (50,00)	298 [23; 298]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	337 [108; n.b.]
	Nein	6/16 (37,50)	298 [64; 298]
ECOG bei Baseline	0	7/27 (25,93)	n.b. [106; n.b.]
	1	29/67 (43,28)	298 [108; 337]
Geschlecht	Weiblich	18/42 (42,86)	210 [108; n.b.]
	Männlich	18/52 (34,62)	298 [106; n.b.]
Lebermetastasen	Ja	6/16 (37,50)	120 [44; n.b.]
	Nein	30/78 (38,46)	298 [108; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	148 [22; n.b.]
	Nein	29/79 (36,71)	298 [120; n.b.]
Knochenmetastasen	Ja	17/44 (38,64)	n.b. [64; n.b.]
	Nein	19/50 (38,00)	298 [148; n.b.]
QLQ-C30 Schmerz			
Alter	< 65 Jahre	28/49 (57,14)	64 [43; 177]
	≥ 65 Jahre	24/45 (53,33)	125 [65; 170]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [64; n.b.]
	2	9/16 (56,25)	85 [43; n.b.]
	>2	41/72 (56,94)	107 [44; 169]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	47/86 (54,65)	85 [63; 127]
	Nein	5/8 (62,50)	170 [43; 177]
Vorangegangene Platinum-basierte Chemotherapie	Ja	49/86 (56,98)	85 [63; 127]
	Nein	3/8 (37,50)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	44/78 (56,41)	73 [44; 127]
	Nein	8/16 (50,00)	170 [64; n.b.]
ECOG bei Baseline	0	13/27 (48,15)	107 [43; n.b.]
	1	39/67 (58,21)	85 [45; 169]
Geschlecht	Weiblich	24/42 (57,14)	85 [63; 210]
	Männlich	28/52 (53,85)	125 [43; 177]
Lebermetastasen	Ja	10/16 (62,50)	63 [23; 107]
	Nein	42/78 (53,85)	125 [64; 177]
Hirnmetastasen	Ja	8/15 (53,33)	64 [22; n.b.]
	Nein	44/79 (55,70)	107 [64; 170]
Knochenmetastasen	Ja	27/44 (61,36)	65 [43; 125]
	Nein	25/50 (50,00)	169 [44; n.b.]
QLQ-C30 Atemnot			
Alter	< 65 Jahre	18/49 (36,73)	n.b. [86; n.b.]
	≥ 65 Jahre	10/45 (22,22)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	5/16 (31,25)	n.b. [23; n.b.]
	>2	23/72 (31,94)	n.b. [199; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	26/86 (30,23)	n.b. [199; n.b.]
	Nein	2/8 (25,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/86 (31,40)	n.b. [199; n.b.]
	Nein	1/8 (12,50)	n.b. [23; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	25/78 (32,05)	n.b. [199; n.b.]
	Nein	3/16 (18,75)	n.b. [127; n.b.]
ECOG bei Baseline	0	7/27 (25,93)	n.b. [127; n.b.]
	1	21/67 (31,34)	n.b. [199; n.b.]
Geschlecht	Weiblich	11/42 (26,19)	n.b. [n.b.; n.b.]
	Männlich	17/52 (32,69)	n.b. [127; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	n.b. [43; n.b.]
	Nein	24/78 (30,77)	n.b. [199; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [29; n.b.]
	Nein	24/79 (30,38)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	16/44 (36,36)	n.b. [85; n.b.]
	Nein	12/50 (24,00)	n.b. [n.b.; n.b.]
QLQ-C30 Insomnie			
Alter	< 65 Jahre	17/49 (34,69)	n.b. [83; n.b.]
	≥ 65 Jahre	16/45 (35,56)	293 [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [10; n.b.]
	2	6/16 (37,50)	n.b. [30; n.b.]
	>2	26/72 (36,11)	293 [106; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	30/86 (34,88)	n.b. [293; n.b.]
	Nein	3/8 (37,50)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	32/86 (37,21)	293 [106; n.b.]
	Nein	1/8 (12,50)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	29/78 (37,18)	293 [106; n.b.]
	Nein	4/16 (25,00)	n.b. [43; n.b.]
ECOG bei Baseline	0	10/27 (37,04)	n.b. [43; n.b.]
	1	23/67 (34,33)	293 [293; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	n.b. [44; n.b.]
	Männlich	16/52 (30,77)	n.b. [293; n.b.]
Lebermetastasen	Ja	6/16 (37,50)	293 [23; 293]
	Nein	27/78 (34,62)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	6/15 (40,00)	n.b. [21; n.b.]
	Nein	27/79 (34,18)	n.b. [293; n.b.]
Knochenmetastasen	Ja	15/44 (34,09)	293 [83; n.b.]
	Nein	18/50 (36,00)	n.b. [73; n.b.]
QLQ-C30 Appetitverlust			
Alter	< 65 Jahre	21/49 (42,86)	199 [85; n.b.]
	≥ 65 Jahre	15/45 (33,33)	n.b. [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [169; n.b.]
	2	5/16 (31,25)	n.b. [44; n.b.]
	>2	30/72 (41,67)	246 [85; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	n.b. [106; n.b.]
	Nein	4/8 (50,00)	177 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	34/86 (39,53)	246 [87; n.b.]
	Nein	2/8 (25,00)	n.b. [71; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	246 [87; n.b.]
	Nein	6/16 (37,50)	n.b. [71; n.b.]
ECOG bei Baseline	0	9/27 (33,33)	n.b. [85; n.b.]
	1	27/67 (40,30)	199 [85; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	169 [85; n.b.]
	Männlich	19/52 (36,54)	n.b. [85; n.b.]
Lebermetastasen	Ja	7/16 (43,75)	87 [43; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Nein	29/78 (37,18)	n.b. [169; n.b.]
Hirnmetastasen	Ja	7/15 (46,67)	199 [22; n.b.]
	Nein	29/79 (36,71)	n.b. [107; n.b.]
Knochenmetastasen	Ja	19/44 (43,18)	177 [65; n.b.]
	Nein	17/50 (34,00)	n.b. [85; n.b.]
QLQ-C30 Obstipation			
Alter	< 65 Jahre	15/49 (30,61)	n.b. [148; n.b.]
	≥ 65 Jahre	11/45 (24,44)	n.b. [211; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [211; n.b.]
	2	4/16 (25,00)	n.b. [148; n.b.]
	>2	21/72 (29,17)	n.b. [203; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/86 (29,07)	n.b. [203; n.b.]
	Nein	1/8 (12,50)	n.b. [148; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/86 (27,91)	n.b. [203; n.b.]
	Nein	2/8 (25,00)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	23/78 (29,49)	n.b. [203; n.b.]
	Nein	3/16 (18,75)	n.b. [148; n.b.]
ECOG bei Baseline	0	6/27 (22,22)	n.b. [203; n.b.]
	1	20/67 (29,85)	n.b. [168; n.b.]
Geschlecht	Weiblich	14/42 (33,33)	211 [148; n.b.]
	Männlich	12/52 (23,08)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	4/16 (25,00)	203 [43; n.b.]
	Nein	22/78 (28,21)	n.b. [211; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	168 [148; n.b.]
	Nein	22/79 (27,85)	n.b. [211; n.b.]
Knochenmetastasen	Ja	13/44 (29,55)	n.b. [168; n.b.]
	Nein	13/50 (26,00)	n.b. [n.b.; n.b.]
QLQ-C30 Diarrhoe			
Alter	< 65 Jahre	25/49 (51,02)	106 [64; n.b.]
	≥ 65 Jahre	22/45 (48,89)	129 [64; 260]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	43 [23; n.b.]
	2	7/16 (43,75)	113 [44; n.b.]
	>2	37/72 (51,39)	129 [85; 217]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	43/86 (50,00)	127 [85; 209]
	Nein	4/8 (50,00)	113 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	43/86 (50,00)	113 [85; 209]
	Nein	4/8 (50,00)	169 [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	39/78 (50,00)	127 [85; 217]
	Nein	8/16 (50,00)	113 [43; n.b.]
ECOG bei Baseline	0	13/27 (48,15)	106 [64; n.b.]
	1	34/67 (50,75)	127 [85; 217]
Geschlecht	Weiblich	21/42 (50,00)	129 [64; 260]
	Männlich	26/52 (50,00)	106 [64; 170]
Lebermetastasen	Ja	6/16 (37,50)	170 [23; n.b.]
	Nein	41/78 (52,56)	113 [85; 217]
Hirnmetastasen	Ja	7/15 (46,67)	106 [22; n.b.]
	Nein	40/79 (50,63)	129 [64; 209]
Knochenmetastasen	Ja	21/44 (47,73)	85 [43; n.b.]
	Nein	26/50 (52,00)	129 [85; 217]
QLQ-C30 Physisches Funktionsniveau			
Alter	< 65 Jahre	13/49 (26,53)	n.b. [238; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	≥ 65 Jahre	12/45 (26,67)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	3/16 (18,75)	n.b. [211; n.b.]
	>2	20/72 (27,78)	n.b. [210; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	24/86 (27,91)	n.b. [211; n.b.]
	Nein	1/8 (12,50)	n.b. [107; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	23/86 (26,74)	n.b. [210; n.b.]
	Nein	2/8 (25,00)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	22/78 (28,21)	246 [210; n.b.]
	Nein	3/16 (18,75)	n.b. [107; n.b.]
ECOG bei Baseline	0	6/27 (22,22)	n.b. [238; n.b.]
	1	19/67 (28,36)	n.b. [199; n.b.]
Geschlecht	Weiblich	8/42 (19,05)	n.b. [210; n.b.]
	Männlich	17/52 (32,69)	246 [199; n.b.]
Lebermetastasen	Ja	2/16 (12,50)	n.b. [87; n.b.]
	Nein	23/78 (29,49)	n.b. [211; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [29; n.b.]
	Nein	21/79 (26,58)	n.b. [211; n.b.]
Knochenmetastasen	Ja	16/44 (36,36)	211 [107; n.b.]
	Nein	9/50 (18,00)	n.b. [238; n.b.]
QLQ-C30 Rollen-Funktionsniveau			
Alter	< 65 Jahre	25/49 (51,02)	86 [43; n.b.]
	≥ 65 Jahre	24/45 (53,33)	160 [65; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	4/6 (66,67)	33 [10; n.b.]
	2	9/16 (56,25)	85 [22; n.b.]
	>2	36/72 (50,00)	160 [63; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	44/86 (51,16)	160 [43; 255]
	Nein	5/8 (62,50)	85 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	44/86 (51,16)	160 [63; 255]
	Nein	5/8 (62,50)	33 [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	39/78 (50,00)	171 [63; 255]
	Nein	10/16 (62,50)	64 [22; n.b.]
ECOG bei Baseline	0	14/27 (51,85)	211 [43; n.b.]
	1	35/67 (52,24)	114 [43; n.b.]
Geschlecht	Weiblich	19/42 (45,24)	171 [43; n.b.]
	Männlich	30/52 (57,69)	86 [43; 255]
Lebermetastasen	Ja	10/16 (62,50)	43 [22; n.b.]
	Nein	39/78 (50,00)	171 [63; n.b.]
Hirnmetastasen	Ja	8/15 (53,33)	63 [21; n.b.]
	Nein	41/79 (51,90)	160 [44; 255]
Knochenmetastasen	Ja	26/44 (59,09)	85 [41; 211]
	Nein	23/50 (46,00)	238 [44; n.b.]
QLQ-C30 Emotionales Funktionsniveau			
Alter	< 65 Jahre	13/49 (26,53)	n.b. [148; n.b.]
	≥ 65 Jahre	13/45 (28,89)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	4/16 (25,00)	n.b. [106; n.b.]
	>2	20/72 (27,78)	n.b. [211; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	24/86 (27,91)	n.b. [211; n.b.]
	Nein	2/8 (25,00)	n.b. [85; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/86 (27,91)	n.b. [211; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Nein	2/8 (25,00)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	22/78 (28,21)	n.b. [169; n.b.]
	Nein	4/16 (25,00)	n.b. [148; n.b.]
ECOG bei Baseline	0	6/27 (22,22)	n.b. [107; n.b.]
	1	20/67 (29,85)	n.b. [169; n.b.]
Geschlecht	Weiblich	13/42 (30,95)	n.b. [107; n.b.]
	Männlich	13/52 (25,00)	n.b. [211; n.b.]
Lebermetastasen	Ja	5/16 (31,25)	n.b. [44; n.b.]
	Nein	21/78 (26,92)	n.b. [211; n.b.]
Hirnmetastasen	Ja	4/15 (26,67)	n.b. [29; n.b.]
	Nein	22/79 (27,85)	n.b. [211; n.b.]
Knochenmetastasen	Ja	13/44 (29,55)	n.b. [107; n.b.]
	Nein	13/50 (26,00)	n.b. [211; n.b.]
QLQ-C30 Kognitives Funktionsniveau			
Alter	< 65 Jahre	19/49 (38,78)	282 [64; n.b.]
	≥ 65 Jahre	16/45 (35,56)	254 [93; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [23; n.b.]
	2	5/16 (31,25)	n.b. [44; n.b.]
	>2	29/72 (40,28)	254 [93; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	282 [107; n.b.]
	Nein	3/8 (37,50)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	33/86 (38,37)	254 [107; n.b.]
	Nein	2/8 (25,00)	n.b. [21; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	254 [107; n.b.]
	Nein	5/16 (31,25)	n.b. [43; n.b.]
ECOG bei Baseline	0	9/27 (33,33)	282 [64; n.b.]
	1	26/67 (38,81)	254 [93; n.b.]
Geschlecht	Weiblich	17/42 (40,48)	211 [53; n.b.]
	Männlich	18/52 (34,62)	282 [107; n.b.]
Lebermetastasen	Ja	8/16 (50,00)	53 [43; n.b.]
	Nein	27/78 (34,62)	282 [211; n.b.]
Hirnmetastasen	Ja	5/15 (33,33)	n.b. [40; n.b.]
	Nein	30/79 (37,97)	282 [107; n.b.]
Knochenmetastasen	Ja	17/44 (38,64)	211 [64; n.b.]
	Nein	18/50 (36,00)	282 [254; n.b.]
QLQ-C30 Soziales Funktionsniveau			
Alter	< 65 Jahre	20/49 (40,82)	254 [107; 298]
	≥ 65 Jahre	16/45 (35,56)	n.b. [73; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	6/16 (37,50)	298 [43; 298]
	>2	29/72 (40,28)	217 [106; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	32/86 (37,21)	254 [199; n.b.]
	Nein	4/8 (50,00)	113 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	34/86 (39,53)	254 [107; n.b.]
	Nein	2/8 (25,00)	298 [22; 298]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	30/78 (38,46)	254 [107; n.b.]
	Nein	6/16 (37,50)	298 [43; 298]
ECOG bei Baseline	0	8/27 (29,63)	n.b. [106; n.b.]
	1	28/67 (41,79)	217 [107; 298]
Geschlecht	Weiblich	17/42 (40,48)	217 [73; n.b.]
	Männlich	19/52 (36,54)	298 [107; 298]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Lebermetastasen	Ja	7/16 (43,75)	107 [43; n.b.]
	Nein	29/78 (37,18)	298 [199; n.b.]
Hirnmetastasen	Ja	6/15 (40,00)	199 [43; 254]
	Nein	30/79 (37,97)	298 [107; n.b.]
Knochenmetastasen	Ja	21/44 (47,73)	107 [43; n.b.]
	Nein	15/50 (30,00)	298 [217; n.b.]
KI = Konfidenzintervall; n.b. = nicht berechenbar; QLQ-C30 = Quality of Life Questionnaire Core 30			

1.6.2 EORTC QLQ-LC13

1.6.2.1 Verschlechterung um ≥10 Punkte

Tabelle 1-9: Ergebnisse der Subgruppenanalysen für den Endpunkt "QLQ-LC13, Zeit bis zur Verschlechterung um ≥10 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
QLQ-LC13 Dysphagie			
Alter	< 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	9/43 (20,93)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	0/14 (0,00)	n.b. [n.b.; n.b.]
	>2	12/66 (18,18)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	13/80 (16,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [177; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	12/80 (15,00)	n.b. [n.b.; n.b.]
	Nein	2/6 (33,33)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	11/74 (14,86)	n.b. [n.b.; n.b.]
	Nein	3/12 (25,00)	n.b. [22; n.b.]
ECOG bei Baseline	0	3/24 (12,50)	n.b. [n.b.; n.b.]
	1	11/62 (17,74)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	5/38 (13,16)	n.b. [n.b.; n.b.]
	Männlich	9/48 (18,75)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [53; n.b.]
	Nein	11/71 (15,49)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [63; n.b.]
	Nein	12/74 (16,22)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	n.b. [177; n.b.]
	Nein	5/44 (11,36)	n.b. [n.b.; n.b.]
QLQ-LC13 Dyspnoe			
Alter	< 65 Jahre	25/43 (58,14)	64 [44; 246]
	≥ 65 Jahre	22/43 (51,16)	107 [43; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	22 [22; n.b.]
	2	8/14 (57,14)	44 [22; n.b.]
	>2	36/66 (54,55)	107 [55; 246]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	44/80 (55,00)	65 [45; 246]
	Nein	3/6 (50,00)	113 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	44/80 (55,00)	85 [55; 246]
	Nein	3/6 (50,00)	22 [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	41/74 (55,41)	65 [50; 246]
	Nein	6/12 (50,00)	113 [22; n.b.]
ECOG bei Baseline	0	10/24 (41,67)	282 [64; n.b.]
	1	37/62 (59,68)	62 [43; 199]
Geschlecht	Weiblich	21/38 (55,26)	108 [41; n.b.]
	Männlich	26/48 (54,17)	65 [44; 282]
Lebermetastasen	Ja	9/15 (60,00)	44 [22; n.b.]
	Nein	38/71 (53,52)	108 [55; 282]
Hirnmetastasen	Ja	5/12 (41,67)	113 [62; n.b.]
	Nein	42/74 (56,76)	64 [44; 246]
Knochenmetastasen	Ja	24/42 (57,14)	62 [41; 199]
	Nein	23/44 (52,27)	210 [58; n.b.]
QLQ-LC13 Haarausfall			

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Alter	< 65 Jahre	9/43 (20,93)	n.b. [169; n.b.]
	≥ 65 Jahre	9/43 (20,93)	n.b. [217; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [64; n.b.]
	2	7/14 (50,00)	169 [22; n.b.]
	>2	10/66 (15,15)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	16/80 (20,00)	n.b. [n.b.; n.b.]
	Nein	2/6 (33,33)	169 [65; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	17/80 (21,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [64; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	15/74 (20,27)	n.b. [n.b.; n.b.]
	Nein	3/12 (25,00)	n.b. [64; n.b.]
ECOG bei Baseline	0	2/24 (8,33)	n.b. [169; n.b.]
	1	16/62 (25,81)	n.b. [217; n.b.]
Geschlecht	Weiblich	10/38 (26,32)	n.b. [217; n.b.]
	Männlich	8/48 (16,67)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [44; n.b.]
	Nein	16/71 (22,54)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [45; n.b.]
	Nein	15/74 (20,27)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	n.b. [n.b.; n.b.]
	Nein	9/44 (20,45)	n.b. [217; n.b.]
QLQ-LC13 Husten			
Alter	< 65 Jahre	13/43 (30,23)	260 [107; n.b.]
	≥ 65 Jahre	14/43 (32,56)	n.b. [106; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	5/14 (35,71)	211 [43; n.b.]
	>2	22/66 (33,33)	260 [129; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	24/80 (30,00)	n.b. [260; n.b.]
	Nein	3/6 (50,00)	211 [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/80 (33,75)	260 [129; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	24/74 (32,43)	n.b. [129; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	6/24 (25,00)	n.b. [211; n.b.]
	1	21/62 (33,87)	260 [107; n.b.]
Geschlecht	Weiblich	10/38 (26,32)	260 [260; n.b.]
	Männlich	17/48 (35,42)	n.b. [106; n.b.]
Lebermetastasen	Ja	8/15 (53,33)	63 [23; n.b.]
	Nein	19/71 (26,76)	n.b. [260; n.b.]
Hirnmetastasen	Ja	4/12 (33,33)	n.b. [42; n.b.]
	Nein	23/74 (31,08)	n.b. [211; n.b.]
Knochenmetastasen	Ja	18/42 (42,86)	107 [55; n.b.]
	Nein	9/44 (20,45)	n.b. [260; n.b.]
QLQ-LC13 Periphere Neuropathie			
Alter	< 65 Jahre	16/43 (37,21)	n.b. [45; n.b.]
	≥ 65 Jahre	10/43 (23,26)	309 [309; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [23; n.b.]
	2	4/14 (28,57)	n.b. [44; n.b.]
	>2	20/66 (30,30)	309 [211; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/80 (31,25)	309 [211; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/80 (30,00)	309 [211; n.b.]
	Nein	2/6 (33,33)	n.b. [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	23/74 (31,08)	309 [211; n.b.]
	Nein	3/12 (25,00)	n.b. [43; n.b.]
ECOG bei Baseline	0	4/24 (16,67)	n.b. [211; n.b.]
	1	22/62 (35,48)	309 [71; 309]
Geschlecht	Weiblich	13/38 (34,21)	n.b. [71; n.b.]
	Männlich	13/48 (27,08)	309 [160; 309]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [23; n.b.]
	Nein	23/71 (32,39)	309 [211; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [23; n.b.]
	Nein	24/74 (32,43)	309 [211; n.b.]
Knochenmetastasen	Ja	14/42 (33,33)	309 [71; 309]
	Nein	12/44 (27,27)	n.b. [211; n.b.]
QLQ-LC13 Schmerzen (Arm/Schulter)			
Alter	< 65 Jahre	17/43 (39,53)	148 [106; n.b.]
	≥ 65 Jahre	13/43 (30,23)	274 [160; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [43; n.b.]
	2	4/14 (28,57)	148 [126; n.b.]
	>2	25/66 (37,88)	253 [107; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	28/80 (35,00)	274 [126; n.b.]
	Nein	2/6 (33,33)	n.b. [107; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	29/80 (36,25)	253 [126; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	27/74 (36,49)	253 [125; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	8/24 (33,33)	274 [107; n.b.]
	1	22/62 (35,48)	170 [125; n.b.]
Geschlecht	Weiblich	16/38 (42,11)	148 [74; n.b.]
	Männlich	14/48 (29,17)	274 [160; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	107 [43; n.b.]
	Nein	23/71 (32,39)	274 [160; n.b.]
Hirnmetastasen	Ja	5/12 (41,67)	148 [42; n.b.]
	Nein	25/74 (33,78)	274 [126; n.b.]
Knochenmetastasen	Ja	18/42 (42,86)	160 [106; n.b.]
	Nein	12/44 (27,27)	n.b. [148; n.b.]
QLQ-LC13 Schmerzen (andere)			
Alter	< 65 Jahre	22/43 (51,16)	107 [43; n.b.]
	≥ 65 Jahre	21/43 (48,84)	110 [64; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	64 [23; n.b.]
	2	8/14 (57,14)	85 [43; n.b.]
	>2	32/66 (48,48)	125 [44; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	39/80 (48,75)	125 [64; n.b.]
	Nein	4/6 (66,67)	96 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	40/80 (50,00)	110 [65; n.b.]
	Nein	3/6 (50,00)	64 [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	36/74 (48,65)	125 [45; n.b.]
	Nein	7/12 (58,33)	85 [23; n.b.]
ECOG bei Baseline	0	12/24 (50,00)	127 [43; n.b.]
	1	31/62 (50,00)	107 [64; n.b.]
Geschlecht	Weiblich	21/38 (55,26)	85 [45; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Männlich	22/48 (45,83)	125 [44; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	293 [22; 293]
	Nein	36/71 (50,70)	110 [64; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [64; n.b.]
	Nein	40/74 (54,05)	107 [44; 293]
Knochenmetastasen	Ja	21/42 (50,00)	107 [45; 293]
	Nein	22/44 (50,00)	110 [43; n.b.]
QLQ-LC13 Schmerzen (Thorax)			
Alter	< 65 Jahre	17/43 (39,53)	199 [106; n.b.]
	≥ 65 Jahre	11/43 (25,58)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	4/14 (28,57)	n.b. [44; n.b.]
	>2	24/66 (36,36)	254 [129; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/80 (31,25)	n.b. [169; n.b.]
	Nein	3/6 (50,00)	159 [107; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	28/80 (35,00)	254 [148; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	25/74 (33,78)	254 [168; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	5/24 (20,83)	n.b. [n.b.; n.b.]
	1	23/62 (37,10)	199 [129; n.b.]
Geschlecht	Weiblich	15/38 (39,47)	168 [110; n.b.]
	Männlich	13/48 (27,08)	n.b. [170; n.b.]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [23; n.b.]
	Nein	25/71 (35,21)	254 [168; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [148; n.b.]
	Nein	26/74 (35,14)	254 [168; n.b.]
Knochenmetastasen	Ja	10/42 (23,81)	n.b. [169; n.b.]
	Nein	18/44 (40,91)	170 [110; n.b.]
QLQ-LC13 Wirksamkeit der Schmerzmedikation[1]			
Alter	< 65 Jahre	11/32 (34,38)	168 [64; n.b.]
	≥ 65 Jahre	4/27 (14,81)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/4 (0,00)	n.b. [n.b.; n.b.]
	2	3/9 (33,33)	n.b. [22; n.b.]
	>2	12/46 (26,09)	n.b. [168; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	14/55 (25,45)	n.b. [168; n.b.]
	Nein	1/4 (25,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	15/55 (27,27)	n.b. [168; n.b.]
	Nein	0/4 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	14/51 (27,45)	n.b. [128; n.b.]
	Nein	1/8 (12,50)	n.b. [22; n.b.]
ECOG bei Baseline	0	4/12 (33,33)	n.b. [22; n.b.]
	1	11/47 (23,40)	n.b. [168; n.b.]
Geschlecht	Weiblich	8/32 (25,00)	n.b. [128; n.b.]
	Männlich	7/27 (25,93)	n.b. [168; n.b.]
Lebermetastasen	Ja	4/11 (36,36)	44 [23; n.b.]
	Nein	11/48 (22,92)	n.b. [168; n.b.]
Hirnmetastasen	Ja	1/7 (14,29)	n.b. [168; n.b.]
	Nein	14/52 (26,92)	n.b. [128; n.b.]
Knochenmetastasen	Ja	6/30 (20,00)	n.b. [168; n.b.]
	Nein	9/29 (31,03)	n.b. [73; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
QLQ-LC13 Wunder Mund			
Alter	< 65 Jahre	9/43 (20,93)	n.b. [168; n.b.]
	≥ 65 Jahre	8/43 (18,60)	259 [211; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	1/14 (7,14)	n.b. [168; n.b.]
	>2	15/66 (22,73)	259 [246; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	17/80 (21,25)	n.b. [246; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	16/80 (20,00)	259 [246; n.b.]
	Nein	1/6 (16,67)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	16/74 (21,62)	259 [211; n.b.]
	Nein	1/12 (8,33)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	5/24 (20,83)	n.b. [168; n.b.]
	1	12/62 (19,35)	259 [211; 259]
Geschlecht	Weiblich	8/38 (21,05)	n.b. [n.b.; n.b.]
	Männlich	9/48 (18,75)	259 [211; n.b.]
Lebermetastasen	Ja	1/15 (6,67)	n.b. [86; n.b.]
	Nein	16/71 (22,54)	n.b. [246; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [85; n.b.]
	Nein	15/74 (20,27)	n.b. [246; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	259 [168; n.b.]
	Nein	8/44 (18,18)	n.b. [246; n.b.]
QLQ-LC13 Bluthusten			
Alter	< 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	3/14 (21,43)	n.b. [113; n.b.]
	>2	7/66 (10,61)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	9/80 (11,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [113; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	10/80 (12,50)	n.b. [n.b.; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	9/74 (12,16)	n.b. [n.b.; n.b.]
	Nein	1/12 (8,33)	n.b. [113; n.b.]
ECOG bei Baseline	0	1/24 (4,17)	n.b. [n.b.; n.b.]
	1	9/62 (14,52)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	6/38 (15,79)	n.b. [217; n.b.]
	Männlich	4/48 (8,33)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [126; n.b.]
	Nein	8/71 (11,27)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [62; n.b.]
	Nein	8/74 (10,81)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	4/42 (9,52)	n.b. [n.b.; n.b.]
	Nein	6/44 (13,64)	n.b. [n.b.; n.b.]
1) Der Original-Wertebereich {1; 2; 3; 4} wurde zu {0; 33,33; 66,66; 100} transformiert, um eine Veränderung um 10 Punkte abbilden zu können.			
KI = Konfidenzintervall; n.b. = nicht berechenbar; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer 13			

1.6.2.2 Verschlechterung um ≥15 Punkte

Tabelle 1-10: Ergebnisse der Subgruppenanalysen für den Endpunkt "QLQ-LC13, Zeit bis zur Verschlechterung um ≥15 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
QLQ-LC13 Dysphagie			
Alter	< 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	9/43 (20,93)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	0/14 (0,00)	n.b. [n.b.; n.b.]
	>2	12/66 (18,18)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	13/80 (16,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [177; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	12/80 (15,00)	n.b. [n.b.; n.b.]
	Nein	2/6 (33,33)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	11/74 (14,86)	n.b. [n.b.; n.b.]
	Nein	3/12 (25,00)	n.b. [22; n.b.]
ECOG bei Baseline	0	3/24 (12,50)	n.b. [n.b.; n.b.]
	1	11/62 (17,74)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	5/38 (13,16)	n.b. [n.b.; n.b.]
	Männlich	9/48 (18,75)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [53; n.b.]
	Nein	11/71 (15,49)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [63; n.b.]
	Nein	12/74 (16,22)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	n.b. [177; n.b.]
	Nein	5/44 (11,36)	n.b. [n.b.; n.b.]
QLQ-LC13 Dyspnoe			
Alter	< 65 Jahre	14/43 (32,56)	282 [199; n.b.]
	≥ 65 Jahre	14/43 (32,56)	n.b. [129; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	3/14 (21,43)	n.b. [126; n.b.]
	>2	24/66 (36,36)	246 [169; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	28/80 (35,00)	246 [169; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/80 (33,75)	282 [199; n.b.]
	Nein	1/6 (16,67)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	27/74 (36,49)	246 [169; n.b.]
	Nein	1/12 (8,33)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	6/24 (25,00)	282 [246; n.b.]
	1	22/62 (35,48)	217 [129; n.b.]
Geschlecht	Weiblich	12/38 (31,58)	n.b. [129; n.b.]
	Männlich	16/48 (33,33)	282 [169; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	126 [22; n.b.]
	Nein	21/71 (29,58)	282 [199; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [62; n.b.]
	Nein	25/74 (33,78)	282 [169; n.b.]
Knochenmetastasen	Ja	14/42 (33,33)	n.b. [106; n.b.]
	Nein	14/44 (31,82)	282 [217; n.b.]
QLQ-LC13 Haarausfall			
Alter	< 65 Jahre	9/43 (20,93)	n.b. [169; n.b.]
	≥ 65 Jahre	9/43 (20,93)	n.b. [217; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [64; n.b.]
	2	7/14 (50,00)	169 [22; n.b.]
	>2	10/66 (15,15)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	16/80 (20,00)	n.b. [n.b.; n.b.]
	Nein	2/6 (33,33)	169 [65; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	17/80 (21,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [64; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	15/74 (20,27)	n.b. [n.b.; n.b.]
	Nein	3/12 (25,00)	n.b. [64; n.b.]
ECOG bei Baseline	0	2/24 (8,33)	n.b. [169; n.b.]
	1	16/62 (25,81)	n.b. [217; n.b.]
Geschlecht	Weiblich	10/38 (26,32)	n.b. [217; n.b.]
	Männlich	8/48 (16,67)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [44; n.b.]
	Nein	16/71 (22,54)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [45; n.b.]
	Nein	15/74 (20,27)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	n.b. [n.b.; n.b.]
	Nein	9/44 (20,45)	n.b. [217; n.b.]
QLQ-LC13 Husten			
Alter	< 65 Jahre	13/43 (30,23)	260 [107; n.b.]
	≥ 65 Jahre	14/43 (32,56)	n.b. [106; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	5/14 (35,71)	211 [43; n.b.]
	>2	22/66 (33,33)	260 [129; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	24/80 (30,00)	n.b. [260; n.b.]
	Nein	3/6 (50,00)	211 [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/80 (33,75)	260 [129; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	24/74 (32,43)	n.b. [129; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	6/24 (25,00)	n.b. [211; n.b.]
	1	21/62 (33,87)	260 [107; n.b.]
Geschlecht	Weiblich	10/38 (26,32)	260 [260; n.b.]
	Männlich	17/48 (35,42)	n.b. [106; n.b.]
Lebermetastasen	Ja	8/15 (53,33)	63 [23; n.b.]
	Nein	19/71 (26,76)	n.b. [260; n.b.]
Hirnmetastasen	Ja	4/12 (33,33)	n.b. [42; n.b.]
	Nein	23/74 (31,08)	n.b. [211; n.b.]
Knochenmetastasen	Ja	18/42 (42,86)	107 [55; n.b.]
	Nein	9/44 (20,45)	n.b. [260; n.b.]
QLQ-LC13 Periphere Neuropathie			
Alter	< 65 Jahre	16/43 (37,21)	n.b. [45; n.b.]
	≥ 65 Jahre	10/43 (23,26)	309 [309; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [23; n.b.]
	2	4/14 (28,57)	n.b. [44; n.b.]
	>2	20/66 (30,30)	309 [211; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/80 (31,25)	309 [211; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	24/80 (30,00)	309 [211; n.b.]
	Nein	2/6 (33,33)	n.b. [23; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	23/74 (31,08)	309 [211; n.b.]
	Nein	3/12 (25,00)	n.b. [43; n.b.]
ECOG bei Baseline	0	4/24 (16,67)	n.b. [211; n.b.]
	1	22/62 (35,48)	309 [71; 309]
Geschlecht	Weiblich	13/38 (34,21)	n.b. [71; n.b.]
	Männlich	13/48 (27,08)	309 [160; 309]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [23; n.b.]
	Nein	23/71 (32,39)	309 [211; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [23; n.b.]
	Nein	24/74 (32,43)	309 [211; n.b.]
Knochenmetastasen	Ja	14/42 (33,33)	309 [71; 309]
	Nein	12/44 (27,27)	n.b. [211; n.b.]
QLQ-LC13 Schmerzen (Arm/Schulter)			
Alter	< 65 Jahre	17/43 (39,53)	148 [106; n.b.]
	≥ 65 Jahre	13/43 (30,23)	274 [160; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [43; n.b.]
	2	4/14 (28,57)	148 [126; n.b.]
	>2	25/66 (37,88)	253 [107; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	28/80 (35,00)	274 [126; n.b.]
	Nein	2/6 (33,33)	n.b. [107; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	29/80 (36,25)	253 [126; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	27/74 (36,49)	253 [125; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	8/24 (33,33)	274 [107; n.b.]
	1	22/62 (35,48)	170 [125; n.b.]
Geschlecht	Weiblich	16/38 (42,11)	148 [74; n.b.]
	Männlich	14/48 (29,17)	274 [160; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	107 [43; n.b.]
	Nein	23/71 (32,39)	274 [160; n.b.]
Hirnmetastasen	Ja	5/12 (41,67)	148 [42; n.b.]
	Nein	25/74 (33,78)	274 [126; n.b.]
Knochenmetastasen	Ja	18/42 (42,86)	160 [106; n.b.]
	Nein	12/44 (27,27)	n.b. [148; n.b.]
QLQ-LC13 Schmerzen (andere)			
Alter	< 65 Jahre	22/43 (51,16)	107 [43; n.b.]
	≥ 65 Jahre	21/43 (48,84)	110 [64; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	64 [23; n.b.]
	2	8/14 (57,14)	85 [43; n.b.]
	>2	32/66 (48,48)	125 [44; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	39/80 (48,75)	125 [64; n.b.]
	Nein	4/6 (66,67)	96 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	40/80 (50,00)	110 [65; n.b.]
	Nein	3/6 (50,00)	64 [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	36/74 (48,65)	125 [45; n.b.]
	Nein	7/12 (58,33)	85 [23; n.b.]
ECOG bei Baseline	0	12/24 (50,00)	127 [43; n.b.]
	1	31/62 (50,00)	107 [64; n.b.]
Geschlecht	Weiblich	21/38 (55,26)	85 [45; n.b.]
	Männlich	22/48 (45,83)	125 [44; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	293 [22; 293]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Nein	36/71 (50,70)	110 [64; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [64; n.b.]
	Nein	40/74 (54,05)	107 [44; 293]
Knochenmetastasen	Ja	21/42 (50,00)	107 [45; 293]
	Nein	22/44 (50,00)	110 [43; n.b.]
QLQ-LC13 Schmerzen (Thorax)			
Alter	< 65 Jahre	17/43 (39,53)	199 [106; n.b.]
	≥ 65 Jahre	11/43 (25,58)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	4/14 (28,57)	n.b. [44; n.b.]
	>2	24/66 (36,36)	254 [129; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/80 (31,25)	n.b. [169; n.b.]
	Nein	3/6 (50,00)	159 [107; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	28/80 (35,00)	254 [148; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	25/74 (33,78)	254 [168; n.b.]
	Nein	3/12 (25,00)	n.b. [107; n.b.]
ECOG bei Baseline	0	5/24 (20,83)	n.b. [n.b.; n.b.]
	1	23/62 (37,10)	199 [129; n.b.]
Geschlecht	Weiblich	15/38 (39,47)	168 [110; n.b.]
	Männlich	13/48 (27,08)	n.b. [170; n.b.]
Lebermetastasen	Ja	3/15 (20,00)	n.b. [23; n.b.]
	Nein	25/71 (35,21)	254 [168; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [148; n.b.]
	Nein	26/74 (35,14)	254 [168; n.b.]
Knochenmetastasen	Ja	10/42 (23,81)	n.b. [169; n.b.]
	Nein	18/44 (40,91)	170 [110; n.b.]
QLQ-LC13 Wirksamkeit der Schmerzmedikation[1]			
Alter	< 65 Jahre	11/32 (34,38)	168 [64; n.b.]
	≥ 65 Jahre	4/27 (14,81)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/4 (0,00)	n.b. [n.b.; n.b.]
	2	3/9 (33,33)	n.b. [22; n.b.]
	>2	12/46 (26,09)	n.b. [168; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	14/55 (25,45)	n.b. [168; n.b.]
	Nein	1/4 (25,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	15/55 (27,27)	n.b. [168; n.b.]
	Nein	0/4 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	14/51 (27,45)	n.b. [128; n.b.]
	Nein	1/8 (12,50)	n.b. [22; n.b.]
ECOG bei Baseline	0	4/12 (33,33)	n.b. [22; n.b.]
	1	11/47 (23,40)	n.b. [168; n.b.]
Geschlecht	Weiblich	8/32 (25,00)	n.b. [128; n.b.]
	Männlich	7/27 (25,93)	n.b. [168; n.b.]
Lebermetastasen	Ja	4/11 (36,36)	44 [23; n.b.]
	Nein	11/48 (22,92)	n.b. [168; n.b.]
Hirnmetastasen	Ja	1/7 (14,29)	n.b. [168; n.b.]
	Nein	14/52 (26,92)	n.b. [128; n.b.]
Knochenmetastasen	Ja	6/30 (20,00)	n.b. [168; n.b.]
	Nein	9/29 (31,03)	n.b. [73; n.b.]
QLQ-LC13 Wunder Mund			
Alter	< 65 Jahre	9/43 (20,93)	n.b. [168; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	≥ 65 Jahre	8/43 (18,60)	259 [211; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	1/14 (7,14)	n.b. [168; n.b.]
	>2	15/66 (22,73)	259 [246; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	17/80 (21,25)	n.b. [246; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	16/80 (20,00)	259 [246; n.b.]
	Nein	1/6 (16,67)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	16/74 (21,62)	259 [211; n.b.]
	Nein	1/12 (8,33)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	5/24 (20,83)	n.b. [168; n.b.]
	1	12/62 (19,35)	259 [211; 259]
Geschlecht	Weiblich	8/38 (21,05)	n.b. [n.b.; n.b.]
	Männlich	9/48 (18,75)	259 [211; n.b.]
Lebermetastasen	Ja	1/15 (6,67)	n.b. [86; n.b.]
	Nein	16/71 (22,54)	n.b. [246; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [85; n.b.]
	Nein	15/74 (20,27)	n.b. [246; n.b.]
Knochenmetastasen	Ja	9/42 (21,43)	259 [168; n.b.]
	Nein	8/44 (18,18)	n.b. [246; n.b.]
QLQ-LC13 Bluthusten			
Alter	< 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	5/43 (11,63)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/6 (0,00)	n.b. [n.b.; n.b.]
	2	3/14 (21,43)	n.b. [113; n.b.]
	>2	7/66 (10,61)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	9/80 (11,25)	n.b. [n.b.; n.b.]
	Nein	1/6 (16,67)	n.b. [113; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	10/80 (12,50)	n.b. [n.b.; n.b.]
	Nein	0/6 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	9/74 (12,16)	n.b. [n.b.; n.b.]
	Nein	1/12 (8,33)	n.b. [113; n.b.]
ECOG bei Baseline	0	1/24 (4,17)	n.b. [n.b.; n.b.]
	1	9/62 (14,52)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	6/38 (15,79)	n.b. [217; n.b.]
	Männlich	4/48 (8,33)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [126; n.b.]
	Nein	8/71 (11,27)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [62; n.b.]
	Nein	8/74 (10,81)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	4/42 (9,52)	n.b. [n.b.; n.b.]
	Nein	6/44 (13,64)	n.b. [n.b.; n.b.]
1) Der Original-Wertebereich {1; 2; 3; 4} wurde zu {0; 33,33; 66,66; 100} transformiert, um eine Veränderung um 15 Punkte abbilden zu können.			
KI = Konfidenzintervall; n.b. = nicht berechenbar; QLQ-LC13 = Quality of Life Questionnaire Lung Cancer 13			

1.6.3 EQ5D-VAS

1.6.3.1 MID=15

Tabelle 1-10: Ergebnisse der Subgruppenanalysen für den Endpunkt "EQ-5D VAS, Zeit bis zur Verschlechterung um ≥15 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
EQ-5D VAS			
Alter	< 65 Jahre	15/43 (34,88)	199 [127; 282]
	≥ 65 Jahre	19/43 (44,19)	211 [85; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [10; n.b.]
	2	7/14 (50,00)	127 [43; 148]
	>2	25/66 (37,88)	282 [177; 309]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	30/80 (37,50)	282 [127; 309]
	Nein	4/6 (66,67)	148 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	32/80 (40,00)	211 [148; 309]
	Nein	2/6 (33,33)	n.b. [10; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	28/74 (37,84)	282 [127; 309]
	Nein	6/12 (50,00)	177 [22; n.b.]
ECOG bei Baseline	0	9/24 (37,50)	282 [85; n.b.]
	1	25/62 (40,32)	210 [148; 309]
Geschlecht	Weiblich	13/38 (34,21)	n.b. [93; n.b.]
	Männlich	21/48 (43,75)	211 [106; 309]
Lebermetastasen	Ja	6/15 (40,00)	65 [23; n.b.]
	Nein	28/71 (39,44)	211 [148; 309]
Hirnmetastasen	Ja	5/12 (41,67)	199 [45; n.b.]
	Nein	29/74 (39,19)	282 [127; 309]
Knochenmetastasen	Ja	18/42 (42,86)	177 [65; 309]
	Nein	16/44 (36,36)	282 [148; n.b.]
KI = Konfidenzintervall; n.b. = nicht berechenbar; VAS = Visuelle Analogskala			

1.6.4 PG-IC

1.6.4.1 Verschlechterung um ≥15 Punkte

Tabelle 1-11: Ergebnisse der Subgruppenanalysen für den Endpunkt "PG-IC, Zeit bis zur Verschlechterung um ≥15 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
PG-IC Husten			
Alter	< 65 Jahre	6/28 (21,43)	n.b. [246; n.b.]
	≥ 65 Jahre	1/28 (3,57)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/4 (0,00)	n.b. [n.b.; n.b.]
	2	0/8 (0,00)	n.b. [n.b.; n.b.]
	>2	7/44 (15,91)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	7/53 (13,21)	n.b. [n.b.; n.b.]
	Nein	0/3 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	7/49 (14,29)	n.b. [n.b.; n.b.]
	Nein	0/7 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	7/46 (15,22)	n.b. [n.b.; n.b.]
	Nein	0/10 (0,00)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	2/19 (10,53)	n.b. [n.b.; n.b.]
	1	5/37 (13,51)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	3/28 (10,71)	n.b. [n.b.; n.b.]
	Männlich	4/28 (14,29)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	1/7 (14,29)	n.b. [120; n.b.]
	Nein	6/49 (12,24)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	1/10 (10,00)	n.b. [199; n.b.]
	Nein	6/46 (13,04)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	3/23 (13,04)	n.b. [n.b.; n.b.]
	Nein	4/33 (12,12)	n.b. [n.b.; n.b.]
PG-IC Brustschmerz			
Alter	< 65 Jahre	2/28 (7,14)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	2/28 (7,14)	n.b. [275; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/4 (0,00)	n.b. [n.b.; n.b.]
	2	0/8 (0,00)	n.b. [n.b.; n.b.]
	>2	4/44 (9,09)	n.b. [275; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	4/53 (7,55)	n.b. [275; n.b.]
	Nein	0/3 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	4/49 (8,16)	n.b. [275; n.b.]
	Nein	0/7 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	4/46 (8,70)	n.b. [275; n.b.]
	Nein	0/10 (0,00)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	1/19 (5,26)	n.b. [n.b.; n.b.]
	1	3/37 (8,11)	n.b. [275; n.b.]
Geschlecht	Weiblich	2/28 (7,14)	n.b. [275; n.b.]
	Männlich	2/28 (7,14)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	0/7 (0,00)	n.b. [n.b.; n.b.]
	Nein	4/49 (8,16)	n.b. [275; n.b.]
Hirnmetastasen	Ja	2/10 (20,00)	275 [199; 275]
	Nein	2/46 (4,35)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	2/23 (8,70)	n.b. [275; n.b.]
	Nein	2/33 (6,06)	n.b. [n.b.; n.b.]
PG-IC Kurzatmigkeit			

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Alter	< 65 Jahre	7/28 (25,00)	n.b. [238; n.b.]
	≥ 65 Jahre	2/28 (7,14)	n.b. [n.b.; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	0/4 (0,00)	n.b. [n.b.; n.b.]
	2	0/8 (0,00)	n.b. [n.b.; n.b.]
	>2	9/44 (20,45)	n.b. [238; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	9/53 (16,98)	n.b. [n.b.; n.b.]
	Nein	0/3 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	9/49 (18,37)	n.b. [n.b.; n.b.]
	Nein	0/7 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	9/46 (19,57)	n.b. [246; n.b.]
	Nein	0/10 (0,00)	n.b. [n.b.; n.b.]
ECOG bei Baseline	0	3/19 (15,79)	n.b. [n.b.; n.b.]
	1	6/37 (16,22)	n.b. [n.b.; n.b.]
Geschlecht	Weiblich	5/28 (17,86)	n.b. [217; n.b.]
	Männlich	4/28 (14,29)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	1/7 (14,29)	n.b. [120; n.b.]
	Nein	8/49 (16,33)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	1/10 (10,00)	n.b. [199; n.b.]
	Nein	8/46 (17,39)	n.b. [n.b.; n.b.]
Knochenmetastasen	Ja	3/23 (13,04)	n.b. [n.b.; n.b.]
	Nein	6/33 (18,18)	n.b. [246; n.b.]
Die Beobachtungen 4 ("ein bisschen schlechter") und 5 ("viel schlechter") wurden als Verschlechterung gewertet und auf den Wert 100 gesetzt, um die Verschlechterung um 15 Punkte abbilden zu können.			
KI = Konfidenzintervall; n.b. = nicht berechenbar; PG-IC = Patienten-Eindruck der Veränderung			

1.6.5 PRO-CTCAE

1.6.5.1 Verschlechterung um ≥15 Punkte

Tabelle 1-12: Ergebnisse der Subgruppenanalysen für den Endpunkt "PRO-CTCAE, Zeit bis zur Verschlechterung um ≥15 Punkte" aus Studie 20170543 mit dem zu bewertenden Arzneimittel.

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
PRO-CTCAE, Schweregrad von Wunden oder offenen Stellen in Mund oder Hals			
Alter	< 65 Jahre	9/44 (20,45)	n.b. [176; n.b.]
	≥ 65 Jahre	15/44 (34,09)	259 [106; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [22; n.b.]
	2	2/14 (14,29)	n.b. [168; n.b.]
	>2	21/68 (30,88)	259 [127; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	23/81 (28,40)	259 [168; n.b.]
	Nein	1/7 (14,29)	n.b. [177; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	23/82 (28,05)	259 [176; n.b.]
	Nein	1/6 (16,67)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	22/75 (29,33)	259 [127; n.b.]
	Nein	2/13 (15,38)	n.b. [177; n.b.]
ECOG bei Baseline	0	5/25 (20,00)	n.b. [127; n.b.]
	1	19/63 (30,16)	259 [176; 259]
Geschlecht	Weiblich	11/39 (28,21)	n.b. [106; n.b.]
	Männlich	13/49 (26,53)	259 [127; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [86; n.b.]
	Nein	22/73 (30,14)	259 [168; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [43; n.b.]
	Nein	22/76 (28,95)	259 [168; n.b.]
Knochenmetastasen	Ja	14/42 (33,33)	177 [106; n.b.]
	Nein	10/46 (21,74)	n.b. [176; n.b.]
PRO-CTCAE, Schweregrad von rissigen Mundwinkeln			
Alter	< 65 Jahre	5/44 (11,36)	n.b. [260; n.b.]
	≥ 65 Jahre	9/44 (20,45)	309 [309; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [43; n.b.]
	2	1/14 (7,14)	n.b. [n.b.; n.b.]
	>2	12/68 (17,65)	309 [260; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	13/81 (16,05)	309 [260; n.b.]
	Nein	1/7 (14,29)	n.b. [85; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	13/82 (15,85)	309 [260; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	12/75 (16,00)	309 [260; n.b.]
	Nein	2/13 (15,38)	n.b. [85; n.b.]
ECOG bei Baseline	0	2/25 (8,00)	n.b. [n.b.; n.b.]
	1	12/63 (19,05)	260 [260; 309]
Geschlecht	Weiblich	6/39 (15,38)	n.b. [260; n.b.]
	Männlich	8/49 (16,33)	309 [n.b.; n.b.]
Lebermetastasen	Ja	2/15 (13,33)	n.b. [86; n.b.]
	Nein	12/73 (16,44)	309 [260; n.b.]
Hirnmetastasen	Ja	2/12 (16,67)	n.b. [85; n.b.]
	Nein	12/76 (15,79)	309 [260; n.b.]
Knochenmetastasen	Ja	6/42 (14,29)	309 [n.b.; n.b.]
	Nein	8/46 (17,39)	n.b. [260; n.b.]
PRO-CTCAE, Schweregrad von juckender Haut			

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Alter	< 65 Jahre	18/44 (40,91)	n.b. [63; n.b.]
	≥ 65 Jahre	20/44 (45,45)	212 [64; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [22; n.b.]
	2	8/14 (57,14)	64 [22; n.b.]
	>2	28/68 (41,18)	212 [86; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	36/81 (44,44)	114 [64; n.b.]
	Nein	2/7 (28,57)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	36/82 (43,90)	212 [84; n.b.]
	Nein	2/6 (33,33)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	34/75 (45,33)	114 [64; n.b.]
	Nein	4/13 (30,77)	n.b. [22; n.b.]
ECOG bei Baseline	0	9/25 (36,00)	n.b. [64; n.b.]
	1	29/63 (46,03)	114 [63; n.b.]
Geschlecht	Weiblich	17/39 (43,59)	n.b. [84; n.b.]
	Männlich	21/49 (42,86)	212 [63; n.b.]
Lebermetastasen	Ja	4/15 (26,67)	212 [44; 212]
	Nein	34/73 (46,58)	114 [64; n.b.]
Hirnmetastasen	Ja	4/12 (33,33)	n.b. [40; n.b.]
	Nein	34/76 (44,74)	212 [84; n.b.]
Knochenmetastasen	Ja	20/42 (47,62)	106 [43; n.b.]
	Nein	18/46 (39,13)	n.b. [85; n.b.]
PRO-CTCAE, Schweregrad von Taubheitsgefühl in Händen oder Füßen			
Alter	< 65 Jahre	14/44 (31,82)	n.b. [86; n.b.]
	≥ 65 Jahre	14/44 (31,82)	n.b. [160; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	3/6 (50,00)	93 [22; n.b.]
	2	4/14 (28,57)	n.b. [71; n.b.]
	>2	21/68 (30,88)	n.b. [160; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/81 (30,86)	n.b. [160; n.b.]
	Nein	3/7 (42,86)	177 [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	25/82 (30,49)	n.b. [177; n.b.]
	Nein	3/6 (50,00)	93 [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	22/75 (29,33)	n.b. [160; n.b.]
	Nein	6/13 (46,15)	177 [22; n.b.]
ECOG bei Baseline	0	7/25 (28,00)	n.b. [85; n.b.]
	1	21/63 (33,33)	216 [160; n.b.]
Geschlecht	Weiblich	16/39 (41,03)	n.b. [71; n.b.]
	Männlich	12/49 (24,49)	n.b. [177; n.b.]
Lebermetastasen	Ja	1/15 (6,67)	n.b. [n.b.; n.b.]
	Nein	27/73 (36,99)	216 [93; n.b.]
Hirnmetastasen	Ja	3/12 (25,00)	n.b. [22; n.b.]
	Nein	25/76 (32,89)	n.b. [160; n.b.]
Knochenmetastasen	Ja	16/42 (38,10)	177 [74; n.b.]
	Nein	12/46 (26,09)	n.b. [104; n.b.]
PRO-CTCAE, Schweregrad von Schmerzen			
Alter	< 65 Jahre	16/40 (40,00)	128 [44; n.b.]
	≥ 65 Jahre	12/36 (33,33)	n.b. [85; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/5 (20,00)	n.b. [22; n.b.]
	2	3/13 (23,08)	n.b. [43; n.b.]
	>2	24/58 (41,38)	211 [73; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	27/70 (38,57)	211 [93; n.b.]
	Nein	1/6 (16,67)	n.b. [43; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Platinum-basierte Chemotherapie	Ja	27/71 (38,03)	211 [93; n.b.]
	Nein	1/5 (20,00)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	26/65 (40,00)	211 [85; n.b.]
	Nein	2/11 (18,18)	n.b. [43; n.b.]
ECOG bei Baseline	0	7/21 (33,33)	n.b. [58; n.b.]
	1	21/55 (38,18)	211 [73; n.b.]
Geschlecht	Weiblich	15/35 (42,86)	128 [73; n.b.]
	Männlich	13/41 (31,71)	n.b. [85; n.b.]
Lebermetastasen	Ja	6/13 (46,15)	71 [23; n.b.]
	Nein	22/63 (34,92)	n.b. [127; n.b.]
Hirnmetastasen	Ja	2/9 (22,22)	n.b. [22; n.b.]
	Nein	26/67 (38,81)	211 [93; n.b.]
Knochenmetastasen	Ja	11/39 (28,21)	n.b. [85; n.b.]
	Nein	17/37 (45,95)	211 [71; n.b.]
PRO-CTCAE, Schweregrad von Muskelschmerzen			
Alter	< 65 Jahre	14/36 (38,89)	148 [86; n.b.]
	≥ 65 Jahre	8/33 (24,24)	n.b. [167; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/5 (20,00)	n.b. [22; n.b.]
	2	6/12 (50,00)	148 [22; n.b.]
	>2	15/52 (28,85)	n.b. [127; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	20/63 (31,75)	n.b. [127; n.b.]
	Nein	2/6 (33,33)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	21/64 (32,81)	n.b. [148; n.b.]
	Nein	1/5 (20,00)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	19/58 (32,76)	n.b. [127; n.b.]
	Nein	3/11 (27,27)	n.b. [22; n.b.]
ECOG bei Baseline	0	5/19 (26,32)	n.b. [85; n.b.]
	1	17/50 (34,00)	n.b. [148; n.b.]
Geschlecht	Weiblich	12/34 (35,29)	167 [104; n.b.]
	Männlich	10/35 (28,57)	n.b. [199; n.b.]
Lebermetastasen	Ja	4/12 (33,33)	167 [22; n.b.]
	Nein	18/57 (31,58)	n.b. [148; n.b.]
Hirnmetastasen	Ja	3/9 (33,33)	199 [22; n.b.]
	Nein	19/60 (31,67)	n.b. [127; n.b.]
Knochenmetastasen	Ja	9/36 (25,00)	n.b. [167; n.b.]
	Nein	13/33 (39,39)	148 [86; n.b.]
PRO-CTCAE, Schweregrad von Gelenkschmerzen			
Alter	< 65 Jahre	13/36 (36,11)	n.b. [64; n.b.]
	≥ 65 Jahre	8/29 (27,59)	253 [106; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/4 (25,00)	n.b. [22; n.b.]
	2	6/10 (60,00)	106 [22; 253]
	>2	14/51 (27,45)	n.b. [199; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	19/60 (31,67)	253 [199; n.b.]
	Nein	2/5 (40,00)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	20/61 (32,79)	253 [199; n.b.]
	Nein	1/4 (25,00)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	18/56 (32,14)	253 [199; n.b.]
	Nein	3/9 (33,33)	n.b. [22; n.b.]
ECOG bei Baseline	0	7/20 (35,00)	n.b. [44; n.b.]
	1	14/45 (31,11)	n.b. [106; n.b.]
Geschlecht	Weiblich	8/27 (29,63)	n.b. [64; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	Männlich	13/38 (34,21)	253 [199; n.b.]
Lebermetastasen	Ja	5/12 (41,67)	106 [23; n.b.]
	Nein	16/53 (30,19)	253 [199; n.b.]
Hirnmetastasen	Ja	1/10 (10,00)	199 [n.b.; n.b.]
	Nein	20/55 (36,36)	253 [64; n.b.]
Knochenmetastasen	Ja	11/32 (34,38)	199 [106; n.b.]
	Nein	10/33 (30,30)	n.b. [64; n.b.]
PRO-CTCAE, Beeinträchtigung durch Wunden oder offene Stellen in Mund oder Hals			
Alter	< 65 Jahre	1/14 (7,14)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	2/16 (12,50)	n.b. [210; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/2 (50,00)	n.b. [43; n.b.]
	2	0/3 (0,00)	n.b. [n.b.; n.b.]
	>2	2/25 (8,00)	n.b. [210; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	3/29 (10,34)	n.b. [210; n.b.]
	Nein	0/1 (0,00)	n.b. [n.b.; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	2/28 (7,14)	n.b. [210; n.b.]
	Nein	1/2 (50,00)	n.b. [43; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	2/27 (7,41)	n.b. [210; n.b.]
	Nein	1/3 (33,33)	n.b. [43; n.b.]
ECOG bei Baseline	0	2/7 (28,57)	n.b. [23; n.b.]
	1	1/23 (4,35)	n.b. [210; n.b.]
Geschlecht	Weiblich	1/13 (7,69)	n.b. [210; n.b.]
	Männlich	2/17 (11,76)	n.b. [n.b.; n.b.]
Lebermetastasen	Ja	0/2 (0,00)	n.b. [n.b.; n.b.]
	Nein	3/28 (10,71)	n.b. [210; n.b.]
Hirnmetastasen	Ja	0/3 (0,00)	n.b. [n.b.; n.b.]
	Nein	3/27 (11,11)	n.b. [210; n.b.]
Knochenmetastasen	Ja	1/17 (5,88)	n.b. [n.b.; n.b.]
	Nein	2/13 (15,38)	n.b. [210; n.b.]
PRO-CTCAE, Beeinträchtigung durch Taubheitsgefühl in Händen oder Füßen			
Alter	< 65 Jahre	5/27 (18,52)	n.b. [n.b.; n.b.]
	≥ 65 Jahre	9/25 (36,00)	212 [85; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/3 (33,33)	n.b. [85; n.b.]
	2	3/8 (37,50)	n.b. [22; n.b.]
	>2	10/41 (24,39)	n.b. [169; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	12/47 (25,53)	212 [169; n.b.]
	Nein	2/5 (40,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	13/49 (26,53)	n.b. [169; n.b.]
	Nein	1/3 (33,33)	n.b. [85; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	11/44 (25,00)	212 [169; n.b.]
	Nein	3/8 (37,50)	n.b. [22; n.b.]
ECOG bei Baseline	0	2/11 (18,18)	n.b. [43; n.b.]
	1	12/41 (29,27)	212 [85; n.b.]
Geschlecht	Weiblich	6/22 (27,27)	n.b. [85; n.b.]
	Männlich	8/30 (26,67)	212 [85; n.b.]
Lebermetastasen	Ja	0/7 (0,00)	n.b. [n.b.; n.b.]
	Nein	14/45 (31,11)	212 [85; n.b.]
Hirnmetastasen	Ja	0/6 (0,00)	n.b. [n.b.; n.b.]
	Nein	14/46 (30,43)	212 [85; n.b.]
Knochenmetastasen	Ja	8/27 (29,63)	169 [65; n.b.]
	Nein	6/25 (24,00)	n.b. [212; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
PRO-CTCAE, Beeinträchtigung durch Schmerzen			
Alter	< 65 Jahre	14/39 (35,90)	199 [64; n.b.]
	≥ 65 Jahre	13/35 (37,14)	217 [93; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/5 (40,00)	n.b. [64; n.b.]
	2	3/13 (23,08)	n.b. [106; n.b.]
	>2	22/56 (39,29)	199 [93; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	25/68 (36,76)	217 [106; n.b.]
	Nein	2/6 (33,33)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	25/69 (36,23)	217 [106; n.b.]
	Nein	2/5 (40,00)	n.b. [64; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	23/63 (36,51)	199 [106; n.b.]
	Nein	4/11 (36,36)	n.b. [64; n.b.]
ECOG bei Baseline	0	8/21 (38,10)	n.b. [43; n.b.]
	1	19/53 (35,85)	217 [106; n.b.]
Geschlecht	Weiblich	11/34 (32,35)	217 [93; n.b.]
	Männlich	16/40 (40,00)	199 [85; n.b.]
Lebermetastasen	Ja	3/12 (25,00)	n.b. [23; n.b.]
	Nein	24/62 (38,71)	217 [106; n.b.]
Hirnmetastasen	Ja	1/9 (11,11)	n.b. [199; n.b.]
	Nein	26/65 (40,00)	217 [93; n.b.]
Knochenmetastasen	Ja	12/38 (31,58)	199 [85; n.b.]
	Nein	15/36 (41,67)	217 [73; n.b.]
PRO-CTCAE, Beeinträchtigung durch Muskelschmerzen			
Alter	< 65 Jahre	14/36 (38,89)	n.b. [43; n.b.]
	≥ 65 Jahre	10/31 (32,26)	351 [217; 351]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/5 (40,00)	n.b. [22; n.b.]
	2	8/11 (72,73)	64 [22; 148]
	>2	14/51 (27,45)	351 [217; 351]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	21/61 (34,43)	351 [217; 351]
	Nein	3/6 (50,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	22/62 (35,48)	351 [148; 351]
	Nein	2/5 (40,00)	n.b. [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	19/56 (33,93)	351 [217; 351]
	Nein	5/11 (45,45)	n.b. [22; n.b.]
ECOG bei Baseline	0	9/19 (47,37)	85 [22; n.b.]
	1	15/48 (31,25)	351 [217; 351]
Geschlecht	Weiblich	10/34 (29,41)	n.b. [148; n.b.]
	Männlich	14/33 (42,42)	351 [43; 351]
Lebermetastasen	Ja	6/11 (54,55)	44 [22; n.b.]
	Nein	18/56 (32,14)	351 [217; 351]
Hirnmetastasen	Ja	3/8 (37,50)	148 [21; n.b.]
	Nein	21/59 (35,59)	351 [217; 351]
Knochenmetastasen	Ja	13/35 (37,14)	351 [64; 351]
	Nein	11/32 (34,38)	n.b. [148; n.b.]
PRO-CTCAE, Beeinträchtigung durch Gelenkschmerzen			
Alter	< 65 Jahre	11/35 (31,43)	n.b. [64; n.b.]
	≥ 65 Jahre	7/28 (25,00)	n.b. [167; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/4 (50,00)	64 [22; n.b.]
	2	7/10 (70,00)	66 [22; 167]
	>2	9/49 (18,37)	n.b. [n.b.; n.b.]
	Ja	17/58 (29,31)	n.b. [167; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Nein	1/5 (20,00)	n.b. [22; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	16/59 (27,12)	n.b. [167; n.b.]
	Nein	2/4 (50,00)	64 [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	15/54 (27,78)	n.b. [167; n.b.]
	Nein	3/9 (33,33)	n.b. [22; n.b.]
ECOG bei Baseline	0	6/20 (30,00)	n.b. [43; n.b.]
	1	12/43 (27,91)	n.b. [167; n.b.]
Geschlecht	Weiblich	8/27 (29,63)	n.b. [85; n.b.]
	Männlich	10/36 (27,78)	n.b. [89; n.b.]
Lebermetastasen	Ja	3/10 (30,00)	n.b. [22; n.b.]
	Nein	15/53 (28,30)	n.b. [n.b.; n.b.]
Hirnmetastasen	Ja	1/9 (11,11)	n.b. [21; n.b.]
	Nein	17/54 (31,48)	n.b. [167; n.b.]
Knochenmetastasen	Ja	10/30 (33,33)	n.b. [64; n.b.]
	Nein	8/33 (24,24)	n.b. [n.b.; n.b.]
PRO-CTCAE, Schmerzfrequenz			
Alter	< 65 Jahre	22/44 (50,00)	107 [44; n.b.]
	≥ 65 Jahre	20/44 (45,45)	254 [43; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	1/6 (16,67)	n.b. [23; n.b.]
	2	10/14 (71,43)	63 [22; 127]
	>2	31/68 (45,59)	254 [65; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	38/81 (46,91)	127 [63; n.b.]
	Nein	4/7 (57,14)	107 [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	41/82 (50,00)	125 [64; n.b.]
	Nein	1/6 (16,67)	n.b. [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	37/75 (49,33)	127 [44; n.b.]
	Nein	5/13 (38,46)	n.b. [43; n.b.]
ECOG bei Baseline	0	13/25 (52,00)	127 [43; n.b.]
	1	29/63 (46,03)	254 [63; n.b.]
Geschlecht	Weiblich	18/39 (46,15)	127 [64; n.b.]
	Männlich	24/49 (48,98)	125 [43; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	107 [23; n.b.]
	Nein	35/73 (47,95)	127 [65; n.b.]
Hirnmetastasen	Ja	4/12 (33,33)	n.b. [23; n.b.]
	Nein	38/76 (50,00)	125 [63; n.b.]
Knochenmetastasen	Ja	24/42 (57,14)	74 [43; 127]
	Nein	18/46 (39,13)	n.b. [85; n.b.]
PRO-CTCAE, Frequenz von Muskelschmerzen			
Alter	< 65 Jahre	19/44 (43,18)	148 [64; n.b.]
	≥ 65 Jahre	18/44 (40,91)	n.b. [55; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	127 [22; n.b.]
	2	6/14 (42,86)	148 [30; n.b.]
	>2	29/68 (42,65)	169 [64; n.b.]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	35/81 (43,21)	169 [64; n.b.]
	Nein	2/7 (28,57)	n.b. [86; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	35/82 (42,68)	169 [74; n.b.]
	Nein	2/6 (33,33)	127 [22; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	33/75 (44,00)	169 [55; n.b.]
	Nein	4/13 (30,77)	n.b. [86; n.b.]
ECOG bei Baseline	0	4/25 (16,00)	n.b. [n.b.; n.b.]

		Sotorasib	
Subgruppe	**Kategorie**	**Patienten mit Ereignis n/N (%)**	**Median [95% KI]**
	1	33/63 (52,38)	127 [43; n.b.]
Geschlecht	Weiblich	22/39 (56,41)	74 [43; n.b.]
	Männlich	15/49 (30,61)	n.b. [160; n.b.]
Lebermetastasen	Ja	6/15 (40,00)	n.b. [22; n.b.]
	Nein	31/73 (42,47)	n.b. [85; n.b.]
Hirnmetastasen	Ja	5/12 (41,67)	148 [43; n.b.]
	Nein	32/76 (42,11)	n.b. [74; n.b.]
Knochenmetastasen	Ja	19/42 (45,24)	160 [55; n.b.]
	Nein	18/46 (39,13)	n.b. [64; n.b.]
PRO-CTCAE, Frequenz von Gelenkschmerzen			
Alter	< 65 Jahre	24/44 (54,55)	74 [45; 253]
	≥ 65 Jahre	20/44 (45,45)	211 [62; n.b.]
Vorangegangene Linien von Anti-Krebs Therapien	1	2/6 (33,33)	n.b. [23; n.b.]
	2	6/14 (42,86)	n.b. [43; n.b.]
	>2	36/68 (52,94)	85 [62; 253]
Vorangegangene Linien von Anti-PD-1 oder Anti-PD-L1 Therapien	Ja	41/81 (50,62)	85 [64; 253]
	Nein	3/7 (42,86)	n.b. [43; n.b.]
Vorangegangene Platinum-basierte Chemotherapie	Ja	42/82 (51,22)	85 [64; 253]
	Nein	2/6 (33,33)	n.b. [23; n.b.]
Vorangegangene Chemo- und Anti-PD-1 oder Anti-PD-L1 Therapie	Ja	39/75 (52,00)	85 [64; 253]
	Nein	5/13 (38,46)	n.b. [43; n.b.]
ECOG bei Baseline	0	11/25 (44,00)	253 [43; n.b.]
	1	33/63 (52,38)	85 [62; n.b.]
Geschlecht	Weiblich	21/39 (53,85)	74 [45; n.b.]
	Männlich	23/49 (46,94)	105 [64; n.b.]
Lebermetastasen	Ja	7/15 (46,67)	85 [22; n.b.]
	Nein	37/73 (50,68)	105 [64; n.b.]
Hirnmetastasen	Ja	6/12 (50,00)	64 [22; n.b.]
	Nein	38/76 (50,00)	105 [64; n.b.]
Knochenmetastasen	Ja	19/42 (45,24)	85 [62; n.b.]
	Nein	25/46 (54,35)	65 [43; n.b.]
Der Original-Wertebereich {1; 2; 3; 4; 5} wurde zu {0; 25; 50; 75; 100} transformiert, um eine Veränderung um 15 Punkte abbilden zu können.			
KI = Konfidenzintervall; n.b. = nicht berechenbar; PRO-CTCAE = Patient-Reported Outcome Version der Common Technology Criteria for Adverse Events			

1.7 Subgruppenanalysen – Sicherheit

Table 14-6.3.1. Summary of Time to First Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first TEAE		
Overall	125 / 126	0.2 (0.2, 0.3)
Age at baseline		
< 65 years	66 / 67	0.3 (0.1, 0.3)
≥ 65 years	59 / 59	0.2 (0.2, 0.3)
Prior lines of anti-cancer therapy		
1	54 / 54	0.2 (0.1, 0.3)
2	43 / 44	0.5 (0.2, 0.6)
> 2	28 / 28	0.2 (0.1, 0.3)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	114 / 115	0.2 (0.2, 0.3)
No	11 / 11	0.2 (0.0, 0.9)
Prior platinum-base chemotherapy		
Yes	112 / 113	0.3 (0.2, 0.3)
No	13 / 13	0.1 (0.0, 0.3)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	101 / 102	0.3 (0.2, 0.3)
No	24 / 24	0.2 (0.0, 0.3)
PD-L1 protein expression		
< 1%	33 / 33	0.2 (0.1, 0.5)
≥ 1% and < 50%	24 / 24	0.2 (0.1, 0.5)
≥ 50%	34 / 35	0.3 (0.2, 0.4)
ECOG		
0	38 / 38	0.3 (0.1, 0.6)
1	87 / 88	0.2 (0.2, 0.3)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-001-teae-sum-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.1. Summary of Time to First Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	103 / 103	0.3 (0.2, 0.3)
Black	2 / 2	0.0 (NE, NE)
Asian	18 / 19	0.5 (0.0, 1.0)
Other	2 / 2	0.1 (0.0, NE)
Sex		
Male	63 / 63	0.2 (0.1, 0.5)
Female	62 / 63	0.2 (0.2, 0.3)
Histopathology		
Squamous	1 / 1	0.5 (NE, NE)
Non-squamous	124 / 125	0.2 (0.2, 0.3)
Metastatic		
Yes	121 / 122	0.2 (0.2, 0.3)
No	4 / 4	0.1 (0.0, NE)
Liver metastasis		
Yes	26 / 26	0.3 (0.1, 0.5)
No	99 / 100	0.2 (0.2, 0.3)
Brain metastasis		
Yes	26 / 26	0.2 (0.0, 0.3)
No	99 / 100	0.3 (0.2, 0.3)
Bone metastasis		
Yes	61 / 61	0.3 (0.2, 0.5)
No	64 / 65	0.2 (0.1, 0.3)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-001-teae-sum-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.1. Summary of Time to First Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	5 / 6	0.0 (0.0, NE)
Current	15 / 15	0.2 (0.0, 0.7)
Former	102 / 102	0.2 (0.2, 0.3)
Region		
North America	78 / 79	0.2 (0.2, 0.3)
Europe	30 / 30	0.3 (0.1, 0.5)
Asia	12 / 12	0.5 (0.0, 1.1)
Rest of the world	5 / 5	0.1 (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-001-teae-sum-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.2. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first grade ≥ 3 TEAE		
Overall	75 / 126	4.3 (2.6, 7.0)
Age at baseline		
< 65 years	41 / 67	3.0 (2.0, 7.4)
≥ 65 years	34 / 59	6.0 (2.3, 9.4)
Prior lines of anti-cancer therapy		
1	30 / 54	6.0 (2.3, NE)
2	28 / 44	2.6 (1.4, 9.0)
> 2	17 / 28	6.6 (2.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	69 / 115	4.3 (2.4, 7.4)
No	6 / 11	3.8 (1.4, NE)
Prior platinum-base chemotherapy		
Yes	69 / 113	3.7 (2.5, 6.7)
No	6 / 13	NE (1.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	63 / 102	3.7 (2.3, 6.7)
No	12 / 24	9.0 (1.4, NE)
PD-L1 protein expression		
< 1%	20 / 33	6.3 (2.5, NE)
≥ 1% and < 50%	15 / 24	2.8 (1.4, NE)
≥ 50%	23 / 35	2.3 (1.4, 5.7)
ECOG		
0	17 / 38	NE (2.7, NE)
1	58 / 88	3.3 (2.1, 6.3)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-002-teae-sum-grd3-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:48) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.2. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	61 / 103	4.3 (2.5, 8.0)
Black	1 / 2	NE (1.8, NE)
Asian	12 / 19	3.7 (1.1, NE)
Other	1 / 2	NE (1.4, NE)
Sex		
Male	35 / 63	6.0 (2.7, NE)
Female	40 / 63	2.8 (2.0, 7.0)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	75 / 125	3.8 (2.5, 7.0)
Metastatic		
Yes	74 / 122	3.8 (2.5, 6.7)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	16 / 26	2.8 (1.4, NE)
No	59 / 100	5.7 (2.6, 9.0)
Brain metastasis		
Yes	17 / 26	3.0 (1.8, 5.7)
No	58 / 100	6.0 (2.6, 9.0)
Bone metastasis		
Yes	44 / 61	2.6 (1.9, 3.5)
No	31 / 65	NE (3.7, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-002-teae-sum-grd3-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:48) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.2. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	4 / 6	2.0 (0.2, NE)
Current	8 / 15	2.4 (1.0, NE)
Former	62 / 102	4.3 (2.8, 7.4)
Region		
North America	43 / 79	6.7 (2.8, NE)
Europe	21 / 30	2.6 (1.6, 6.3)
Asia	9 / 12	1.8 (0.5, 6.0)
Rest of the world	2 / 5	NE (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-002-teae-sum-grd3-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:48) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.3. Summary of Time to First Serious Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first serious TEAE		
Overall	63 / 126	8.5 (5.1, NE)
Age at baseline		
< 65 years	35 / 67	8.0 (3.0, NE)
≥ 65 years	28 / 59	9.0 (3.8, NE)
Prior lines of anti-cancer therapy		
1	27 / 54	8.5 (2.8, NE)
2	22 / 44	8.5 (2.1, NE)
> 2	14 / 28	8.0 (4.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	58 / 115	8.0 (5.1, NE)
No	5 / 11	NE (2.3, NE)
Prior platinum-base chemotherapy		
Yes	59 / 113	7.4 (3.7, NE)
No	4 / 13	NE (8.5, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	54 / 102	7.4 (3.5, NE)
No	9 / 24	NE (3.8, NE)
PD-L1 protein expression		
< 1%	16 / 33	9.4 (2.8, NE)
≥ 1% and < 50%	13 / 24	8.0 (1.8, NE)
≥ 50%	20 / 35	6.3 (1.9, NE)
ECOG		
0	13 / 38	NE (7.4, NE)
1	50 / 88	6.0 (2.8, 9.4)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-003-teae-sum-ser-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:52) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.3. Summary of Time to First Serious Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	53 / 103	8.0 (3.8, NE)
Black	1 / 2	NE (1.8, NE)
Asian	9 / 19	6.0 (2.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	28 / 63	9.4 (5.1, NE)
Female	35 / 63	7.4 (2.7, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	63 / 125	8.0 (4.6, NE)
Metastatic		
Yes	62 / 122	8.0 (4.6, NE)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	13 / 26	8.0 (2.3, NE)
No	50 / 100	8.5 (4.6, NE)
Brain metastasis		
Yes	16 / 26	3.0 (2.1, NE)
No	47 / 100	9.0 (6.3, NE)
Bone metastasis		
Yes	38 / 61	3.7 (2.7, 8.5)
No	25 / 65	NE (7.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-003-teae-sum-ser-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:52) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.3. Summary of Time to First Serious Treatment Emergent Adverse Event (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	6 / 15	NE (1.3, NE)
Former	54 / 102	8.0 (3.8, NE)
Region		
North America	36 / 79	9.4 (5.1, NE)
Europe	18 / 30	6.3 (2.3, 9.0)
Asia	7 / 12	5.7 (0.5, NE)
Rest of the world	2 / 5	NE (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-003-teae-sum-ser-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:52) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.4. Summary of Time to First Treatment Emergent Adverse Event Leading to Discontinuation of AMG 510 (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first TEAE leading to discontinuation of AMG 510		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	6 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	4 / 54	NE (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	11 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	11 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	4 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	9 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-004-teae-sum-disc-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:55) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.4. Summary of Time to First Treatment Emergent Adverse Event Leading to Discontinuation of AMG 510 (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	9 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	9 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-004-teae-sum-disc-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:55) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.4. Summary of Time to First Treatment Emergent Adverse Event Leading to Discontinuation of AMG 510 (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	9 / 102	NE (NE, NE)
Region		
North America	4 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.0, NE)
Rest of the world	1 / 5	NE (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-004-teae-sum-disc-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:55) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Blood and lymphatic system disorders TEAE		
Overall	17 / 126	NE (NE, NE)
Age at baseline		
< 65 years	14 / 67	NE (NE, NE)
≥ 65 years	3 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	6 / 54	NE (NE, NE)
2	8 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	15 / 115	NE (NE, NE)
No	2 / 11	NE (4.3, NE)
Prior platinum-base chemotherapy		
Yes	16 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	14 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	2 / 38	NE (NE, NE)
1	15 / 88	NE (NE, NE)
Race		
White	13 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	1 / 2	NE (1.4, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	13 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	17 / 125	NE (NE, NE)
Metastatic		
Yes	17 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	16 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (4.4, NE)
No	13 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	11 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	4 / 15	NE (2.0, NE)
Former	11 / 102	NE (NE, NE)
Region		
North America	10 / 79	NE (NE, NE)
Europe	5 / 30	NE (NE, NE)
Asia	2 / 12	NE (2.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Anaemia TEAE		
Overall	14 / 126	NE (NE, NE)
Age at baseline		
< 65 years	11 / 67	NE (NE, NE)
≥ 65 years	3 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	13 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	13 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	12 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	13 / 88	NE (NE, NE)
Race		
White	10 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	1 / 2	NE (1.4, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	10 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	14 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	14 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	13 / 100	NE (NE, NE)
Brain metastasis		
Yes	2 / 26	NE (NE, NE)
No	12 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	8 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	4 / 15	NE (2.0, NE)
Former	8 / 102	NE (NE, NE)
Region		
North America	8 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (2.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Cardiac disorders TEAE		
Overall	10 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	2 / 11	NE (2.7, NE)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	9 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	6 / 103	NE (NE, NE)
Black	1 / 2	NE (1.8, NE)
Asian	3 / 19	NE (6.0, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	4 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	10 / 125	NE (NE, NE)
Metastatic		
Yes	10 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	1 / 6	NE (3.1, NE)
Current	2 / 15	NE (4.2, NE)
Former	7 / 102	NE (NE, NE)
Region		
North America	6 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	2 / 12	NE (6.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Eye disorders TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	4 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	2 / 13	NE (7.5, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	9 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	9 / 88	NE (NE, NE)
Race		
White	9 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (6.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	2 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	10 / 122	NE (NE, NE)
No	1 / 4	NE (0.5, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	3 / 61	NE (NE, NE)
No	8 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)
Region		
North America	6 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	3 / 5	2.1 (0.3, NE)
Time to first Gastrointestinal disorders TEAE		
Overall	93 / 126	1.2 (0.7, 2.3)
Age at baseline		
< 65 years	47 / 67	1.8 (0.6, 2.7)
≥ 65 years	46 / 59	1.2 (0.5, 2.1)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	41 / 54	1.1 (0.3, 2.3)
2	32 / 44	1.2 (0.6, 2.3)
> 2	20 / 28	2.6 (0.2, 5.4)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	85 / 115	1.3 (0.7, 2.3)
No	8 / 11	0.9 (0.1, NE)
Prior platinum-base chemotherapy		
Yes	84 / 113	1.3 (0.7, 2.3)
No	9 / 13	0.8 (0.1, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	76 / 102	1.3 (0.7, 2.5)
No	17 / 24	0.9 (0.3, 2.6)
PD-L1 protein expression		
< 1%	24 / 33	1.4 (0.3, 2.7)
≥ 1% and < 50%	18 / 24	0.9 (0.2, 2.5)
≥ 50%	24 / 35	1.1 (0.6, 6.3)
ECOG		
0	27 / 38	2.5 (1.2, 4.4)
1	66 / 88	0.9 (0.5, 1.4)
Race		
White	78 / 103	1.1 (0.6, 2.2)
Black	1 / 2	NE (0.0, NE)
Asian	12 / 19	2.6 (0.7, NE)
Other	2 / 2	0.6 (0.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	46 / 63	1.4 (0.9, 2.6)
Female	47 / 63	0.8 (0.5, 2.5)
Histopathology		
Squamous	1 / 1	0.7 (NE, NE)
Non-squamous	92 / 125	1.3 (0.8, 2.3)
Metastatic		
Yes	90 / 122	1.2 (0.7, 2.3)
No	3 / 4	1.2 (0.1, NE)
Liver metastasis		
Yes	21 / 26	0.9 (0.3, 2.5)
No	72 / 100	1.3 (0.8, 2.5)
Brain metastasis		
Yes	21 / 26	0.4 (0.1, 1.1)
No	72 / 100	1.4 (0.8, 2.6)
Bone metastasis		
Yes	44 / 61	1.2 (0.5, 2.5)
No	49 / 65	1.3 (0.7, 2.6)
Smoking history		
Never	5 / 6	0.2 (0.0, NE)
Current	10 / 15	2.3 (0.6, NE)
Former	76 / 102	1.0 (0.5, 2.3)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	61 / 79	1.0 (0.5, 2.1)
Europe	20 / 30	1.6 (0.6, NE)
Asia	8 / 12	2.3 (0.2, NE)
Rest of the world	4 / 5	0.1 (0.0, NE)
Time to first Diarrhoea TEAE		
Overall	62 / 126	5.5 (2.5, NE)
Age at baseline		
< 65 years	30 / 67	6.8 (2.5, NE)
≥ 65 years	32 / 59	4.4 (1.8, NE)
Prior lines of anti-cancer therapy		
1	29 / 54	4.1 (1.8, NE)
2	23 / 44	3.9 (1.5, NE)
> 2	10 / 28	NE (4.4, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	56 / 115	5.6 (2.6, NE)
No	6 / 11	1.8 (0.2, NE)
Prior platinum-base chemotherapy		
Yes	54 / 113	5.6 (3.4, NE)
No	8 / 13	2.0 (0.8, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	48 / 102	6.3 (3.9, NE)
No	14 / 24	1.8 (0.9, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	20 / 33	3.4 (1.3, NE)
≥ 1% and < 50%	11 / 24	6.7 (1.8, NE)
≥ 50%	15 / 35	6.3 (1.8, NE)
ECOG		
0	21 / 38	4.4 (1.8, NE)
1	41 / 88	6.3 (2.5, NE)
Race		
White	51 / 103	5.6 (3.4, NE)
Black	1 / 2	NE (0.0, NE)
Asian	8 / 19	NE (1.2, NE)
Other	2 / 2	1.4 (0.9, NE)
Sex		
Male	32 / 63	5.5 (1.8, NE)
Female	30 / 63	5.6 (3.4, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	62 / 125	5.5 (2.5, NE)
Metastatic		
Yes	59 / 122	5.6 (2.5, NE)
No	3 / 4	3.6 (0.1, NE)
Liver metastasis		
Yes	14 / 26	4.4 (1.1, NE)
No	48 / 100	6.7 (2.5, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	12 / 26	5.6 (1.8, NE)
No	50 / 100	5.5 (2.5, NE)
Bone metastasis		
Yes	30 / 61	5.5 (1.8, NE)
No	32 / 65	6.7 (2.6, NE)
Smoking history		
Never	5 / 6	0.7 (0.0, NE)
Current	8 / 15	4.1 (1.2, NE)
Former	47 / 102	6.3 (2.5, NE)
Region		
North America	43 / 79	4.4 (1.8, NE)
Europe	14 / 30	6.7 (2.5, NE)
Asia	4 / 12	NE (0.2, NE)
Rest of the world	1 / 5	NE (0.1, NE)
Time to first Nausea TEAE		
Overall	37 / 126	NE (NE, NE)
Age at baseline		
< 65 years	19 / 67	NE (9.4, NE)
≥ 65 years	18 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	17 / 54	NE (9.4, NE)
2	11 / 44	NE (NE, NE)
> 2	9 / 28	NE (7.6, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	33 / 115	NE (9.4, NE)
No	4 / 11	NE (0.5, NE)
Prior platinum-base chemotherapy		
Yes	33 / 113	NE (NE, NE)
No	4 / 13	9.4 (1.1, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	29 / 102	NE (NE, NE)
No	8 / 24	9.4 (1.1, NE)
PD-L1 protein expression		
< 1%	9 / 33	NE (9.4, NE)
≥ 1% and < 50%	8 / 24	NE (2.8, NE)
≥ 50%	8 / 35	NE (7.6, NE)
ECOG		
0	13 / 38	9.4 (7.6, NE)
1	24 / 88	NE (NE, NE)
Race		
White	34 / 103	NE (9.4, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	1 / 2	NE (0.9, NE)
Sex		
Male	13 / 63	NE (NE, NE)
Female	24 / 63	NE (4.2, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	37 / 125	NE (NE, NE)
Metastatic		
Yes	36 / 122	NE (9.4, NE)
No	1 / 4	NE (0.1, NE)
Liver metastasis		
Yes	5 / 26	NE (2.9, NE)
No	32 / 100	NE (9.4, NE)
Brain metastasis		
Yes	8 / 26	NE (7.6, NE)
No	29 / 100	NE (9.4, NE)
Bone metastasis		
Yes	13 / 61	NE (NE, NE)
No	24 / 65	NE (7.6, NE)
Smoking history		
Never	4 / 6	1.8 (0.0, NE)
Current	3 / 15	NE (4.1, NE)
Former	29 / 102	NE (NE, NE)
Region		
North America	23 / 79	NE (9.4, NE)
Europe	10 / 30	NE (2.8, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	3 / 5	7.6 (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Vomiting TEAE		
Overall	23 / 126	NE (NE, NE)
Age at baseline		
< 65 years	11 / 67	NE (NE, NE)
≥ 65 years	12 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	10 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	22 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	22 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	21 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	7 / 33	NE (NE, NE)
≥ 1% and < 50%	5 / 24	NE (4.2, NE)
≥ 50%	5 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	7 / 38	NE (NE, NE)
1	16 / 88	NE (NE, NE)
Race		
White	20 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (6.0, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	11 / 63	NE (NE, NE)
Female	12 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	23 / 125	NE (NE, NE)
Metastatic		
Yes	23 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (8.1, NE)
No	19 / 100	NE (NE, NE)
Brain metastasis		
Yes	5 / 26	NE (NE, NE)
No	18 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	9 / 61	NE (NE, NE)
No	14 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	4 / 15	NE (1.3, NE)
Former	16 / 102	NE (NE, NE)
Region		
North America	16 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.3, NE)
Rest of the world	1 / 5	NE (0.0, NE)
Time to first Constipation TEAE		
Overall	22 / 126	NE (NE, NE)
Age at baseline		
< 65 years	11 / 67	NE (NE, NE)
≥ 65 years	11 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	8 / 54	NE (NE, NE)
2	9 / 44	NE (NE, NE)
> 2	5 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	21 / 115	NE (NE, NE)
No	1 / 11	NE (4.7, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	20 / 113	NE (NE, NE)
No	2 / 13	NE (8.5, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	19 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	5 / 24	NE (NE, NE)
≥ 50%	8 / 35	NE (8.5, NE)
ECOG		
0	6 / 38	NE (NE, NE)
1	16 / 88	NE (NE, NE)
Race		
White	20 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (8.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	8 / 63	NE (NE, NE)
Female	14 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	22 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	21 / 122	NE (NE, NE)
No	1 / 4	NE (4.2, NE)
Liver metastasis		
Yes	7 / 26	NE (8.5, NE)
No	15 / 100	NE (NE, NE)
Brain metastasis		
Yes	5 / 26	NE (4.7, NE)
No	17 / 100	NE (NE, NE)
Bone metastasis		
Yes	10 / 61	NE (NE, NE)
No	12 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (0.2, NE)
Current	1 / 15	NE (NE, NE)
Former	18 / 102	NE (NE, NE)
Region		
North America	13 / 79	NE (NE, NE)
Europe	6 / 30	NE (NE, NE)
Asia	1 / 12	NE (3.6, NE)
Rest of the world	2 / 5	NE (4.6, NE)
Time to first Abdominal pain TEAE		
Overall	11 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	4 / 67	NE (NE, NE)
≥ 65 years	7 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	10 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	9 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	5 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	3 / 38	NE (NE, NE)
1	8 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	9 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	1 / 2	NE (2.8, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	1 / 1	0.7 (NE, NE)
Non-squamous	10 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	9 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	1 / 6	NE (3.9, NE)
Current	0 / 15	NE (NE, NE)
Former	9 / 102	NE (NE, NE)
Region		
North America	8 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first General disorders and administration site conditions TEAE		
Overall	58 / 126	7.4 (4.5, NE)
Age at baseline		
< 65 years	32 / 67	5.2 (3.5, NE)
≥ 65 years	26 / 59	8.2 (3.2, NE)
Prior lines of anti-cancer therapy		
1	26 / 54	6.5 (1.9, NE)
2	16 / 44	NE (4.6, NE)
> 2	16 / 28	4.6 (1.0, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	52 / 115	7.4 (4.5, NE)
No	6 / 11	4.8 (0.3, NE)
Prior platinum-base chemotherapy		
Yes	53 / 113	6.5 (4.2, NE)
No	5 / 13	NE (0.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	47 / 102	6.6 (3.7, NE)
No	11 / 24	8.2 (0.7, NE)
PD-L1 protein expression		
< 1%	16 / 33	6.6 (1.1, NE)
≥ 1% and < 50%	13 / 24	7.4 (0.6, NE)
≥ 50%	13 / 35	NE (4.5, NE)
ECOG		
0	21 / 38	4.6 (1.2, NE)
1	37 / 88	8.2 (4.8, NE)
Race		
White	53 / 103	4.8 (3.2, NE)
Black	0 / 2	NE (NE, NE)
Asian	5 / 19	NE (2.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	26 / 63	NE (3.7, NE)
Female	32 / 63	5.2 (1.9, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	58 / 125	6.6 (4.5, NE)
Metastatic		
Yes	54 / 122	8.2 (4.6, NE)
No	4 / 4	0.8 (0.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	9 / 26	NE (3.5, NE)
No	49 / 100	6.6 (3.7, NE)
Brain metastasis		
Yes	7 / 26	NE (4.6, NE)
No	51 / 100	6.5 (2.7, NE)
Bone metastasis		
Yes	24 / 61	8.2 (4.5, NE)
No	34 / 65	5.2 (1.8, NE)
Smoking history		
Never	4 / 6	3.4 (0.0, NE)
Current	8 / 15	4.5 (0.4, NE)
Former	45 / 102	8.2 (4.6, NE)
Region		
North America	40 / 79	5.2 (1.9, NE)
Europe	12 / 30	8.2 (4.5, NE)
Asia	2 / 12	NE (0.4, NE)
Rest of the world	4 / 5	1.9 (0.0, NE)
Time to first Fatigue TEAE		
Overall	31 / 126	NE (NE, NE)
Age at baseline		
< 65 years	13 / 67	NE (NE, NE)
≥ 65 years	18 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	14 / 54	NE (NE, NE)
2	8 / 44	NE (NE, NE)
> 2	9 / 28	NE (4.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	28 / 115	NE (NE, NE)
No	3 / 11	NE (0.3, NE)
Prior platinum-base chemotherapy		
Yes	28 / 113	NE (NE, NE)
No	3 / 13	NE (0.7, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	25 / 102	NE (NE, NE)
No	6 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	9 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	8 / 35	NE (NE, NE)
ECOG		
0	12 / 38	NE (6.5, NE)
1	19 / 88	NE (NE, NE)
Race		
White	29 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	16 / 63	NE (NE, NE)
Female	15 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	31 / 125	NE (NE, NE)
Metastatic		
Yes	29 / 122	NE (NE, NE)
No	2 / 4	NE (0.4, NE)
Liver metastasis		
Yes	4 / 26	NE (4.2, NE)
No	27 / 100	NE (NE, NE)
Brain metastasis		
Yes	5 / 26	NE (NE, NE)
No	26 / 100	NE (NE, NE)
Bone metastasis		
Yes	12 / 61	NE (NE, NE)
No	19 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	5.8 (2.7, NE)
Current	3 / 15	NE (3.5, NE)
Former	26 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	22 / 79	NE (NE, NE)
Europe	5 / 30	NE (6.5, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	4 / 5	3.7 (0.0, NE)
Time to first Oedema peripheral TEAE		
Overall	17 / 126	NE (10.2, NE)
Age at baseline		
< 65 years	9 / 67	NE (NE, NE)
≥ 65 years	8 / 59	NE (10.2, NE)
Prior lines of anti-cancer therapy		
1	8 / 54	10.2 (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	15 / 115	NE (10.2, NE)
No	2 / 11	NE (4.2, NE)
Prior platinum-base chemotherapy		
Yes	16 / 113	NE (10.2, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	14 / 102	NE (10.2, NE)
No	3 / 24	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	4 / 33	10.2 (10.2, NE)
≥ 1% and < 50%	6 / 24	NE (8.2, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	12 / 88	NE (10.2, NE)
Race		
White	17 / 103	NE (10.2, NE)
Black	0 / 2	NE (NE, NE)
Asian	0 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	7 / 63	10.2 (NE, NE)
Female	10 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	17 / 125	NE (10.2, NE)
Metastatic		
Yes	15 / 122	NE (10.2, NE)
No	2 / 4	4.2 (0.5, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	14 / 100	NE (10.2, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	14 / 100	NE (10.2, NE)
Bone metastasis		
Yes	8 / 61	10.2 (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	4.2 (0.5, NE)
Current	1 / 15	NE (NE, NE)
Former	13 / 102	NE (10.2, NE)
Region		
North America	10 / 79	NE (10.2, NE)
Europe	7 / 30	NE (8.2, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Pyrexia TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	6 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	4 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	10 / 115	NE (NE, NE)
No	1 / 11	NE (4.9, NE)
Prior platinum-base chemotherapy		
Yes	11 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	10 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	10 / 88	NE (NE, NE)
Race		
White	10 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	7 / 63	NE (NE, NE)
Female	4 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	11 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (2.8, NE)
Current	3 / 15	NE (4.2, NE)
Former	7 / 102	NE (NE, NE)
Region		
North America	7 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Hepatobiliary disorders TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	7 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	11 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	11 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	4 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	5 / 38	NE (NE, NE)
1	6 / 88	NE (NE, NE)
Race		
White	9 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (0.8, NE)
Current	1 / 15	NE (NE, NE)
Former	8 / 102	NE (NE, NE)
Region		
North America	4 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (0.8, NE)
Rest of the world	1 / 5	NE (2.3, NE)
Time to first Infections and infestations TEAE		
Overall	56 / 126	7.4 (4.4, NE)
Age at baseline		
< 65 years	27 / 67	NE (3.8, NE)
≥ 65 years	29 / 59	5.0 (3.9, NE)
Prior lines of anti-cancer therapy		
1	23 / 54	7.4 (3.4, NE)
2	20 / 44	5.0 (3.8, NE)
> 2	13 / 28	8.4 (2.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	49 / 115	8.4 (4.6, NE)
No	7 / 11	3.9 (1.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	50 / 113	6.2 (4.4, NE)
No	6 / 13	NE (0.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	43 / 102	7.4 (4.6, NE)
No	13 / 24	4.1 (2.5, NE)
PD-L1 protein expression		
< 1%	16 / 33	5.0 (2.5, NE)
≥ 1% and < 50%	10 / 24	8.4 (3.1, NE)
≥ 50%	13 / 35	NE (3.5, NE)
ECOG		
0	19 / 38	6.2 (3.5, NE)
1	37 / 88	8.4 (4.1, NE)
Race		
White	53 / 103	4.6 (3.8, 8.4)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (5.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	26 / 63	8.4 (4.6, NE)
Female	30 / 63	4.8 (3.8, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	56 / 125	6.2 (4.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	55 / 122	6.2 (4.2, NE)
No	1 / 4	NE (0.5, NE)
Liver metastasis		
Yes	9 / 26	NE (2.7, NE)
No	47 / 100	5.7 (4.2, NE)
Brain metastasis		
Yes	8 / 26	8.4 (3.0, NE)
No	48 / 100	5.7 (4.1, NE)
Bone metastasis		
Yes	24 / 61	NE (3.4, NE)
No	32 / 65	6.2 (4.4, NE)
Smoking history		
Never	1 / 6	NE (0.5, NE)
Current	6 / 15	NE (0.6, NE)
Former	47 / 102	5.7 (3.9, NE)
Region		
North America	34 / 79	8.4 (4.1, NE)
Europe	15 / 30	6.2 (2.2, NE)
Asia	3 / 12	NE (0.6, NE)
Rest of the world	4 / 5	4.2 (0.3, NE)
Time to first Pneumonia TEAE		
Overall	12 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	8 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	6 / 54	NE (NE, NE)
2	2 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	9 / 115	NE (NE, NE)
No	3 / 11	NE (2.6, NE)
Prior platinum-base chemotherapy		
Yes	12 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	9 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	10 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	10 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	8 / 63	NE (NE, NE)
Female	4 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	12 / 125	NE (NE, NE)
Metastatic		
Yes	12 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	11 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	11 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	2 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)
Region		
North America	10 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	2 / 12	NE (5.7, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Injury, poisoning and procedural complications TEAE		
Overall	17 / 126	NE (NE, NE)
Age at baseline		
< 65 years	8 / 67	NE (NE, NE)
≥ 65 years	9 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	8 / 54	NE (NE, NE)
2	5 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	16 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	16 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	15 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	6 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	15 / 88	NE (NE, NE)
Race		
White	15 / 103	NE (NE, NE)
Black	1 / 2	NE (0.3, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	17 / 125	NE (NE, NE)
Metastatic		
Yes	17 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	5 / 26	NE (NE, NE)
No	12 / 100	NE (NE, NE)
Brain metastasis		
Yes	7 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Bone metastasis		
Yes	8 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	16 / 102	NE (NE, NE)
Region		
North America	13 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	1 / 12	NE (1.5, NE)
Rest of the world	1 / 5	NE (3.5, NE)
Time to first Fall TEAE		
Overall	10 / 126	NE (NE, NE)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	6 / 54	NE (NE, NE)
2	2 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	9 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	8 / 88	NE (NE, NE)
Race		
White	9 / 103	NE (NE, NE)
Black	1 / 2	NE (0.3, NE)
Asian	0 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	5 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	10 / 125	NE (NE, NE)
Metastatic		
Yes	10 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	6 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	6 / 100	NE (NE, NE)
Bone metastasis		
Yes	8 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	9 / 79	NE (NE, NE)
Europe	1 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Investigations TEAE		
Overall	50 / 126	NE (4.9, NE)
Age at baseline		
< 65 years	22 / 67	NE (4.8, NE)
≥ 65 years	28 / 59	6.9 (3.5, NE)
Prior lines of anti-cancer therapy		
1	22 / 54	7.7 (3.5, NE)
2	21 / 44	4.1 (2.0, NE)
> 2	7 / 28	NE (8.3, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	45 / 115	NE (4.9, NE)
No	5 / 11	3.5 (2.1, NE)
Prior platinum-base chemotherapy		
Yes	44 / 113	NE (4.8, NE)
No	6 / 13	6.9 (0.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	39 / 102	NE (4.9, NE)
No	11 / 24	6.9 (2.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	13 / 33	NE (2.9, NE)
≥ 1% and < 50%	14 / 24	2.4 (1.4, NE)
≥ 50%	9 / 35	NE (6.9, NE)
ECOG		
0	15 / 38	NE (2.1, NE)
1	35 / 88	8.3 (4.1, NE)
Race		
White	40 / 103	NE (6.9, NE)
Black	2 / 2	2.8 (0.7, NE)
Asian	6 / 19	NE (2.1, NE)
Other	2 / 2	2.4 (1.4, NE)
Sex		
Male	26 / 63	NE (3.5, NE)
Female	24 / 63	NE (4.1, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	50 / 125	NE (4.8, NE)
Metastatic		
Yes	49 / 122	NE (4.8, NE)
No	1 / 4	NE (3.5, NE)
Liver metastasis		
Yes	10 / 26	NE (2.1, NE)
No	40 / 100	NE (4.9, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	10 / 26	NE (4.1, NE)
No	40 / 100	NE (4.2, NE)
Bone metastasis		
Yes	23 / 61	8.3 (4.8, NE)
No	27 / 65	NE (3.5, NE)
Smoking history		
Never	4 / 6	2.5 (0.3, NE)
Current	6 / 15	NE (1.3, NE)
Former	40 / 102	NE (4.8, NE)
Region		
North America	30 / 79	NE (4.8, NE)
Europe	14 / 30	7.7 (2.8, NE)
Asia	3 / 12	NE (1.4, NE)
Rest of the world	3 / 5	4.9 (1.4, NE)
Time to first Aspartate aminotransferase increased TEAE		
Overall	27 / 126	NE (NE, NE)
Age at baseline		
< 65 years	15 / 67	NE (NE, NE)
≥ 65 years	12 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	16 / 44	NE (3.5, NE)
> 2	2 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	24 / 115	NE (NE, NE)
No	3 / 11	NE (2.1, NE)
Prior platinum-base chemotherapy		
Yes	25 / 113	NE (NE, NE)
No	2 / 13	NE (3.5, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	22 / 102	NE (NE, NE)
No	5 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	9 / 24	NE (2.8, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	9 / 38	NE (NE, NE)
1	18 / 88	NE (NE, NE)
Race		
White	20 / 103	NE (NE, NE)
Black	1 / 2	4.8 (NE, NE)
Asian	4 / 19	NE (3.5, NE)
Other	2 / 2	2.4 (1.4, NE)
Sex		
Male	12 / 63	NE (NE, NE)
Female	15 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	27 / 125	NE (NE, NE)
Metastatic		
Yes	27 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	24 / 100	NE (NE, NE)
Brain metastasis		
Yes	7 / 26	NE (4.3, NE)
No	20 / 100	NE (NE, NE)
Bone metastasis		
Yes	11 / 61	NE (NE, NE)
No	16 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	4 / 15	NE (1.4, NE)
Former	21 / 102	NE (NE, NE)
Region		
North America	15 / 79	NE (NE, NE)
Europe	8 / 30	NE (4.3, NE)
Asia	3 / 12	NE (1.4, NE)
Rest of the world	1 / 5	NE (2.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Alanine aminotransferase increased TEAE		
Overall	26 / 126	NE (NE, NE)
Age at baseline		
< 65 years	14 / 67	NE (NE, NE)
≥ 65 years	12 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	15 / 44	NE (4.4, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	23 / 115	NE (NE, NE)
No	3 / 11	NE (2.1, NE)
Prior platinum-base chemotherapy		
Yes	25 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	22 / 102	NE (NE, NE)
No	4 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	7 / 24	NE (2.1, NE)
≥ 50%	6 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	9 / 38	NE (NE, NE)
1	17 / 88	NE (NE, NE)
Race		
White	20 / 103	NE (NE, NE)
Black	1 / 2	4.9 (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	2 / 2	2.4 (1.4, NE)
Sex		
Male	12 / 63	NE (NE, NE)
Female	14 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	26 / 125	NE (NE, NE)
Metastatic		
Yes	26 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	22 / 100	NE (NE, NE)
Brain metastasis		
Yes	7 / 26	NE (4.4, NE)
No	19 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	11 / 61	NE (NE, NE)
No	15 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	4 / 15	NE (1.4, NE)
Former	20 / 102	NE (NE, NE)
Region		
North America	15 / 79	NE (NE, NE)
Europe	7 / 30	NE (NE, NE)
Asia	3 / 12	NE (1.4, NE)
Rest of the world	1 / 5	NE (2.1, NE)
Time to first Blood alkaline phosphatase increased TEAE		
Overall	17 / 126	NE (NE, NE)
Age at baseline		
< 65 years	9 / 67	NE (NE, NE)
≥ 65 years	8 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	8 / 54	NE (NE, NE)
2	8 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	15 / 115	NE (NE, NE)
No	2 / 11	NE (2.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	15 / 113	NE (NE, NE)
No	2 / 13	NE (2.2, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	13 / 102	NE (NE, NE)
No	4 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	6 / 24	NE (4.2, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	4 / 38	NE (NE, NE)
1	13 / 88	NE (NE, NE)
Race		
White	12 / 103	NE (NE, NE)
Black	1 / 2	4.9 (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	1 / 2	NE (2.1, NE)
Sex		
Male	9 / 63	NE (NE, NE)
Female	8 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	17 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	17 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	15 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	13 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	11 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (2.1, NE)
Current	5 / 15	NE (1.4, NE)
Former	10 / 102	NE (NE, NE)
Region		
North America	9 / 79	NE (NE, NE)
Europe	5 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.4, NE)
Rest of the world	1 / 5	NE (2.1, NE)
Time to first Metabolism and nutrition disorders TEAE		
Overall	51 / 126	NE (4.9, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	27 / 67	NE (4.9, NE)
≥ 65 years	24 / 59	NE (3.7, NE)
Prior lines of anti-cancer therapy		
1	23 / 54	NE (3.0, NE)
2	21 / 44	4.4 (2.5, NE)
> 2	7 / 28	NE (5.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	46 / 115	NE (4.9, NE)
No	5 / 11	NE (0.1, NE)
Prior platinum-base chemotherapy		
Yes	43 / 113	NE (4.9, NE)
No	8 / 13	2.5 (0.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	38 / 102	NE (5.2, NE)
No	13 / 24	2.6 (0.5, NE)
PD-L1 protein expression		
< 1%	11 / 33	NE (3.5, NE)
≥ 1% and < 50%	12 / 24	3.4 (1.3, NE)
≥ 50%	13 / 35	7.9 (4.2, NE)
ECOG		
0	10 / 38	NE (NE, NE)
1	41 / 88	5.6 (3.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	41 / 103	NE (4.4, NE)
Black	2 / 2	1.2 (0.3, NE)
Asian	7 / 19	NE (1.2, NE)
Other	1 / 2	NE (0.0, NE)
Sex		
Male	23 / 63	NE (4.9, NE)
Female	28 / 63	7.9 (3.7, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	51 / 125	NE (4.9, NE)
Metastatic		
Yes	50 / 122	NE (4.9, NE)
No	1 / 4	NE (0.1, NE)
Liver metastasis		
Yes	10 / 26	7.9 (2.8, NE)
No	41 / 100	NE (4.4, NE)
Brain metastasis		
Yes	12 / 26	4.9 (3.0, NE)
No	39 / 100	NE (5.2, NE)
Bone metastasis		
Yes	21 / 61	NE (4.1, NE)
No	30 / 65	5.6 (3.8, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	4 / 6	1.9 (0.0, NE)
Current	6 / 15	NE (0.3, NE)
Former	41 / 102	NE (4.4, NE)
Region		
North America	34 / 79	NE (3.8, NE)
Europe	10 / 30	NE (4.1, NE)
Asia	4 / 12	NE (1.2, NE)
Rest of the world	3 / 5	3.7 (0.3, NE)
Time to first Decreased appetite TEAE		
Overall	15 / 126	NE (NE, NE)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	9 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	14 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	5 / 13	NE (1.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	9 / 102	NE (NE, NE)
No	6 / 24	NE (9.0, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (9.0, NE)
≥ 50%	6 / 35	NE (NE, NE)
ECOG		
0	3 / 38	NE (NE, NE)
1	12 / 88	NE (NE, NE)
Race		
White	12 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	15 / 125	NE (NE, NE)
Metastatic		
Yes	14 / 122	NE (NE, NE)
No	1 / 4	NE (0.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	3 / 26	NE (7.9, NE)
No	12 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	12 / 100	NE (NE, NE)
Bone metastasis		
Yes	9 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (0.1, NE)
Current	1 / 15	NE (NE, NE)
Former	12 / 102	NE (NE, NE)
Region		
North America	9 / 79	NE (NE, NE)
Europe	3 / 30	NE (9.0, NE)
Asia	2 / 12	NE (2.0, NE)
Rest of the world	1 / 5	NE (3.7, NE)
Time to first Hypokalaemia TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	4 / 67	NE (NE, NE)
≥ 65 years	7 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	3 / 54	NE (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	3 / 11	NE (2.6, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	2 / 13	NE (9.0, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	6 / 102	NE (NE, NE)
No	5 / 24	NE (9.0, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	11 / 88	NE (NE, NE)
Race		
White	9 / 103	NE (NE, NE)
Black	1 / 2	5.5 (NE, NE)
Asian	0 / 19	NE (NE, NE)
Other	1 / 2	NE (1.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	5 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (1.4, NE)
Current	0 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	9 / 79	NE (NE, NE)
Europe	2 / 30	NE (9.0, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Musculoskeletal and connective tissue disorders TEAE		
Overall	65 / 126	5.7 (3.9, 9.0)
Age at baseline		
< 65 years	33 / 67	4.4 (3.0, NE)
≥ 65 years	32 / 59	6.2 (3.5, 11.5)
Prior lines of anti-cancer therapy		
1	32 / 54	3.5 (2.1, 8.5)
2	20 / 44	8.6 (3.8, NE)
> 2	13 / 28	8.0 (4.2, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	62 / 115	5.1 (3.5, 8.5)
No	3 / 11	NE (2.6, NE)
Prior platinum-base chemotherapy		
Yes	55 / 113	6.5 (4.2, NE)
No	10 / 13	2.1 (0.2, 6.1)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	52 / 102	6.2 (3.9, 9.0)
No	13 / 24	4.3 (2.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	15 / 33	9.0 (4.2, NE)
≥ 1% and < 50%	8 / 24	NE (4.1, NE)
≥ 50%	22 / 35	3.3 (1.3, 4.4)
ECOG		
0	21 / 38	4.2 (1.8, NE)
1	44 / 88	5.7 (3.9, 9.0)
Race		
White	57 / 103	4.4 (3.5, 8.6)
Black	1 / 2	3.3 (NE, NE)
Asian	6 / 19	NE (2.8, NE)
Other	1 / 2	NE (0.1, NE)
Sex		
Male	30 / 63	8.6 (4.2, NE)
Female	35 / 63	4.2 (2.5, 8.0)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	65 / 125	5.7 (3.9, 9.0)
Metastatic		
Yes	62 / 122	5.7 (4.1, 9.0)
No	3 / 4	2.1 (0.2, NE)
Liver metastasis		
Yes	13 / 26	3.5 (2.0, NE)
No	52 / 100	6.1 (4.2, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	14 / 26	4.4 (2.1, 9.0)
No	51 / 100	6.1 (3.9, NE)
Bone metastasis		
Yes	35 / 61	3.5 (2.5, 8.5)
No	30 / 65	6.5 (4.2, NE)
Smoking history		
Never	2 / 6	NE (2.6, NE)
Current	4 / 15	NE (1.8, NE)
Former	59 / 102	4.3 (3.5, 6.5)
Region		
North America	49 / 79	4.2 (2.7, 6.1)
Europe	11 / 30	NE (4.1, NE)
Asia	1 / 12	NE (2.8, NE)
Rest of the world	4 / 5	3.4 (0.3, NE)
Time to first Back pain TEAE		
Overall	20 / 126	NE (11.5, NE)
Age at baseline		
< 65 years	7 / 67	NE (NE, NE)
≥ 65 years	13 / 59	11.5 (11.5, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	11.5 (11.5, NE)
2	5 / 44	NE (NE, NE)
> 2	6 / 28	NE (8.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	19 / 115	NE (11.5, NE)
No	1 / 11	NE (3.5, NE)
Prior platinum-base chemotherapy		
Yes	18 / 113	NE (11.5, NE)
No	2 / 13	NE (8.8, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	17 / 102	NE (11.5, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (11.5, NE)
≥ 1% and < 50%	3 / 24	NE (8.8, NE)
≥ 50%	8 / 35	NE (8.0, NE)
ECOG		
0	3 / 38	NE (NE, NE)
1	17 / 88	NE (11.5, NE)
Race		
White	17 / 103	NE (11.5, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	1 / 2	NE (0.1, NE)
Sex		
Male	7 / 63	11.5 (NE, NE)
Female	13 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	20 / 125	NE (11.5, NE)
Metastatic		
Yes	19 / 122	NE (11.5, NE)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	17 / 100	NE (11.5, NE)
Brain metastasis		
Yes	3 / 26	NE (8.0, NE)
No	17 / 100	NE (11.5, NE)
Bone metastasis		
Yes	13 / 61	11.5 (NE, NE)
No	7 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (2.7, NE)
Current	1 / 15	NE (NE, NE)
Former	18 / 102	NE (11.5, NE)
Region		
North America	17 / 79	NE (11.5, NE)
Europe	1 / 30	NE (8.8, NE)
Asia	1 / 12	NE (2.8, NE)
Rest of the world	1 / 5	NE (4.6, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Arthralgia TEAE		
Overall	16 / 126	NE (NE, NE)
Age at baseline		
< 65 years	9 / 67	NE (NE, NE)
≥ 65 years	7 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	10 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	15 / 115	NE (NE, NE)
No	1 / 11	NE (3.0, NE)
Prior platinum-base chemotherapy		
Yes	14 / 113	NE (NE, NE)
No	2 / 13	NE (2.7, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	13 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	9 / 38	NE (NE, NE)
1	7 / 88	NE (NE, NE)
Race		
White	13 / 103	NE (NE, NE)
Black	1 / 2	4.0 (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	1 / 2	6.6 (NE, NE)
Sex		
Male	7 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	16 / 125	NE (NE, NE)
Metastatic		
Yes	15 / 122	NE (NE, NE)
No	1 / 4	NE (3.0, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	14 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	12 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	7 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (3.0, NE)
Current	3 / 15	NE (2.8, NE)
Former	12 / 102	NE (NE, NE)
Region		
North America	9 / 79	NE (NE, NE)
Europe	5 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	2 / 5	NE (0.3, NE)
Time to first Neoplasms benign, malignant and unspecified (incl cysts and polyps) TEAE		
Overall	16 / 126	12.0 (12.0, NE)
Age at baseline		
< 65 years	10 / 67	NE (NE, NE)
≥ 65 years	6 / 59	12.0 (NE, NE)
Prior lines of anti-cancer therapy		
1	7 / 54	12.0 (12.0, NE)
2	6 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	14 / 115	12.0 (NE, NE)
No	2 / 11	NE (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	16 / 113	12.0 (12.0, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	14 / 102	12.0 (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	6 / 33	12.0 (12.0, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	14 / 88	12.0 (12.0, NE)
Race		
White	14 / 103	12.0 (12.0, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	5 / 63	12.0 (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	16 / 125	12.0 (12.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	16 / 122	12.0 (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	6 / 26	NE (6.3, NE)
No	10 / 100	12.0 (12.0, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	13 / 100	12.0 (12.0, NE)
Bone metastasis		
Yes	15 / 61	12.0 (NE, NE)
No	1 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (4.0, NE)
Current	1 / 15	NE (NE, NE)
Former	14 / 102	12.0 (NE, NE)
Region		
North America	10 / 79	12.0 (12.0, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (4.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Nervous system disorders TEAE		
Overall	27 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	14 / 67	NE (NE, NE)
≥ 65 years	13 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	11 / 54	NE (NE, NE)
2	9 / 44	NE (NE, NE)
> 2	7 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	23 / 115	NE (NE, NE)
No	4 / 11	NE (0.7, NE)
Prior platinum-base chemotherapy		
Yes	24 / 113	NE (NE, NE)
No	3 / 13	NE (0.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	20 / 102	NE (NE, NE)
No	7 / 24	NE (4.3, NE)
PD-L1 protein expression		
< 1%	8 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	8 / 35	NE (NE, NE)
ECOG		
0	8 / 38	NE (NE, NE)
1	19 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	23 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	1 / 2	NE (0.1, NE)
Sex		
Male	12 / 63	NE (NE, NE)
Female	15 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	27 / 125	NE (NE, NE)
Metastatic		
Yes	27 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	26 / 100	NE (NE, NE)
Brain metastasis		
Yes	7 / 26	NE (6.2, NE)
No	20 / 100	NE (NE, NE)
Bone metastasis		
Yes	11 / 61	NE (NE, NE)
No	16 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	2 / 6	NE (0.1, NE)
Current	4 / 15	NE (1.4, NE)
Former	21 / 102	NE (NE, NE)
Region		
North America	21 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	3 / 5	3.7 (0.0, NE)
Time to first Psychiatric disorders TEAE		
Overall	22 / 126	NE (NE, NE)
Age at baseline		
< 65 years	13 / 67	NE (8.6, NE)
≥ 65 years	9 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	6 / 44	NE (8.3, NE)
> 2	7 / 28	NE (8.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	20 / 115	NE (NE, NE)
No	2 / 11	NE (0.6, NE)
Prior platinum-base chemotherapy		
Yes	19 / 113	NE (NE, NE)
No	3 / 13	NE (5.6, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	17 / 102	NE (NE, NE)
No	5 / 24	NE (7.5, NE)
PD-L1 protein expression		
< 1%	10 / 33	NE (6.6, NE)
≥ 1% and < 50%	6 / 24	NE (5.6, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	7 / 38	NE (NE, NE)
1	15 / 88	NE (NE, NE)
Race		
White	18 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	4 / 19	NE (5.6, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	12 / 63	NE (NE, NE)
Female	10 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	22 / 125	NE (NE, NE)
Metastatic		
Yes	21 / 122	NE (NE, NE)
No	1 / 4	NE (0.2, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	20 / 100	NE (NE, NE)
Brain metastasis		
Yes	2 / 26	NE (NE, NE)
No	20 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	16 / 65	NE (NE, NE)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	1 / 15	NE (NE, NE)
Former	18 / 102	NE (NE, NE)
Region		
North America	15 / 79	NE (NE, NE)
Europe	3 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.6, NE)
Rest of the world	2 / 5	NE (0.2, NE)
Time to first Respiratory, thoracic and mediastinal disorders TEAE		
Overall	62 / 126	5.1 (3.5, NE)
Age at baseline		
< 65 years	35 / 67	4.9 (2.7, NE)
≥ 65 years	27 / 59	NE (2.8, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	29 / 54	4.0 (1.9, NE)
2	17 / 44	NE (1.7, NE)
> 2	16 / 28	4.5 (1.8, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	56 / 115	5.1 (3.0, NE)
No	6 / 11	4.9 (0.9, NE)
Prior platinum-base chemotherapy		
Yes	57 / 113	4.9 (3.4, NE)
No	5 / 13	NE (0.2, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	51 / 102	4.6 (2.9, NE)
No	11 / 24	9.3 (0.9, NE)
PD-L1 protein expression		
< 1%	16 / 33	4.6 (2.8, NE)
≥ 1% and < 50%	14 / 24	4.1 (0.8, NE)
≥ 50%	16 / 35	NE (1.0, NE)
ECOG		
0	21 / 38	5.1 (1.2, NE)
1	41 / 88	4.9 (3.5, NE)
Race		
White	52 / 103	4.9 (3.0, NE)
Black	2 / 2	0.5 (0.0, NE)
Asian	7 / 19	NE (1.8, NE)
Other	1 / 2	NE (4.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	32 / 63	5.1 (2.8, NE)
Female	30 / 63	4.6 (2.9, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	62 / 125	5.1 (3.5, NE)
Metastatic		
Yes	61 / 122	4.9 (3.4, NE)
No	1 / 4	NE (0.1, NE)
Liver metastasis		
Yes	11 / 26	NE (1.2, NE)
No	51 / 100	5.1 (3.0, NE)
Brain metastasis		
Yes	13 / 26	3.5 (1.4, NE)
No	49 / 100	6.5 (3.7, NE)
Bone metastasis		
Yes	30 / 61	4.5 (2.7, NE)
No	32 / 65	9.3 (3.5, NE)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	8 / 15	1.8 (0.4, NE)
Former	51 / 102	4.9 (3.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	47 / 79	3.5 (1.8, 5.1)
Europe	9 / 30	NE (6.5, NE)
Asia	4 / 12	NE (0.5, NE)
Rest of the world	2 / 5	NE (1.1, NE)
Time to first Dyspnoea TEAE		
Overall	24 / 126	NE (NE, NE)
Age at baseline		
< 65 years	13 / 67	NE (NE, NE)
≥ 65 years	11 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	13 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	7 / 28	NE (5.1, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	23 / 115	NE (NE, NE)
No	1 / 11	NE (4.9, NE)
Prior platinum-base chemotherapy		
Yes	21 / 113	NE (NE, NE)
No	3 / 13	NE (0.4, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	20 / 102	NE (NE, NE)
No	4 / 24	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	7 / 33	NE (NE, NE)
≥ 1% and < 50%	7 / 24	NE (5.2, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	12 / 38	NE (6.5, NE)
1	12 / 88	NE (NE, NE)
Race		
White	22 / 103	NE (NE, NE)
Black	1 / 2	NE (0.3, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	15 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	24 / 125	NE (NE, NE)
Metastatic		
Yes	23 / 122	NE (NE, NE)
No	1 / 4	NE (1.1, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	22 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	20 / 100	NE (NE, NE)
Bone metastasis		
Yes	11 / 61	NE (NE, NE)
No	13 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (0.2, NE)
Current	3 / 15	NE (4.2, NE)
Former	19 / 102	NE (NE, NE)
Region		
North America	18 / 79	NE (NE, NE)
Europe	5 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (3.7, NE)
Time to first Cough TEAE		
Overall	16 / 126	NE (NE, NE)
Age at baseline		
< 65 years	8 / 67	NE (NE, NE)
≥ 65 years	8 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	10 / 54	NE (NE, NE)
2	1 / 44	NE (NE, NE)
> 2	5 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	13 / 115	NE (NE, NE)
No	3 / 11	NE (3.5, NE)
Prior platinum-base chemotherapy		
Yes	14 / 113	NE (NE, NE)
No	2 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	11 / 102	NE (NE, NE)
No	5 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	11 / 88	NE (NE, NE)
Race		
White	14 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	11 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	16 / 125	NE (NE, NE)
Metastatic		
Yes	15 / 122	NE (NE, NE)
No	1 / 4	NE (0.1, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	16 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	12 / 100	NE (NE, NE)
Bone metastasis		
Yes	7 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	3 / 15	NE (2.8, NE)
Former	13 / 102	NE (NE, NE)
Region		
North America	14 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (1.9, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first Pleural effusion TEAE		
Overall	12 / 126	NE (NE, NE)
Age at baseline		
< 65 years	8 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	3 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	5 / 28	NE (8.0, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	1 / 11	NE (6.4, NE)
Prior platinum-base chemotherapy		
Yes	12 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	11 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	4 / 24	NE (8.0, NE)
≥ 50%	3 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	2 / 38	NE (NE, NE)
1	10 / 88	NE (NE, NE)
Race		
White	11 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	12 / 125	NE (NE, NE)
Metastatic		
Yes	12 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	11 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	10 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (0.2, NE)
Current	1 / 15	NE (NE, NE)
Former	9 / 102	NE (NE, NE)
Region		
North America	7 / 79	NE (NE, NE)
Europe	4 / 30	NE (8.0, NE)
Asia	1 / 12	NE (3.5, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Productive cough TEAE		
Overall	10 / 126	NE (NE, NE)
Age at baseline		
< 65 years	4 / 67	NE (NE, NE)
≥ 65 years	6 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	10 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	10 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	5 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	9 / 88	NE (NE, NE)
Race		
White	7 / 103	NE (NE, NE)
Black	2 / 2	0.5 (0.0, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	10 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	10 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	9 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	6 / 100	NE (NE, NE)
Bone metastasis		
Yes	4 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	9 / 102	NE (NE, NE)
Region		
North America	9 / 79	NE (NE, NE)
Europe	1 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Skin and subcutaneous tissue disorders TEAE		
Overall	35 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	17 / 67	NE (NE, NE)
≥ 65 years	18 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	16 / 54	NE (NE, NE)
2	11 / 44	NE (5.6, NE)
> 2	8 / 28	NE (7.4, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	33 / 115	NE (NE, NE)
No	2 / 11	NE (0.7, NE)
Prior platinum-base chemotherapy		
Yes	30 / 113	NE (NE, NE)
No	5 / 13	NE (0.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	28 / 102	NE (NE, NE)
No	7 / 24	NE (7.4, NE)
PD-L1 protein expression		
< 1%	8 / 33	NE (7.4, NE)
≥ 1% and < 50%	8 / 24	NE (3.0, NE)
≥ 50%	7 / 35	NE (NE, NE)
ECOG		
0	12 / 38	NE (6.5, NE)
1	23 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	29 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	6 / 19	NE (1.4, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	17 / 63	NE (NE, NE)
Female	18 / 63	NE (NE, NE)
Histopathology		
Squamous	1 / 1	0.5 (NE, NE)
Non-squamous	34 / 125	NE (NE, NE)
Metastatic		
Yes	34 / 122	NE (NE, NE)
No	1 / 4	NE (0.4, NE)
Liver metastasis		
Yes	9 / 26	NE (3.8, NE)
No	26 / 100	NE (NE, NE)
Brain metastasis		
Yes	6 / 26	NE (NE, NE)
No	29 / 100	NE (NE, NE)
Bone metastasis		
Yes	19 / 61	NE (NE, NE)
No	16 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	2 / 6	NE (0.4, NE)
Current	4 / 15	NE (4.2, NE)
Former	29 / 102	NE (NE, NE)
Region		
North America	19 / 79	NE (NE, NE)
Europe	8 / 30	NE (6.5, NE)
Asia	5 / 12	NE (0.5, NE)
Rest of the world	3 / 5	2.6 (0.7, NE)
Time to first Pruritus TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	3 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	10 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	9 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	4 / 38	NE (NE, NE)
1	7 / 88	NE (NE, NE)
Race		
White	8 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	7 / 61	NE (NE, NE)
No	4 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)
Region		
North America	7 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.4, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first Vascular disorders TEAE		
Overall	21 / 126	NE (NE, NE)
Age at baseline		
< 65 years	12 / 67	NE (NE, NE)
≥ 65 years	9 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	9 / 54	NE (NE, NE)
2	8 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	18 / 115	NE (NE, NE)
No	3 / 11	NE (3.8, NE)
Prior platinum-base chemotherapy		
Yes	19 / 113	NE (NE, NE)
No	2 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	16 / 102	NE (NE, NE)
No	5 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	4 / 24	NE (NE, NE)
≥ 50%	9 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	16 / 88	NE (NE, NE)
Race		
White	18 / 103	NE (NE, NE)
Black	1 / 2	NE (0.7, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	10 / 63	NE (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	21 / 125	NE (NE, NE)
Metastatic		
Yes	20 / 122	NE (NE, NE)
No	1 / 4	NE (0.0, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	18 / 100	NE (NE, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	17 / 100	NE (NE, NE)
Bone metastasis		
Yes	15 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)
Smoking history		
Never	3 / 6	NE (0.0, NE)
Current	1 / 15	NE (NE, NE)
Former	17 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.5. Summary of Time to First Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 10 Subjects and ≥ 1% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	15 / 79	NE (NE, NE)
Europe	5 / 30	NE (NE, NE)
Asia	1 / 12	NE (1.6, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-005-teae-sum-soc-pref-10subj-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:50)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first grade ≥ 3 Gastrointestinal disorders TEAE		
Overall	13 / 126	NE (NE, NE)
Age at baseline		
< 65 years	8 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	4 / 54	NE (NE, NE)
2	7 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	2 / 11	NE (1.6, NE)
Prior platinum-base chemotherapy		
Yes	12 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	10 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	2 / 38	NE (NE, NE)
1	11 / 88	NE (NE, NE)
Race		
White	11 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	1 / 2	NE (1.6, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	13 / 125	NE (NE, NE)
Metastatic		
Yes	13 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	11 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	10 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	7 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.6, NE)
Current	2 / 15	NE (NE, NE)
Former	9 / 102	NE (NE, NE)
Region		
North America	6 / 79	NE (NE, NE)
Europe	6 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Diarrhoea TEAE		
Overall	7 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	2 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	5 / 115	NE (NE, NE)
No	2 / 11	NE (1.6, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	6 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	4 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	5 / 88	NE (NE, NE)
Race		
White	6 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	0 / 19	NE (NE, NE)
Other	1 / 2	NE (1.6, NE)
Sex		
Male	1 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	7 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	7 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	6 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	6 / 100	NE (NE, NE)
Bone metastasis		
Yes	3 / 61	NE (NE, NE)
No	4 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.6, NE)
Current	1 / 15	NE (NE, NE)
Former	4 / 102	NE (NE, NE)
Region		
North America	4 / 79	NE (NE, NE)
Europe	3 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Hepatobiliary disorders TEAE		
Overall	8 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	4 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	4 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	8 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	4 / 38	NE (NE, NE)
1	4 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	7 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	4 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	8 / 125	NE (NE, NE)
Metastatic		
Yes	8 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	5 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	3 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	1 / 6	NE (0.8, NE)
Current	1 / 15	NE (NE, NE)
Former	5 / 102	NE (NE, NE)
Region		
North America	3 / 79	NE (NE, NE)
Europe	3 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (2.3, NE)
Time to first grade ≥ 3 Infections and infestations TEAE		
Overall	16 / 126	NE (NE, NE)
Age at baseline		
< 65 years	12 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	10 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	12 / 115	NE (NE, NE)
No	4 / 11	NE (2.3, NE)
Prior platinum-base chemotherapy		
Yes	16 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	12 / 102	NE (NE, NE)
No	4 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	11 / 88	NE (NE, NE)
Race		
White	14 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (5.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	7 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	16 / 125	NE (NE, NE)
Metastatic		
Yes	16 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	15 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	13 / 100	NE (NE, NE)
Bone metastasis		
Yes	7 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	3 / 15	NE (2.3, NE)
Former	13 / 102	NE (NE, NE)
Region		
North America	12 / 79	NE (NE, NE)
Europe	1 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.5, NE)
Rest of the world	1 / 5	NE (4.2, NE)
Time to first grade ≥ 3 Pneumonia TEAE		
Overall	9 / 126	NE (NE, NE)
Age at baseline		
< 65 years	7 / 67	NE (NE, NE)
≥ 65 years	2 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	1 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	1 / 11	NE (2.6, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	7 / 88	NE (NE, NE)
Race		
White	7 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (5.7, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	6 / 63	NE (NE, NE)
Female	3 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	9 / 125	NE (NE, NE)
Metastatic		
Yes	9 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	4 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	2 / 15	NE (NE, NE)
Former	7 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	7 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.5, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Investigations TEAE		
Overall	21 / 126	NE (NE, NE)
Age at baseline		
< 65 years	11 / 67	NE (NE, NE)
≥ 65 years	10 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	7 / 54	NE (NE, NE)
2	12 / 44	NE (9.0, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	19 / 115	NE (NE, NE)
No	2 / 11	NE (2.1, NE)
Prior platinum-base chemotherapy		
Yes	18 / 113	NE (NE, NE)
No	3 / 13	NE (1.4, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	16 / 102	NE (NE, NE)
No	5 / 24	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	7 / 24	NE (4.6, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	6 / 38	NE (NE, NE)
1	15 / 88	NE (NE, NE)
Race		
White	16 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	4 / 19	NE (2.1, NE)
Other	1 / 2	NE (2.1, NE)
Sex		
Male	11 / 63	NE (NE, NE)
Female	10 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	21 / 125	NE (NE, NE)
Metastatic		
Yes	21 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	5 / 26	NE (3.5, NE)
No	16 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	5 / 26	NE (4.3, NE)
No	16 / 100	NE (NE, NE)
Bone metastasis		
Yes	9 / 61	NE (NE, NE)
No	12 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	4.6 (2.1, NE)
Current	4 / 15	NE (1.4, NE)
Former	15 / 102	NE (NE, NE)
Region		
North America	7 / 79	NE (NE, NE)
Europe	10 / 30	NE (4.1, NE)
Asia	3 / 12	NE (1.4, NE)
Rest of the world	1 / 5	NE (2.1, NE)
Time to first grade ≥ 3 Alanine aminotransferase increased TEAE		
Overall	9 / 126	NE (NE, NE)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	2 / 54	NE (NE, NE)
2	7 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)
ECOG		
0	3 / 38	NE (NE, NE)
1	6 / 88	NE (NE, NE)
Race		
White	7 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	1 / 2	NE (2.1, NE)
Sex		
Male	3 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	9 / 125	NE (NE, NE)
Metastatic		
Yes	9 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Brain metastasis		
Yes	2 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Bone metastasis		
Yes	3 / 61	NE (NE, NE)
No	6 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (2.1, NE)
Current	0 / 15	NE (NE, NE)
Former	8 / 102	NE (NE, NE)
Region		
North America	3 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	1 / 12	NE (2.1, NE)
Rest of the world	1 / 5	NE (2.1, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first grade ≥ 3 Aspartate aminotransferase increased TEAE		
Overall	9 / 126	NE (NE, NE)
Age at baseline		
< 65 years	5 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	2 / 54	NE (NE, NE)
2	7 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	4 / 38	NE (NE, NE)
1	5 / 88	NE (NE, NE)
Race		
White	5 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	3 / 19	NE (NE, NE)
Other	1 / 2	NE (2.1, NE)
Sex		
Male	5 / 63	NE (NE, NE)
Female	4 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	9 / 125	NE (NE, NE)
Metastatic		
Yes	9 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	4 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (2.1, NE)
Current	2 / 15	NE (NE, NE)
Former	6 / 102	NE (NE, NE)
Region		
North America	2 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	3 / 12	NE (1.4, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Metabolism and nutrition disorders TEAE		
Overall	8 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	5 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	2 / 54	NE (NE, NE)
2	5 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	7 / 115	NE (NE, NE)
No	1 / 11	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	7 / 113	NE (NE, NE)
No	1 / 13	NE (9.0, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	6 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (9.0, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	7 / 88	NE (NE, NE)
Race		
White	5 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	1 / 2	NE (1.4, NE)
Sex		
Male	2 / 63	NE (NE, NE)
Female	6 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	8 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	8 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Bone metastasis		
Yes	4 / 61	NE (NE, NE)
No	4 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (1.4, NE)
Current	1 / 15	NE (NE, NE)
Former	5 / 102	NE (NE, NE)
Region		
North America	4 / 79	NE (NE, NE)
Europe	3 / 30	NE (9.0, NE)
Asia	1 / 12	NE (2.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Musculoskeletal and connective tissue disorders TEAE		
Overall	12 / 126	NE (11.8, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	6 / 59	11.8 (11.8, NE)
Prior lines of anti-cancer therapy		
1	8 / 54	11.8 (11.8, NE)
2	2 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	12 / 115	11.8 (11.8, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	11 / 113	NE (11.8, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	11 / 102	11.8 (11.8, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	8 / 33	11.8 (11.8, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	10 / 88	11.8 (11.8, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	11 / 103	NE (11.8, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	7 / 63	11.8 (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	12 / 125	NE (11.8, NE)
Metastatic		
Yes	11 / 122	11.8 (11.8, NE)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	11 / 100	NE (11.8, NE)
Brain metastasis		
Yes	4 / 26	NE (NE, NE)
No	8 / 100	NE (11.8, NE)
Bone metastasis		
Yes	8 / 61	11.8 (NE, NE)
No	4 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	1 / 6	NE (2.7, NE)
Current	0 / 15	NE (NE, NE)
Former	11 / 102	11.8 (NE, NE)
Region		
North America	9 / 79	NE (11.8, NE)
Europe	3 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) TEAE		
Overall	15 / 126	12.0 (12.0, NE)
Age at baseline		
< 65 years	10 / 67	NE (NE, NE)
≥ 65 years	5 / 59	12.0 (NE, NE)
Prior lines of anti-cancer therapy		
1	6 / 54	12.0 (12.0, NE)
2	6 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	13 / 115	12.0 (NE, NE)
No	2 / 11	NE (2.3, NE)
Prior platinum-base chemotherapy		
Yes	15 / 113	12.0 (12.0, NE)
No	0 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	13 / 102	12.0 (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	12.0 (12.0, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	13 / 88	12.0 (12.0, NE)
Race		
White	13 / 103	12.0 (12.0, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	4 / 63	12.0 (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	15 / 125	12.0 (12.0, NE)
Metastatic		
Yes	15 / 122	12.0 (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	6 / 26	NE (6.3, NE)
No	9 / 100	12.0 (12.0, NE)
Brain metastasis		
Yes	2 / 26	NE (NE, NE)
No	13 / 100	12.0 (12.0, NE)
Bone metastasis		
Yes	14 / 61	12.0 (NE, NE)
No	1 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (4.0, NE)
Current	1 / 15	NE (NE, NE)
Former	13 / 102	12.0 (NE, NE)
Region		
North America	9 / 79	12.0 (12.0, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (4.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Non-small cell lung cancer TEAE		
Overall	8 / 126	12.0 (12.0, NE)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	2 / 59	12.0 (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	2 / 54	12.0 (12.0, NE)
2	4 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	12.0 (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	8 / 113	12.0 (12.0, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	12.0 (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	12.0 (12.0, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	6 / 88	12.0 (12.0, NE)
Race		
White	6 / 103	12.0 (12.0, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	3 / 63	12.0 (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	8 / 125	12.0 (12.0, NE)
Metastatic		
Yes	8 / 122	12.0 (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	3 / 26	NE (6.3, NE)
No	5 / 100	12.0 (12.0, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	7 / 100	12.0 (12.0, NE)
Bone metastasis		
Yes	8 / 61	12.0 (NE, NE)
No	0 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (4.0, NE)
Current	0 / 15	NE (NE, NE)
Former	7 / 102	12.0 (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	5 / 79	12.0 (12.0, NE)
Europe	1 / 30	NE (NE, NE)
Asia	2 / 12	NE (4.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 Respiratory, thoracic and mediastinal disorders TEAE		
Overall	22 / 126	NE (NE, NE)
Age at baseline		
< 65 years	14 / 67	NE (NE, NE)
≥ 65 years	8 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	7 / 54	NE (NE, NE)
2	9 / 44	NE (NE, NE)
> 2	6 / 28	NE (7.0, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	20 / 115	NE (NE, NE)
No	2 / 11	NE (3.5, NE)
Prior platinum-base chemotherapy		
Yes	21 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	19 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	6 / 24	NE (7.0, NE)
≥ 50%	7 / 35	NE (NE, NE)
ECOG		
0	3 / 38	NE (NE, NE)
1	19 / 88	NE (NE, NE)
Race		
White	16 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	6 / 19	NE (3.5, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	11 / 63	NE (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	22 / 125	NE (NE, NE)
Metastatic		
Yes	22 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	18 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	19 / 100	NE (NE, NE)
Bone metastasis		
Yes	12 / 61	NE (NE, NE)
No	10 / 65	NE (NE, NE)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	3 / 15	NE (2.4, NE)
Former	16 / 102	NE (NE, NE)
Region		
North America	15 / 79	NE (NE, NE)
Europe	2 / 30	NE (NE, NE)
Asia	4 / 12	NE (0.5, NE)
Rest of the world	1 / 5	NE (4.2, NE)
Time to first grade ≥ 3 Pleural effusion TEAE		
Overall	7 / 126	NE (NE, NE)
Age at baseline		
< 65 years	4 / 67	NE (NE, NE)
≥ 65 years	3 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	0 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	6 / 115	NE (NE, NE)
No	1 / 11	NE (6.4, NE)
Prior platinum-base chemotherapy		
Yes	7 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	6 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	2 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	6 / 88	NE (NE, NE)
Race		
White	6 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	3 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.6. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	7 / 125	NE (NE, NE)
Metastatic		
Yes	7 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (NE, NE)
No	5 / 100	NE (NE, NE)
Brain metastasis		
Yes	0 / 26	NE (NE, NE)
No	7 / 100	NE (NE, NE)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	1 / 65	NE (NE, NE)
Smoking history		
Never	2 / 6	NE (0.2, NE)
Current	0 / 15	NE (NE, NE)
Former	5 / 102	NE (NE, NE)
Region		
North America	5 / 79	NE (NE, NE)
Europe	1 / 30	NE (NE, NE)
Asia	1 / 12	NE (3.5, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-006-teae-sum-grd3-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first serious Gastrointestinal disorders TEAE		
Overall	11 / 126	NE (NE, NE)
Age at baseline		
< 65 years	7 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	3 / 54	NE (NE, NE)
2	6 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	11 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	10 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	10 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	3 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	4 / 35	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	1 / 38	NE (NE, NE)
1	10 / 88	NE (NE, NE)
Race		
White	10 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	4 / 63	NE (NE, NE)
Female	7 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	11 / 125	NE (NE, NE)
Metastatic		
Yes	11 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	2 / 26	NE (8.5, NE)
No	9 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	6 / 61	NE (NE, NE)
No	5 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	10 / 102	NE (NE, NE)
Region		
North America	5 / 79	NE (NE, NE)
Europe	4 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (4.6, NE)
Time to first serious Infections and infestations TEAE		
Overall	16 / 126	NE (NE, NE)
Age at baseline		
< 65 years	12 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	10 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	12 / 115	NE (NE, NE)
No	4 / 11	NE (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy		
Yes	16 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	12 / 102	NE (NE, NE)
No	4 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	11 / 88	NE (NE, NE)
Race		
White	14 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (5.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	7 / 63	NE (NE, NE)
Female	9 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	16 / 125	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Metastatic		
Yes	16 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	15 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	13 / 100	NE (NE, NE)
Bone metastasis		
Yes	7 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	3 / 15	NE (2.3, NE)
Former	13 / 102	NE (NE, NE)
Region		
North America	12 / 79	NE (NE, NE)
Europe	1 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.5, NE)
Rest of the world	1 / 5	NE (4.2, NE)
Time to first serious Pneumonia TEAE		
Overall	9 / 126	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Age at baseline		
< 65 years	7 / 67	NE (NE, NE)
≥ 65 years	2 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	5 / 54	NE (NE, NE)
2	1 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	NE (NE, NE)
No	1 / 11	NE (2.6, NE)
Prior platinum-base chemotherapy		
Yes	9 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	NE (NE, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	2 / 33	NE (NE, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	7 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	7 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (5.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	6 / 63	NE (NE, NE)
Female	3 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	9 / 125	NE (NE, NE)
Metastatic		
Yes	9 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	8 / 100	NE (NE, NE)
Bone metastasis		
Yes	5 / 61	NE (NE, NE)
No	4 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	2 / 15	NE (NE, NE)
Former	7 / 102	NE (NE, NE)
Region		
North America	7 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	2 / 12	NE (1.5, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first serious Musculoskeletal and connective tissue disorders TEAE		
Overall	7 / 126	NE (11.8, NE)
Age at baseline		
< 65 years	1 / 67	NE (NE, NE)
≥ 65 years	6 / 59	11.8 (11.8, NE)
Prior lines of anti-cancer therapy		
1	6 / 54	11.8 (11.8, NE)
2	0 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	7 / 115	NE (11.8, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	6 / 113	NE (11.8, NE)
No	1 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	6 / 102	NE (11.8, NE)
No	1 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (11.8, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	1 / 38	NE (NE, NE)
1	6 / 88	NE (11.8, NE)
Race		
White	7 / 103	NE (11.8, NE)
Black	0 / 2	NE (NE, NE)
Asian	0 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	5 / 63	11.8 (NE, NE)
Female	2 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	7 / 125	NE (11.8, NE)
Metastatic		
Yes	6 / 122	NE (11.8, NE)
No	1 / 4	NE (1.7, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	1 / 26	NE (NE, NE)
No	6 / 100	NE (11.8, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	6 / 100	NE (11.8, NE)
Bone metastasis		
Yes	5 / 61	11.8 (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	7 / 102	11.8 (11.8, NE)
Region		
North America	5 / 79	NE (11.8, NE)
Europe	1 / 30	NE (NE, NE)
Asia	0 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (4.6, NE)
Time to first serious Neoplasms benign, malignant and unspecified (incl cysts and polyps) TEAE		
Overall	14 / 126	12.0 (12.0, NE)
Age at baseline		
< 65 years	10 / 67	NE (NE, NE)
≥ 65 years	4 / 59	12.0 (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	6 / 54	12.0 (12.0, NE)
2	5 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	12 / 115	12.0 (NE, NE)
No	2 / 11	NE (2.3, NE)
Prior platinum-base chemotherapy		
Yes	14 / 113	12.0 (12.0, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	12 / 102	12.0 (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	12.0 (12.0, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	3 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	12 / 88	12.0 (12.0, NE)
Race		
White	12 / 103	12.0 (12.0, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	3 / 63	12.0 (NE, NE)
Female	11 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	14 / 125	12.0 (12.0, NE)
Metastatic		
Yes	14 / 122	12.0 (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	5 / 26	NE (6.3, NE)
No	9 / 100	12.0 (12.0, NE)
Brain metastasis		
Yes	2 / 26	NE (NE, NE)
No	12 / 100	12.0 (12.0, NE)
Bone metastasis		
Yes	13 / 61	12.0 (NE, NE)
No	1 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (4.0, NE)
Current	1 / 15	NE (NE, NE)
Former	12 / 102	12.0 (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	8 / 79	12.0 (12.0, NE)
Europe	4 / 30	NE (NE, NE)
Asia	2 / 12	NE (4.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first serious Non-small cell lung cancer TEAE		
Overall	8 / 126	12.0 (12.0, NE)
Age at baseline		
< 65 years	6 / 67	NE (NE, NE)
≥ 65 years	2 / 59	12.0 (NE, NE)
Prior lines of anti-cancer therapy		
1	2 / 54	12.0 (12.0, NE)
2	4 / 44	NE (NE, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	8 / 115	12.0 (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	8 / 113	12.0 (12.0, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	8 / 102	12.0 (NE, NE)
No	0 / 24	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
PD-L1 protein expression		
< 1%	4 / 33	12.0 (12.0, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	6 / 88	12.0 (12.0, NE)
Race		
White	6 / 103	12.0 (12.0, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	3 / 63	12.0 (NE, NE)
Female	5 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	8 / 125	12.0 (12.0, NE)
Metastatic		
Yes	8 / 122	12.0 (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	3 / 26	NE (6.3, NE)
No	5 / 100	12.0 (12.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	7 / 100	12.0 (12.0, NE)
Bone metastasis		
Yes	8 / 61	12.0 (NE, NE)
No	0 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (4.0, NE)
Current	0 / 15	NE (NE, NE)
Former	7 / 102	12.0 (NE, NE)
Region		
North America	5 / 79	12.0 (12.0, NE)
Europe	1 / 30	NE (NE, NE)
Asia	2 / 12	NE (4.0, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first serious Respiratory, thoracic and mediastinal disorders TEAE		
Overall	18 / 126	NE (NE, NE)
Age at baseline		
< 65 years	12 / 67	NE (NE, NE)
≥ 65 years	6 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	6 / 54	NE (NE, NE)
2	8 / 44	NE (NE, NE)
> 2	4 / 28	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	17 / 115	NE (NE, NE)
No	1 / 11	NE (3.5, NE)
Prior platinum-base chemotherapy		
Yes	17 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	16 / 102	NE (NE, NE)
No	2 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	5 / 24	NE (8.0, NE)
≥ 50%	7 / 35	NE (NE, NE)
ECOG		
0	4 / 38	NE (NE, NE)
1	14 / 88	NE (NE, NE)
Race		
White	12 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	6 / 19	NE (3.5, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	10 / 63	NE (NE, NE)
Female	8 / 63	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.7. Summary of Time to First Serious Treatment Emergent Adverse Event by MedDRA SOC and PT (Most Frequent TEAEs (≥ 5% Subjects)) (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	18 / 125	NE (NE, NE)
Metastatic		
Yes	18 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	4 / 26	NE (NE, NE)
No	14 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	15 / 100	NE (NE, NE)
Bone metastasis		
Yes	9 / 61	NE (NE, NE)
No	9 / 65	NE (NE, NE)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	2 / 15	NE (NE, NE)
Former	13 / 102	NE (NE, NE)
Region		
North America	12 / 79	NE (NE, NE)
Europe	2 / 30	NE (8.0, NE)
Asia	4 / 12	NE (0.5, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-soc-pref-subgroup.sas
Output: t14-06-003-007-teae-sum-ser-soc-pref-5pct-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:07)
Source: a0543pa.adsl, a0543pa.adae

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first hepatotoxicity TEAE		
Overall	40 / 126	NE (NE, NE)
Age at baseline		
< 65 years	23 / 67	NE (4.8, NE)
≥ 65 years	17 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	15 / 54	NE (NE, NE)
2	20 / 44	NE (2.0, NE)
> 2	5 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	37 / 115	NE (NE, NE)
No	3 / 11	NE (2.1, NE)
Prior platinum-base chemotherapy		
Yes	37 / 113	NE (NE, NE)
No	3 / 13	NE (3.5, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	34 / 102	NE (NE, NE)
No	6 / 24	NE (3.5, NE)
PD-L1 protein expression		
< 1%	5 / 33	NE (NE, NE)
≥ 1% and < 50%	14 / 24	2.4 (1.4, NE)
≥ 50%	9 / 35	NE (NE, NE)
ECOG		
0	13 / 38	NE (4.2, NE)
1	27 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	29 / 103	NE (NE, NE)
Black	2 / 2	2.6 (0.3, NE)
Asian	7 / 19	NE (1.2, NE)
Other	2 / 2	2.4 (1.4, NE)
Sex		
Male	20 / 63	NE (NE, NE)
Female	20 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	40 / 125	NE (NE, NE)
Metastatic		
Yes	40 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	10 / 26	NE (2.1, NE)
No	30 / 100	NE (NE, NE)
Brain metastasis		
Yes	11 / 26	NE (2.1, NE)
No	29 / 100	NE (NE, NE)
Bone metastasis		
Yes	19 / 61	NE (4.8, NE)
No	21 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	3 / 6	NE (0.8, NE)
Current	5 / 15	NE (1.4, NE)
Former	31 / 102	NE (NE, NE)
Region		
North America	21 / 79	NE (NE, NE)
Europe	12 / 30	NE (2.8, NE)
Asia	6 / 12	2.1 (0.8, NE)
Rest of the world	1 / 5	NE (2.1, NE)
Time to first renal toxicity TEAE		
Overall	21 / 126	NE (NE, NE)
Age at baseline		
< 65 years	13 / 67	NE (NE, NE)
≥ 65 years	8 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	7 / 54	NE (NE, NE)
2	12 / 44	NE (8.3, NE)
> 2	2 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	19 / 115	NE (NE, NE)
No	2 / 11	NE (3.5, NE)
Prior platinum-base chemotherapy		
Yes	18 / 113	NE (NE, NE)
No	3 / 13	NE (8.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	16 / 102	NE (NE, NE)
No	5 / 24	NE (8.3, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	8 / 24	NE (4.9, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	5 / 38	NE (NE, NE)
1	16 / 88	NE (NE, NE)
Race		
White	17 / 103	NE (NE, NE)
Black	2 / 2	2.7 (0.3, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	8 / 63	NE (NE, NE)
Female	13 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	21 / 125	NE (NE, NE)
Metastatic		
Yes	20 / 122	NE (NE, NE)
No	1 / 4	NE (3.5, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	5 / 26	NE (NE, NE)
No	16 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	18 / 100	NE (NE, NE)
Bone metastasis		
Yes	9 / 61	NE (NE, NE)
No	12 / 65	NE (NE, NE)
Smoking history		
Never	1 / 6	NE (3.5, NE)
Current	4 / 15	NE (0.3, NE)
Former	16 / 102	NE (NE, NE)
Region		
North America	15 / 79	NE (NE, NE)
Europe	5 / 30	NE (8.3, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first pneumonitis TEAE		
Overall	3 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	0 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	2 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	3 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	3 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	3 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	3 / 88	NE (NE, NE)
Race		
White	1 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	2 / 63	NE (NE, NE)
Female	1 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	3 / 125	NE (NE, NE)
Metastatic		
Yes	3 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	3 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	2 / 100	NE (NE, NE)
Bone metastasis		
Yes	1 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	3 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.8. Summary of Time to First Treatment Emergent Adverse Event of Interest
(Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	2 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-008-teae-sum-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:45) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first grade ≥ 3 hepatotoxicity TEAE		
Overall	22 / 126	NE (NE, NE)
Age at baseline		
< 65 years	13 / 67	NE (NE, NE)
≥ 65 years	9 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	7 / 54	NE (NE, NE)
2	12 / 44	NE (NE, NE)
> 2	3 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	20 / 115	NE (NE, NE)
No	2 / 11	NE (2.1, NE)
Prior platinum-base chemotherapy		
Yes	21 / 113	NE (NE, NE)
No	1 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	19 / 102	NE (NE, NE)
No	3 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	4 / 33	NE (NE, NE)
≥ 1% and < 50%	6 / 24	NE (4.6, NE)
≥ 50%	5 / 35	NE (NE, NE)
ECOG		
0	8 / 38	NE (NE, NE)
1	14 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	16 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	5 / 19	NE (2.1, NE)
Other	1 / 2	NE (2.1, NE)
Sex		
Male	12 / 63	NE (NE, NE)
Female	10 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	22 / 125	NE (NE, NE)
Metastatic		
Yes	22 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	7 / 26	NE (2.8, NE)
No	15 / 100	NE (NE, NE)
Brain metastasis		
Yes	7 / 26	NE (4.1, NE)
No	15 / 100	NE (NE, NE)
Bone metastasis		
Yes	11 / 61	NE (NE, NE)
No	11 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	3 / 6	4.6 (0.8, NE)
Current	4 / 15	NE (1.4, NE)
Former	14 / 102	NE (NE, NE)
Region		
North America	6 / 79	NE (NE, NE)
Europe	10 / 30	NE (4.1, NE)
Asia	5 / 12	NE (1.1, NE)
Rest of the world	1 / 5	NE (2.1, NE)
Time to first grade ≥ 3 renal toxicity TEAE		
Overall	3 / 126	NE (NE, NE)
Age at baseline		
< 65 years	2 / 67	NE (NE, NE)
≥ 65 years	1 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	1 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	3 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	3 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	3 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	3 / 88	NE (NE, NE)
Race		
White	2 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	1 / 63	NE (NE, NE)
Female	2 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	3 / 125	NE (NE, NE)
Metastatic		
Yes	3 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	3 / 100	NE (NE, NE)
Brain metastasis		
Yes	0 / 26	NE (NE, NE)
No	3 / 100	NE (NE, NE)
Bone metastasis		
Yes	1 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (4.6, NE)
Former	2 / 102	NE (NE, NE)
Region		
North America	2 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (4.6, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first grade ≥ 3 pneumonitis TEAE		
Overall	3 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	0 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	2 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	3 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	3 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	3 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	3 / 88	NE (NE, NE)
Race		
White	1 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	2 / 63	NE (NE, NE)
Female	1 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	3 / 125	NE (NE, NE)
Metastatic		
Yes	3 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	3 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	2 / 100	NE (NE, NE)
Bone metastasis		
Yes	1 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	3 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.9. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	2 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas
Output: t14-06-003-009-teae-sum-grd3-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:49)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first serious hepatotoxicity TEAE		
Overall	7 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	4 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	3 / 54	NE (NE, NE)
2	3 / 44	NE (NE, NE)
> 2	1 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	7 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	7 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	7 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	0 / 33	NE (NE, NE)
≥ 1% and < 50%	3 / 24	NE (NE, NE)
≥ 50%	2 / 35	NE (NE, NE)
ECOG		
0	2 / 38	NE (NE, NE)
1	5 / 88	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Race		
White	6 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	5 / 63	NE (NE, NE)
Female	2 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	7 / 125	NE (NE, NE)
Metastatic		
Yes	7 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	3 / 26	NE (NE, NE)
No	4 / 100	NE (NE, NE)
Brain metastasis		
Yes	3 / 26	NE (NE, NE)
No	4 / 100	NE (NE, NE)
Bone metastasis		
Yes	4 / 61	NE (NE, NE)
No	3 / 65	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (NE, NE)
Former	6 / 102	NE (NE, NE)
Region		
North America	2 / 79	NE (NE, NE)
Europe	3 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	1 / 5	NE (2.3, NE)
Time to first serious renal toxicity TEAE		
Overall	1 / 126	NE (NE, NE)
Age at baseline		
< 65 years	1 / 67	NE (NE, NE)
≥ 65 years	0 / 59	NE (NE, NE)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	0 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	1 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	1 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	1 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	0 / 24	NE (NE, NE)
≥ 50%	0 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	1 / 88	NE (NE, NE)
Race		
White	0 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	1 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	1 / 63	NE (NE, NE)
Female	0 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	1 / 125	NE (NE, NE)
Metastatic		
Yes	1 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	1 / 100	NE (NE, NE)
Brain metastasis		
Yes	0 / 26	NE (NE, NE)
No	1 / 100	NE (NE, NE)
Bone metastasis		
Yes	0 / 61	NE (NE, NE)
No	1 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	1 / 15	NE (4.6, NE)
Former	0 / 102	NE (NE, NE)
Region		
North America	0 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (4.6, NE)
Rest of the world	0 / 5	NE (NE, NE)
Time to first serious pneumonitis TEAE		
Overall	3 / 126	NE (NE, NE)
Age at baseline		
< 65 years	3 / 67	NE (NE, NE)
≥ 65 years	0 / 59	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Prior lines of anti-cancer therapy		
1	1 / 54	NE (NE, NE)
2	2 / 44	NE (NE, NE)
> 2	0 / 28	NE (NE, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	3 / 115	NE (NE, NE)
No	0 / 11	NE (NE, NE)
Prior platinum-base chemotherapy		
Yes	3 / 113	NE (NE, NE)
No	0 / 13	NE (NE, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	3 / 102	NE (NE, NE)
No	0 / 24	NE (NE, NE)
PD-L1 protein expression		
< 1%	1 / 33	NE (NE, NE)
≥ 1% and < 50%	1 / 24	NE (NE, NE)
≥ 50%	1 / 35	NE (NE, NE)
ECOG		
0	0 / 38	NE (NE, NE)
1	3 / 88	NE (NE, NE)
Race		
White	1 / 103	NE (NE, NE)
Black	0 / 2	NE (NE, NE)
Asian	2 / 19	NE (NE, NE)
Other	0 / 2	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Sex		
Male	2 / 63	NE (NE, NE)
Female	1 / 63	NE (NE, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	3 / 125	NE (NE, NE)
Metastatic		
Yes	3 / 122	NE (NE, NE)
No	0 / 4	NE (NE, NE)
Liver metastasis		
Yes	0 / 26	NE (NE, NE)
No	3 / 100	NE (NE, NE)
Brain metastasis		
Yes	1 / 26	NE (NE, NE)
No	2 / 100	NE (NE, NE)
Bone metastasis		
Yes	1 / 61	NE (NE, NE)
No	2 / 65	NE (NE, NE)
Smoking history		
Never	0 / 6	NE (NE, NE)
Current	0 / 15	NE (NE, NE)
Former	3 / 102	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.10. Summary of Time to First Serious Treatment Emergent Adverse Event of Interest (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Region		
North America	2 / 79	NE (NE, NE)
Europe	0 / 30	NE (NE, NE)
Asia	1 / 12	NE (NE, NE)
Rest of the world	0 / 5	NE (NE, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-eoi-cat-subgroup.sas Output: t14-06-003-010-teae-sum-ser-eoi-cat-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:53) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.11. Summary of Time to First Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first TEAE excluding disease progression events		
Overall	124 / 126	0.2 (0.2, 0.3)
Age at baseline		
< 65 years	65 / 67	0.3 (0.1, 0.3)
≥ 65 years	59 / 59	0.2 (0.2, 0.3)
Prior lines of anti-cancer therapy		
1	54 / 54	0.2 (0.1, 0.3)
2	42 / 44	0.5 (0.2, 0.6)
> 2	28 / 28	0.2 (0.1, 0.3)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	113 / 115	0.2 (0.2, 0.3)
No	11 / 11	0.2 (0.0, 0.9)
Prior platinum-base chemotherapy		
Yes	111 / 113	0.3 (0.2, 0.3)
No	13 / 13	0.1 (0.0, 0.3)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	100 / 102	0.3 (0.2, 0.3)
No	24 / 24	0.2 (0.0, 0.3)
PD-L1 protein expression		
< 1%	32 / 33	0.2 (0.1, 0.5)
≥ 1% and < 50%	24 / 24	0.2 (0.1, 0.5)
≥ 50%	34 / 35	0.3 (0.2, 0.5)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-011-teae-sum-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:58) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.11. Summary of Time to First Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	38 / 38	0.3 (0.1, 0.6)
1	86 / 88	0.2 (0.2, 0.3)
Race		
White	102 / 103	0.3 (0.2, 0.3)
Black	2 / 2	0.0 (NE, NE)
Asian	18 / 19	0.5 (0.0, 1.0)
Other	2 / 2	0.1 (0.0, NE)
Sex		
Male	63 / 63	0.2 (0.1, 0.5)
Female	61 / 63	0.2 (0.2, 0.3)
Histopathology		
Squamous	1 / 1	0.5 (NE, NE)
Non-squamous	123 / 125	0.2 (0.2, 0.3)
Metastatic		
Yes	120 / 122	0.2 (0.2, 0.3)
No	4 / 4	0.1 (0.0, NE)
Liver metastasis		
Yes	26 / 26	0.3 (0.1, 0.5)
No	98 / 100	0.2 (0.2, 0.3)
Brain metastasis		
Yes	26 / 26	0.2 (0.0, 0.3)
No	98 / 100	0.3 (0.2, 0.3)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas Output: t14-06-003-011-teae-sum-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:58) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.11. Summary of Time to First Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	60 / 61	0.3 (0.2, 0.5)
No	64 / 65	0.2 (0.1, 0.3)
Smoking history		
Never	5 / 6	0.0 (0.0, NE)
Current	15 / 15	0.2 (0.0, 0.7)
Former	101 / 102	0.2 (0.2, 0.3)
Region		
North America	77 / 79	0.2 (0.2, 0.3)
Europe	30 / 30	0.3 (0.1, 0.5)
Asia	12 / 12	0.5 (0.0, 1.1)
Rest of the world	5 / 5	0.1 (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-011-teae-sum-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:47:58) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.12. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first grade ≥ 3 TEAE excluding disease progression events		
Overall	72 / 126	5.1 (2.8, 7.4)
Age at baseline		
< 65 years	38 / 67	4.3 (2.1, NE)
≥ 65 years	34 / 59	6.0 (2.3, 9.4)
Prior lines of anti-cancer therapy		
1	29 / 54	6.3 (2.5, NE)
2	27 / 44	2.8 (1.4, 9.0)
> 2	16 / 28	6.6 (2.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	66 / 115	5.7 (2.8, 9.0)
No	6 / 11	3.8 (1.4, NE)
Prior platinum-base chemotherapy		
Yes	66 / 113	4.3 (2.7, 7.0)
No	6 / 13	NE (1.3, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	60 / 102	4.3 (2.7, 7.0)
No	12 / 24	9.0 (1.4, NE)
PD-L1 protein expression		
< 1%	18 / 33	6.3 (2.7, NE)
≥ 1% and < 50%	15 / 24	2.8 (1.4, NE)
≥ 50%	22 / 35	3.2 (1.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-012-teae-sum-grd3-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.12. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	17 / 38	NE (2.7, NE)
1	55 / 88	3.7 (2.3, 6.6)
Race		
White	58 / 103	5.7 (2.8, 9.4)
Black	1 / 2	NE (1.8, NE)
Asian	12 / 19	3.7 (1.1, NE)
Other	1 / 2	NE (1.4, NE)
Sex		
Male	35 / 63	6.0 (2.7, NE)
Female	37 / 63	4.3 (2.1, 9.0)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	72 / 125	5.1 (2.7, 7.4)
Metastatic		
Yes	71 / 122	4.3 (2.7, 7.0)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	15 / 26	2.8 (1.4, NE)
No	57 / 100	5.7 (2.8, 9.4)
Brain metastasis		
Yes	17 / 26	3.0 (1.8, 5.7)
No	55 / 100	6.3 (2.8, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-012-teae-sum-grd3-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.12. Summary of Time to First Grade ≥ 3 Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	41 / 61	2.8 (2.1, 6.0)
No	31 / 65	NE (3.7, NE)
Smoking history		
Never	4 / 6	2.0 (0.2, NE)
Current	8 / 15	2.4 (1.0, NE)
Former	59 / 102	5.7 (2.8, 9.0)
Region		
North America	41 / 79	6.7 (3.0, NE)
Europe	20 / 30	2.8 (1.6, 9.0)
Asia	9 / 12	1.8 (0.5, 6.0)
Rest of the world	2 / 5	NE (0.0, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-012-teae-sum-grd3-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:01)
Source: a0543pa.adsl, adam.adtts

Table 14-6.3.13. Summary of Time to First Serious Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Time to first serious TEAE excluding disease progression events		
Overall	59 / 126	9.0 (5.7, NE)
Age at baseline		
< 65 years	31 / 67	8.5 (3.7, NE)
≥ 65 years	28 / 59	9.0 (3.8, NE)
Prior lines of anti-cancer therapy		
1	26 / 54	9.4 (3.0, NE)
2	20 / 44	9.0 (2.7, NE)
> 2	13 / 28	8.0 (4.6, NE)
Prior anti PD-1 or anti PD-L1 therapy		
Yes	54 / 115	9.0 (5.7, NE)
No	5 / 11	NE (2.3, NE)
Prior platinum-base chemotherapy		
Yes	55 / 113	8.0 (3.8, NE)
No	4 / 13	NE (8.5, NE)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1		
Yes	50 / 102	8.0 (3.7, NE)
No	9 / 24	NE (3.8, NE)
PD-L1 protein expression		
< 1%	14 / 33	NE (3.3, NE)
≥ 1% and < 50%	13 / 24	8.0 (1.8, NE)
≥ 50%	18 / 35	8.5 (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-013-teae-sum-ser-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:05) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.13. Summary of Time to First Serious Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
ECOG		
0	12 / 38	NE (8.0, NE)
1	47 / 88	6.3 (3.3, NE)
Race		
White	49 / 103	9.0 (4.6, NE)
Black	1 / 2	NE (1.8, NE)
Asian	9 / 19	6.0 (2.7, NE)
Other	0 / 2	NE (NE, NE)
Sex		
Male	28 / 63	9.4 (5.1, NE)
Female	31 / 63	8.5 (3.5, NE)
Histopathology		
Squamous	0 / 1	NE (NE, NE)
Non-squamous	59 / 125	9.0 (5.7, NE)
Metastatic		
Yes	58 / 122	8.5 (5.1, NE)
No	1 / 4	NE (1.7, NE)
Liver metastasis		
Yes	11 / 26	8.5 (2.3, NE)
No	48 / 100	9.0 (5.1, NE)
Brain metastasis		
Yes	16 / 26	3.0 (2.1, NE)
No	43 / 100	NE (7.4, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-013-teae-sum-ser-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:05) Source: a0543pa.adsl, adam.adtts

Table 14-6.3.13. Summary of Time to First Serious Treatment Emergent Adverse Event Excluding Disease Progression Events (Phase 2 NSCLC in Safety Analysis Set)

Endpoint	Events/Subjects	KM Median (95% CI)[a] (months)
Bone metastasis		
Yes	34 / 61	6.0 (2.7, 9.4)
No	25 / 65	NE (7.4, NE)
Smoking history		
Never	3 / 6	NE (0.2, NE)
Current	6 / 15	NE (1.3, NE)
Former	50 / 102	8.5 (5.1, NE)
Region		
North America	34 / 79	NE (7.4, NE)
Europe	16 / 30	8.0 (2.7, NE)
Asia	7 / 12	5.7 (0.5, NE)
Rest of the world	2 / 5	NE (2.3, NE)

KM = Kaplan-Meier, CI = Confidence Interval, TEAE = Treatment Emergent Adverse Event, NE = Not Estimable.
Disease progression events are defined as any preferred terms that contain the terms metastasis, metastases, metastatic, tumor pain, NSCLC, non-small cell lung cancer or adenocarcinoma of the lung.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
[a] 95% CI is based on the estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Phase 2 data cut-off date 01SEP2020.

Program: /userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202009/tables/t-teae-sum-subgroup.sas
Output: t14-06-003-013-teae-sum-ser-excpd-nsclc-p2saf.rtf (Date Generated: 21MAY21:03:48:05) Source: a0543pa.adsl, adam.adtts

2 Datenschnitt vom 01.12.2020

2.1 Gesamtüberleben

Table 14n-4.3.1. Summary of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 126)
Subject status	
Events - n (%)	59 (46.8)
Death due to any cause	59 (46.8)
Censored - n (%)	67 (53.2)
Alive at last follow-up	56 (44.4)
Lost to follow-up	2 (1.6)
Related to COVID-19	1 (0.8)
Withdrew consent	9 (7.1)
Related to COVID-19	1 (0.8)
Off study due to sponsor decision	0 (0.0)
Related to COVID-19	0 (0.0)
Overall survival (KM) (months)	
25th percentile (95% CI)	6.0 (4.1, 7.9)
Median (95% CI)	12.5 (10.0, NE)
75th percentile (95% CI)	NE (NE, NE)
Min, Max (+ for censored)	1.1, 15.6+
Kaplan-Meier estimate (95% CI)[a]	
At 3 months	89.5 (82.7, 93.8)
At 6 months	75.5 (66.8, 82.2)
At 9 months	63.5 (54.3, 71.4)
At 12 months	51.4 (41.9, 60.1)
Follow-up time for OS[b] (KM) (months)	
25th percentile (95% CI)	11.8 (10.8, 12.0)
Median (95% CI)	12.2 (12.0, 12.5)
75th percentile (95% CI)	12.7 (12.6, 13.6)
Min, Max (+ for censored)	1.1+, 15.6

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b] Follow-up time is summarized by reversing the status indicator for censored and events.
Survival status may include publicly available records (where permitted) searched by investigator after subject ended study.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-nsclc-p2saf.sas
Output: t14n-04-003-001-eff-os-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:51) Source: adam.adsl, adam.adtte

Figure 14n-4.3.1. Kaplan-Meier Plot of Overall Survival
(Phase 2 NSCLC in Safety Analysis Set)



Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
Censor indicated by vertical bar |
NE = Not Estimable.
Death is an event.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/figures/f-eff-km.sas
Output: f14n-04-003-001-eff-km-osm-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:38:17) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	31/67	11.5 (8.6, NE)	75.6 (63.3, 84.3)	49.3 (36.0, 61.3)
≥ 65 years	28/59	12.5 (9.5, NE)	75.4 (62.1, 84.7)	53.6 (39.7, 65.6)
Prior lines of anti-cancer therapy				
1	24/54	NE (7.9, NE)	75.0 (60.9, 84.7)	54.6 (39.9, 67.2)
2	22/44	11.5 (8.8, NE)	74.1 (58.1, 84.7)	46.3 (30.5, 60.7)
> 2	13/28	12.5 (8.0, NE)	78.6 (58.4, 89.8)	53.2 (31.9, 70.5)
Prior anti PD-1 or anti PD-L1				
Yes	55/115	12.0 (10.0, NE)	74.8 (65.7, 81.9)	50.4 (40.5, 59.5)
No	4/11	NE (4.8, NE)	81.8 (44.7, 95.1)	62.3 (27.7, 84.0)
Prior platinum-base chemotherapy				
Yes	57/113	11.2 (9.5, NE)	72.8 (63.4, 80.1)	48.2 (38.3, 57.4)
No	2/13	NE (11.7, NE)	100.0 (NE, NE)	81.5 (43.5, 95.1)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	53/102	11.0 (8.6, NE)	71.8 (61.8, 79.6)	46.7 (36.3, 56.4)
No	6/24	NE (11.7, NE)	91.3 (69.5, 97.8)	72.3 (48.1, 86.6)
PD-L1 protein expression				
< 1%	15/33	NE (8.3, NE)	78.3 (59.8, 89.0)	55.2 (36.2, 70.6)
≥ 1% and < 50%	11/24	NE (7.9, NE)	78.8 (56.2, 90.6)	52.1 (30.3, 70.1)
≥ 50%	21/35	9.5 (5.7, 12.5)	63.8 (45.1, 77.5)	36.9 (20.3, 53.7)
ECOG status at baseline				
0	11/38	NE (NE, NE)	86.3 (70.2, 94.1)	68.3 (50.0, 81.1)
1	48/88	10.2 (7.5, NE)	70.8 (59.9, 79.2)	44.2 (33.1, 54.6)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	49/103	12.5 (10.2, NE)	75.2 (65.6, 82.5)	51.7 (41.3, 61.2)
Black	2/2	4.7 (1.8, 7.6)	50.0 (0.6, 91.0)	0.0 (NE, NE)
Asian	8/19	NE (6.3, NE)	77.3 (50.1, 90.8)	51.0 (24.5, 72.3)
Other	0/2	NE (NE, NE)	100.0 (NE, NE)	100.0 (NE, NE)
Sex				
Male	25/63	NE (10.0, NE)	83.1 (70.9, 90.5)	56.7 (42.4, 68.7)
Female	34/63	11.5 (8.0, NE)	68.2 (55.2, 78.2)	47.0 (34.2, 58.8)
Histopathology type				
Squamous	1/1	10.0 (NE, NE)	100.0 (NE, NE)	0.0 (NE, NE)
Non-squamous	58/125	12.5 (10.2, NE)	75.3 (66.6, 82.0)	51.9 (42.4, 60.6)
Metastatic				
Yes	58/122	12.0 (10.0, NE)	75.5 (66.7, 82.3)	50.5 (40.9, 59.4)
No	1/4	NE (3.2, NE)	75.0 (12.8, 96.1)	75.0 (12.8, 96.1)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Liver metastasis				
Yes	17/26	8.8 (4.0, 11.0)	60.0 (38.4, 76.1)	30.5 (13.9, 49.1)
No	42/100	NE (10.9, NE)	79.4 (69.9, 86.2)	56.8 (46.0, 66.3)
Brain metastasis				
Yes	16/26	8.8 (4.1, 12.5)	71.8 (49.7, 85.4)	35.3 (16.8, 54.6)
No	43/100	NE (10.8, NE)	76.5 (66.8, 83.7)	55.5 (44.8, 64.9)
Bone metastasis				
Yes	38/61	8.6 (5.7, 11.7)	63.7 (49.9, 74.7)	35.8 (23.4, 48.4)
No	21/65	NE (NE, NE)	86.0 (74.8, 92.5)	65.3 (51.8, 75.9)
Smoking history				
Never	2/6	NE (4.0, NE)	60.0 (12.6, 88.2)	60.0 (12.6, 88.2)
Current	8/15	11.0 (5.7, NE)	78.6 (47.2, 92.5)	40.2 (15.1, 64.4)
Former	49/102	12.0 (9.5, NE)	74.9 (65.2, 82.3)	51.0 (40.5, 60.6)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.3.2. Subgroup Analysis of Overall Survival (Phase 2 NSCLC in Safety Analysis Set)

	Events/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Region				
North America	35/79	NE (10.0, NE)	75.2 (63.9, 83.4)	55.0 (42.8, 65.7)
Europe	17/30	11.0 (7.9, NE)	76.5 (57.0, 88.1)	40.5 (22.5, 57.8)
Asia	6/12	10.0 (1.7, NE)	73.3 (37.9, 90.6)	44.0 (14.9, 70.2)
Rest of the world	1/5	NE (5.6, NE)	80.0 (20.4, 96.9)	80.0 (20.4, 96.9)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-os-sub-nsclc-p2saf.sas
Output: t14n-04-003-002-eff-os-sub-nsclc-p2saf.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

2.2 Progressionsfreies Überleben

Table 14n-4.2.1. Summary of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 124)
Subject status	
Events - n (%)	83 (66.9)
Progressive disease	70 (56.5)
Death due to any cause	13 (10.5)
Related to COVID-19	0 (0.0)
Censored - n (%)	41 (33.1)
On study without disease progression	25 (20.2)
No evaluable post-baseline disease assessment	0 (0.0)
Missed more than one consecutive assessments	5 (4.0)
Related to COVID-19	0 (0.0)
Started new anti-cancer therapy	7 (5.6)
Withdrew consent	3 (2.4)
Related to COVID-19	0 (0.0)
Off study due to sponsor decision	0 (0.0)
Related to COVID-19	0 (0.0)
Lost to follow-up	1 (0.8)
Related to COVID-19	1 (0.8)
Progression-free survival (KM) (months)	
25th percentile (95% CI)	2.8 (1.6, 3.9)
Median (95% CI)	6.8 (5.1, 8.2)
75th percentile (95% CI)	11.2 (11.0, 12.4)
Min, Max (+ for censored)	0.3+, 12.6
Kaplan-Meier estimate (95% CI)[a]	
At 3 months	67.8 (58.5, 75.4)
At 6 months	52.2 (42.6, 60.9)
At 9 months	37.2 (28.1, 46.3)
At 12 months	16.3 (7.4, 28.2)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b] Follow-up time is summarized by reversing the status indicator for censored and events.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-nsclc-p2fas.sas Output: t14n-04-002-001-eff-pfs-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:52) Source: adam.adsl, adam.adtte

Table 14n-4.2.1. Summary of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 124)
Follow-up time for PFS[b] (KM) (months)	
25th percentile (95% CI)	8.4 (5.5, 10.8)
Median (95% CI)	11.0 (10.8, 11.1)
75th percentile (95% CI)	11.7 (11.1, NE)
Min, Max (+ for censored)	0.3, 12.6+

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[b] Follow-up time is summarized by reversing the status indicator for censored and events.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-nsclc-p2fas.sas Output: t14n-04-002-001-eff-pfs-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:52) Source: adam.adsl, adam.adtte

Figure 14n-4.2.1. Kaplan-Meier Plot of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)



Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
Censor indicated by vertical bar |
NE = Not Estimable.
Radiological Progression or Death (whichever occurs earlier) is an event.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/figures/f-eff-km.sas
Output: f14n-04-002-001-eff-km-pfs-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:38:15) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	47/65	5.5 (2.9, 8.1)	48.0 (35.0, 59.8)	9.3 (2.0, 23.7)
≥ 65 years	36/59	7.0 (5.1, 11.0)	56.9 (42.4, 69.0)	27.0 (11.0, 46.1)
Prior lines of anti-cancer therapy				
1	31/53	7.8 (5.4, 11.1)	56.2 (40.8, 69.0)	16.4 (3.7, 37.3)
2	33/43	4.1 (2.7, 8.3)	41.5 (26.3, 56.0)	16.1 (4.3, 34.6)
> 2	19/28	7.3 (4.1, 11.1)	61.5 (40.2, 77.1)	19.1 (4.3, 41.8)
Prior anti PD-1 or anti PD-L1				
Yes	75/113	7.0 (5.1, 8.3)	54.1 (44.0, 63.1)	17.1 (7.8, 29.5)
No	8/11	5.4 (1.3, 11.0)	32.7 (8.3, 60.6)	NE (NE, NE)
Prior platinum-base chemotherapy				
Yes	77/111	5.5 (4.1, 7.3)	46.9 (36.9, 56.2)	12.5 (4.1, 25.8)
No	6/13	11.1 (8.0, NE)	100.0 (NE, NE)	39.8 (11.0, 68.0)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	69/100	5.5 (4.1, 7.3)	48.5 (37.9, 58.3)	13.2 (4.3, 27.1)
No	14/24	8.3 (5.4, 11.1)	67.9 (44.1, 83.3)	27.4 (9.4, 49.2)
PD-L1 protein expression				
< 1%	18/33	8.2 (5.5, 11.5)	69.9 (49.8, 83.1)	17.7 (1.6, 48.5)
≥ 1% and < 50%	17/23	5.4 (2.1, 11.1)	46.0 (24.6, 65.0)	NE (NE, NE)
≥ 50%	24/34	5.5 (2.8, 9.6)	47.3 (28.9, 63.6)	18.6 (5.9, 36.7)
ECOG status at baseline				
0	18/37	11.0 (5.4, 12.6)	60.3 (41.5, 74.8)	36.4 (13.8, 59.6)
1	65/87	5.5 (3.9, 7.8)	48.8 (37.5, 59.1)	8.2 (1.8, 21.0)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	68/102	7.0 (5.4, 8.3)	53.8 (43.2, 63.2)	17.8 (8.0, 30.6)
Black	2/2	2.6 (1.3, 3.9)	0.0 (NE, NE)	0.0 (NE, NE)
Asian	12/18	2.9 (1.4, 11.1)	48.8 (22.9, 70.5)	0.0 (NE, NE)
Other	1/2	NE (2.8, NE)	50.0 (0.6, 91.0)	NE (NE, NE)
Sex				
Male	37/62	6.8 (4.1, 10.0)	53.7 (39.7, 65.8)	11.8 (1.2, 35.9)
Female	46/62	6.7 (2.9, 8.1)	50.6 (37.2, 62.6)	16.8 (6.5, 31.3)
Histopathology type				
Squamous	1/1	1.4 (NE, NE)	0.0 (NE, NE)	0.0 (NE, NE)
Non-squamous	82/123	6.8 (5.1, 8.2)	52.6 (43.0, 61.4)	16.4 (7.5, 28.4)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Metastatic				
Yes	82/120	6.7 (4.1, 8.1)	51.8 (42.0, 60.6)	14.3 (5.7, 26.5)
No	1/4	NE (5.5, NE)	66.7 (5.4, 94.5)	NE (NE, NE)
Liver metastasis				
Yes	21/26	2.9 (1.6, 6.8)	31.7 (14.8, 50.0)	0.0 (NE, NE)
No	62/98	7.8 (5.5, 11.0)	57.8 (46.8, 67.3)	20.3 (9.6, 33.8)
Brain metastasis				
Yes	17/26	4.9 (2.5, 8.3)	48.8 (27.5, 67.0)	29.3 (12.3, 48.7)
No	66/98	6.8 (5.3, 8.3)	53.1 (42.3, 62.8)	14.8 (5.8, 27.7)
Bone metastasis				
Yes	41/59	4.1 (2.8, 8.0)	39.5 (26.2, 52.5)	11.9 (2.7, 28.6)
No	42/65	8.1 (5.5, 11.0)	62.8 (49.5, 73.5)	21.6 (8.5, 38.7)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

Table 14n-4.2.2. Subgroup Analysis of Progression-free Survival by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Smoking history				
Never	5/6	2.8 (1.2, NE)	16.7 (0.8, 51.7)	NE (NE, NE)
Current	9/15	6.3 (1.4, 11.2)	56.0 (26.6, 77.6)	0.0 (NE, NE)
Former	67/100	7.0 (5.1, 8.3)	53.4 (42.6, 63.0)	15.2 (6.0, 28.3)
Region				
North America	52/79	7.3 (5.4, 10.0)	55.7 (43.4, 66.4)	18.8 (8.4, 32.5)
Europe	20/29	4.9 (2.8, 8.3)	43.0 (24.6, 60.2)	NE (NE, NE)
Asia	8/11	2.8 (0.9, 8.1)	40.0 (12.3, 67.0)	NE (NE, NE)
Rest of the world	3/5	11.2 (4.1, 11.2)	80.0 (20.4, 96.9)	0.0 (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-pfs-sub-nsclc-p2fas.sas
Output: t14n-04-002-002-eff-pfs-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:55) Source: adam.adsl, adam.adtte

2.3 Ansprechen

Table 14n-4.1.1. Summary of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 124)
Best overall response - n (%)	
Complete response (CR)	3 (2.4)
Partial response (PR)	43 (34.7)
Stable disease (SD)	54 (43.5)
Progressive disease (PD)	20 (16.1)
Not evaluable (NE)	2 (1.6)
Not done	2 (1.6)
Objective response rate (ORR)	
Number of overall responders - N1 (%)	46 (37.1)
95% CI[a]	(28.60, 46.23)
Disease control rate (DCR) - n (%)	100 (80.6)
95% CI[a]	(72.58, 87.19)
Duration of objective response (DOR)[b]	
Observed duration ≥ 3 months - n (%)	37 (80.4)
Observed duration ≥ 6 months - n (%)	26 (56.5)
Observed duration ≥ 9 months - n (%)	15 (32.6)
Observed duration ≥ 12 months - n (%)	0 (0.0)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
N = Number of subjects in the analysis set. n = Number of subjects with observed data.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Months are derived as days x (12/365.25).
[a] Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b] Time to response and duration of response are calculated among confirmed responders N1.
[c] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[d] Follow-up time is measured by reversing the status indicator for censored and events.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-resp-nsclc-p2.sas
Output: t14n-04-001-001-eff-resp-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs, adam.adtte

Table 14n-4.1.1. Summary of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 124)
Subject status - n (%)	
Events	19 (41.3)
Progressive disease	17 (37.0)
Death	2 (4.3)
Related to COVID-19	0 (0.0)
Censored	27 (58.7)
On study without disease progression	21 (45.7)
No evaluable post-baseline disease assessment	0 (0.0)
Missed more than one consecutive assessments	1 (2.2)
Related to COVID-19	0 (0.0)
Started new anti-cancer therapy	4 (8.7)
Withdrew consent	1 (2.2)
Related to COVID-19	0 (0.0)
Off study due to sponsor decision	0 (0.0)
Related to COVID-19	0 (0.0)
Lost to follow-up	0 (0.0)
Related to COVID-19	0 (0.0)
Duration of response (KM) (months)	
25th percentile (95% CI)	5.6 (3.5, 6.9)
Median (95% CI)	10.0 (6.9, 11.1)
75th percentile (95% CI)	11.1 (10.0, 11.1)
Min, Max (+ for censored)	1.2+, 11.1
Kaplan-Meier estimate (95% CI)[c]	
At 3 months	90.3 (76.2, 96.2)
At 6 months	70.2 (53.4, 81.9)
At 9 months	54.7 (37.1, 69.3)
At 12 months	0.0 (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
N = Number of subjects in the analysis set. n = Number of subjects with observed data.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Months are derived as days x (12/365.25).
[a] Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b] Time to response and duration of response are calculated among confirmed responders N1.
[c] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[d] Follow-up time is measured by reversing the status indicator for censored and events.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-resp-nsclc-p2.sas Output: t14n-04-001-001-eff-resp-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs, adam.adtte

Table 14n-4.1.1. Summary of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	Phase 2 NSCLC 960 mg QD Fasted (N = 124)
Follow-up time for DOR[d] (KM) (months)	
25th percentile (95% CI)	6.7 (4.2, 8.3)
Median (95% CI)	9.6 (7.8, 9.7)
75th percentile (95% CI)	9.8 (9.7, 11.0)
Min, Max (+ for censored)	1.2, 11.1+
Time to objective response (months)[b]	
Number of subjects with objective response	46
Mean (SD)	2.11 (1.71)
Median	1.35
Q1, Q3	1.25, 2.69
Min, Max	1.2, 10.1

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
N = Number of subjects in the analysis set. n = Number of subjects with observed data.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
Months are derived as days x (12/365.25).
[a] Exact 95% confidence interval was calculated using the Clopper Pearson method.
[b] Time to response and duration of response are calculated among confirmed responders N1.
[c] 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
[d] Follow-up time is measured by reversing the status indicator for censored and events.
Events marked "Related to COVID-19" were identified from available information collected on CRF and protocol deviation data.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-resp-nsclc-p2.sas Output: t14n-04-001-001-eff-resp-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs, adam.adtte

Figure 14n-4.1.1. Kaplan-Meier Plot of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)



Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
Censor indicated by vertical bar |
NE = Not Estimable.
Radiological Progression or Death (whichever occurs earlier after confirmed CR/PR) is an event.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/figures/f-eff-km.sas
Output: f14n-04-001-001-eff-km-dor-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:38:12) Source: adam.adsl, adam.adtte

Table 14n-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	NSCLC (N = 124) Events[a]/Subjects (%) (95% CI)
Age at baseline	
< 65 years	20/65 (30.8) (19.9, 43.4)
≥ 65 years	26/59 (44.1) (31.2, 57.6)
Prior lines of anti-cancer therapy	
1	21/53 (39.6) (26.5, 54.0)
2	14/43 (32.6) (19.1, 48.5)
> 2	11/28 (39.3) (21.5, 59.4)
Prior anti PD-1 or anti PD-L1	
Yes	41/113 (36.3) (27.4, 45.9)
No	5/11 (45.5) (16.7, 76.6)
Prior platinum-base chemotherapy	
Yes	37/111 (33.3) (24.7, 42.9)
No	9/13 (69.2) (38.6, 90.9)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1	
Yes	32/100 (32.0) (23.0, 42.1)
No	14/24 (58.3) (36.6, 77.9)
PD-L1 protein expression	
< 1%	16/33 (48.5) (30.8, 66.5)
≥ 1% and < 50%	10/23 (43.5) (23.2, 65.5)
≥ 50%	9/34 (26.5) (12.9, 44.4)
ECOG status at baseline	
0	16/37 (43.2) (27.1, 60.5)
1	30/87 (34.5) (24.6, 45.4)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program:
/userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-sub-orr-nsclc-p2.sas
Output: t14n-04-001-002-eff-orr-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs

Table 14n-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	NSCLC (N = 124) Events[a]/Subjects (%) (95% CI)
Race	
White	42/102 (41.2) (31.5, 51.4)
Black	0/2 (0.0) (0.0, 84.2)
Asian	3/18 (16.7) (3.6, 41.4)
Other	1/2 (50.0) (1.3, 98.7)
Sex	
Male	27/62 (43.5) (31.0, 56.7)
Female	19/62 (30.6) (19.6, 43.7)
Histopathology type	
Squamous	0/1 (0.0) (0.0, 97.5)
Non-squamous	46/123 (37.4) (28.8, 46.6)
Metastatic	
Yes	44/120 (36.7) (28.1, 45.9)
No	2/4 (50.0) (6.8, 93.2)
Liver metastasis	
Yes	8/26 (30.8) (14.3, 51.8)
No	38/98 (38.8) (29.1, 49.2)
Brain metastasis	
Yes	4/26 (15.4) (4.4, 34.9)
No	42/98 (42.9) (32.9, 53.3)
Bone metastasis	
Yes	19/59 (32.2) (20.6, 45.6)
No	27/65 (41.5) (29.4, 54.4)
Smoking history	
Never	2/6 (33.3) (4.3, 77.7)
Current	4/15 (26.7) (7.8, 55.1)
Former	40/100 (40.0) (30.3, 50.3)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program:
/userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-sub-orr-nsclc-p2.sas
Output: t14n-04-001-002-eff-orr-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs

Table 14n-4.1.2. Subgroup Analysis of Objective Response by Central Review (Phase 2 NSCLC in Full Analysis Set)

	NSCLC (N = 124) Events[a]/Subjects (%) (95% CI)
Region	
North America	34/79 (43.0) (31.9, 54.7)
Europe	9/29 (31.0) (15.3, 50.8)
Asia	1/11 (9.1) (0.2, 41.3)
Rest of the world	2/5 (40.0) (5.3, 85.3)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
[a] Events are Confirmed Responder (PR/CR).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.

Program:
/userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-sub-orr-nsclc-p2.sas
Output: t14n-04-001-002-eff-orr-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:53) Source: adam.adsl, adam.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Overall	100/124 (80.6) (72.6, 87.2)
Age at baseline	
< 65 years	49/65 (75.4) (63.1, 85.2)
≥ 65 years	51/59 (86.4) (75.0, 94.0)
Prior lines of anti-cancer therapy	
1	41/53 (77.4) (63.8, 87.7)
2	32/43 (74.4) (58.8, 86.5)
> 2	27/28 (96.4) (81.7, 99.9)
Prior anti PD-1 or anti PD-L1	
Yes	91/113 (80.5) (72.0, 87.4)
No	9/11 (81.8) (48.2, 97.7)
Prior platinum-base chemotherapy	
Yes	88/111 (79.3) (70.5, 86.4)
No	12/13 (92.3) (64.0, 99.8)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1	
Yes	79/100 (79.0) (69.7, 86.5)
No	21/24 (87.5) (67.6, 97.3)
PD-L1 protein expression	
< 1%	29/33 (87.9) (71.8, 96.6)
≥ 1% and < 50%	16/23 (69.6) (47.1, 86.8)
≥ 50%	27/34 (79.4) (62.1, 91.3)
ECOG status at baseline	
0	34/37 (91.9) (78.1, 98.3)
1	66/87 (75.9) (65.5, 84.4)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01DEC2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202101/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:46:58) Source: adam.adsl, a0543efu.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Race	
White	85/102 (83.3) (74.7, 90.0)
Black	1/2 (50.0) (1.3, 98.7)
Asian	12/18 (66.7) (41.0, 86.7)
Other	2/2 (100.0) (15.8, 100.0)
Sex	
Male	50/62 (80.6) (68.6, 89.6)
Female	50/62 (80.6) (68.6, 89.6)
Histopathology type	
Squamous	0/1 (0.0) (0.0, 97.5)
Non-squamous	100/123 (81.3) (73.3, 87.8)
Metastatic	
Yes	96/120 (80.0) (71.7, 86.7)
No	4/4 (100.0) (39.8, 100.0)
Liver metastasis	
Yes	17/26 (65.4) (44.3, 82.8)
No	83/98 (84.7) (76.0, 91.2)
Brain metastasis	
Yes	19/26 (73.1) (52.2, 88.4)
No	81/98 (82.7) (73.7, 89.6)
Bone metastasis	
Yes	44/59 (74.6) (61.6, 85.0)
No	56/65 (86.2) (75.3, 93.5)
Smoking history	
Never	4/6 (66.7) (22.3, 95.7)
Current	12/15 (80.0) (51.9, 95.7)
Former	81/100 (81.0) (71.9, 88.2)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01DEC2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202101/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:46:58) Source: adam.adsl, a0543efu.adrs

Table 14-4.5.1. Subgroup Analysis of Disease Control Rate Based on Central Review (Phase 2 NSCLC in Full Analysis Set)

	Events[a]/Subjects (%) (95% CI)
Region	
North America	65/79 (82.3) (72.1, 90.0)
Europe	23/29 (79.3) (60.3, 92.0)
Asia	7/11 (63.6) (30.8, 89.1)
Rest of the world	5/5 (100.0) (47.8, 100.0)

CI = Confidence Interval;
[a] Events are Confirmed Responder (PR/CR) or Stable Disease (SD).
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting.
Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
Subject(s) with unknown or missing subgroup value are not included.
Exact 95% confidence interval was calculated using the Clopper Pearson method.
Phase 2 data cut-off date 01DEC2020.

Program:
/userdata/stat/amg510/onc/20170543/analysis/ger_amnog_202101/tables/t-eff-sub-dcr-nsclc-p2fas.sas
Output: t14-04-005-001-eff-dcr-sub-nsclc-p2fas.rtf (Date Generated: 12JUL21:04:46:58) Source: adam.adsl, a0543efu.adrs

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Age at baseline				
< 65 years	9/20	10.0 (5.6, NE)	73.3 (47.2, 87.9)	NE (NE, NE)
≥ 65 years	10/26	11.1 (5.6, 11.1)	67.4 (43.4, 83.0)	0.0 (NE, NE)
Prior lines of anti-cancer therapy				
1	7/21	NE (6.8, NE)	84.2 (58.7, 94.6)	NE (NE, NE)
2	7/14	10.0 (3.5, 10.0)	57.1 (28.4, 78.0)	0.0 (NE, NE)
> 2	5/11	6.9 (2.8, 11.1)	62.5 (22.9, 86.1)	0.0 (NE, NE)
Prior anti PD-1 or anti PD-L1				
Yes	15/41	10.0 (6.9, 11.1)	77.4 (59.9, 88.0)	0.0 (NE, NE)
No	4/5	4.0 (2.8, NE)	NE (NE, NE)	NE (NE, NE)
Prior platinum-base chemotherapy				
Yes	15/37	10.0 (5.6, 11.1)	64.7 (45.2, 78.7)	0.0 (NE, NE)
No	4/9	8.4 (4.2, NE)	88.9 (43.3, 98.4)	NE (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:54) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Prior platinum-base chemotherapy and prior anti PD-1 or anti PD-L1				
Yes	11/32	10.0 (6.9, 11.1)	73.4 (52.1, 86.4)	0.0 (NE, NE)
No	8/14	7.1 (4.0, NE)	64.3 (34.3, 83.3)	NE (NE, NE)
PD-L1 protein expression				
< 1%	6/16	NE (5.6, NE)	73.3 (43.6, 89.1)	NE (NE, NE)
≥ 1% and < 50%	6/10	5.0 (3.5, 10.0)	37.5 (8.7, 67.4)	0.0 (NE, NE)
≥ 50%	5/9	8.4 (2.5, 11.1)	88.9 (43.3, 98.4)	0.0 (NE, NE)
ECOG status at baseline				
0	3/16	NE (5.6, NE)	77.9 (45.9, 92.3)	NE (NE, NE)
1	16/30	7.1 (5.6, 11.1)	66.1 (44.9, 80.8)	0.0 (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:54) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Race				
White	19/42	10.0 (6.8, 11.1)	68.1 (50.6, 80.5)	0.0 (NE, NE)
Asian	0/3	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Other	0/1	NE (NE, NE)	NE (NE, NE)	NE (NE, NE)
Sex				
Male	8/27	NE (6.9, NE)	77.0 (53.2, 89.7)	NE (NE, NE)
Female	11/19	10.0 (4.2, 11.1)	62.3 (36.7, 80.0)	0.0 (NE, NE)
Histopathology type				
Non-squamous	19/46	10.0 (6.9, 11.1)	70.2 (53.4, 81.9)	0.0 (NE, NE)
Metastatic				
Yes	18/44	10.0 (6.9, 11.1)	71.2 (54.0, 82.9)	0.0 (NE, NE)
No	1/2	NE (2.8, NE)	50.0 (0.6, 91.0)	NE (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:54) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Liver metastasis				
Yes	4/8	7.1 (3.5, NE)	75.0 (31.5, 93.1)	NE (NE, NE)
No	15/38	10.0 (6.9, 11.1)	69.3 (50.3, 82.2)	0.0 (NE, NE)
Brain metastasis				
Yes	2/4	11.1 (3.5, 11.1)	75.0 (12.8, 96.1)	0.0 (NE, NE)
No	17/42	10.0 (6.8, NE)	69.6 (51.8, 81.9)	NE (NE, NE)
Bone metastasis				
Yes	8/19	11.1 (4.2, 11.1)	76.5 (48.8, 90.4)	0.0 (NE, NE)
No	11/27	10.0 (5.6, NE)	66.5 (44.0, 81.7)	NE (NE, NE)
Smoking history				
Never	1/2	2.8 (NE, NE)	0.0 (NE, NE)	0.0 (NE, NE)
Current	0/4	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Former	18/40	10.0 (6.8, 11.1)	69.7 (52.0, 82.0)	0.0 (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:54) Source: adam.adsl, adam.adtte

Table 14n-4.4.1. Subgroup Analysis of Duration of Response by Central Review (Phase 2 NSCLC Responders in Full Analysis Set)

	Events[a]/Subjects	Median (95% CI) (Months)	6 Months KM Estimate (95% CI) (%)	12 Months KM Estimate (95% CI) (%)
Region				
North America	15/34	11.1 (5.8, 11.1)	66.7 (46.9, 80.6)	0.0 (NE, NE)
Europe	3/9	NE (3.5, NE)	71.4 (25.8, 92.0)	NE (NE, NE)
Asia	0/1	NE (NE, NE)	100.0 (NE, NE)	NE (NE, NE)
Rest of the world	1/2	10.0 (NE, NE)	100.0 (NE, NE)	0.0 (NE, NE)

Snapshot date 21JAN2021. Phase 2 data cut-off date 01DEC2020.
CI = Confidence Interval; KM = Kaplan-Meier; NE = Not Estimable.
[a] Duration of response ending events are disease progression and death.
Types of prior anti-cancer therapies were adjudicated and include therapies given in any treatment setting. Number of prior lines of therapy include therapies in metastatic disease and adjuvant therapy immediately before metastasis where progression occurred on or within 6 months of treatment ending.
95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate.
Subject(s) with unknown or missing subgroup value are not included.

Program: /userdata/stat/amg510/onc/20170543/analysis/eff_update_202101/tables/t-eff-dor-sub-nsclc-p2fas.sas
Output: t14n-04-004-001-eff-dor-sub-nsclc-p2fas.rtf (Date Generated: 28JAN21:12:36:54) Source: adam.adsl, adam.adtte